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Multiple myeloma (MM) remains as a predominantly incurable malignancy despite high-dose 
chemotherapy, autologous stem cell transplant and novel agents. MM is a genetically heterogeneous 
disease with increasing genetic complexity as the disease progresses to a more aggressive stage. The 
disease is characterised by the proliferation of plasma cell clone/s, and the continual production of 
immunoglobulin fragments, known as paraprotein. The malignancy most commonly affects an aged 
population with approximately 1200 new cases diagnosed in Australia each year. The introduction of 
proteasome inhibitors (PIs), such as bortezomib (Bz), has improved the life expectancy of MM 
patients significantly. However, not all MM patients respond to Bz. The response rate to Bz and 
dexamethasome in newly diagnosed MM is about 40-80%, while only 30% in relapsed/refractory MM. 
Therefore, relapsed refractory MM, in particular those who are refractory to proteasome inhibitors, 
remain the biggest hurdle in treating the disease.  
Myeloma cells are highly dependent upon the unfolded protein response (UPR) to modulate ER stress 
levels and restore cellular proteostasis. The excessive levels of paraprotein produced by myeloma cells 
surpass the ERs protein folding ability, leading to proteotoxicity and ER stress. The removal of protein 
levels by proteasomal degradation is one way in which the UPR in myeloma cells reduces ER stress 
levels, whilst also orchestrating the reduction of gene transcription and protein translation. The 
activation of the UPR is regulated through three endoplasmic reticulum transmembrane proteins: IRE-
1 (inositol-requiring enzyme-1), PERK (double-stranded RNA-activated protein kinase (PKR) - like 
endoplasmic reticulum kinase) and ATF6 (activating transcription factor 6). One of the most important 
regulators of this pathway, downstream of IRE1, is XBP-1 (X-box Binding Protein 1). XBP-1 is not 
only critical in the activation and regulation of the UPR, but is also important in secretory cells, as 
well as being necessary in plasma cell differentiation. During UPR activation, XBP-1 is activated 
through the splicing of a 26bp intron from XBP-1 mRNA into its active isoform. This is facilitated by 
IRE1, but can also be achieved by ATF6. The expression of XBP-1 is able to predict PI sensitivity in 
MM patients. The mRNA expression of both the total amount and spliced (active) isoform of XBP-1 
are substantially reduced under increasing Bz resistance in MM, although XBP-1 is not a direct target 
of Bz. Its expression is possibly a surrogate marker for dependence on the UPR in MM. Therefore, an 
alternative stress mechanism is likely to be compensating reduced UPR activity and alleviating ER 
stress in Bz resistance.  
It is possible that chaperone-mediated autophagy (CMA) is compensating the UPR in Bz resistance. 
CMA is a highly specific degradation pathway responsible for the removal of damaged and unwanted 
soluble cytosolic proteins. The CMA pathway is already known to be important in modulating 
oxidative stress, nutrient starvation, and eliminating damaged proteins. The activity of CMA is 
directly proportional to the expression of LAMP2A, as LAMP2A is the rate-limiting factor in CMA 
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activity. The expression of LAMP2A is known to be upregulated in a variety of tumours relative to 
untransformed cells, and also promotes tumour proliferation. LAMP2A protein expression is also 
significantly higher in a number of tumour tissues relative to their surrounding untransformed healthy 
tissue, thereby establishing the importance of CMA in tumour biology.  
The purpose of this project was to improve the existing understanding surrounding the role of the UPR 
in Bz sensitivity in MM. The project further aimed to determine the importance of CMA in Bz 
resistance, and whether CMA compensated the UPR in Bz resistant myeloma cells, conferring 
resistance. We hypothesised that reduced dependence on the UPR mediates Bz resistance in MM. We 
further hypothesised that CMA would be upregulated in Bz resistant cells, which subsequently would 
compensate the UPR in alleviating ER stress. Therefore, the inhibition of CMA in Bz resistant cells 
was hypothesised to result in cell death, providing a novel therapeutic target in treating Bz resistance 
in MM. 
Using a KMS11 Bz sensitive and resistant cell line model, and through the analysis of ex-vivo patient 
samples by Real time-PCR, we were able to identify and show that reduced UPR activity is associated 
with Bz resistance, and increased UPR activity is associated with Bz sensitivity in MM. Reduced 
ATF6 expression was shown to mirror Bz resistance in MM patients and Bz resistant cell lines. Live 
cell imaging and electron microscopy revealed that myeloma cells resistant to Bz had smaller ER 
morphologies, and were less dependent on the UPR, making them more resistant to Bz. However, 
myeloma cells that were sensitive to Bz possessed a larger ER morphology reflecting increased UPR 
activity. This subsequently resulted in increased sensitivity to Bz treatment. UPR activation is 
associated with the splicing of XBP-1. In the patient cohort, we found no correlation between SNPs or 
mutations occurring within the splicing site of XBP-1 and Bz resistance. Although, SNPs that 
occurred within the splice site of XBP-1 resulted in a poor prognosis, the occurrence within the patient 
cohort was less than 3% and would not be the cause of resistance in the other patients.  The one patient 
who did possess a SNP within the splice site of XBP-1 died prior to undergoing the second cycle Bz 
therapy. These findings coincide and support one previous study, which found that SNPs occurring 
within the splice site of XBP-1 had a poor prognosis and a low incidence.  
Within Bz resistant MM patients there was a significant increase in LAMP2A gene and protein 
expression levels relative to Bz sensitive MM patients. In-vitro modelling also showed a significant 
increase in LAMP2A gene and protein expression levels within Bz resistant cells compared to Bz 
sensitive parent cells. Resistant cells were also found to possess significantly higher numbers of CMA 
active lysosomes, compared to the sensitive cells. Under basal conditions, resistant cells sustained 
higher levels of CMA activity that were almost at maximum activity. Basal CMA levels were 
significantly lower in Bz sensitive cells compared to the resistant cells, with basal CMA activity half 
of the maximum active capacity. These findings support our hypothesis that CMA is increased in Bz 
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resistance, further suggesting that CMA upregulation could be compensating reduced UPR activity in 
Bz resistant MM.  
Myeloma cells are under continual ER stress, with Bz resistant cells possessing reduced UPR activity 
and decreased dependence on the UPR. Therefore an alternative stress mechanism is likely to be 
responsible for alleviating ER stress. We are already aware that macroautophagy is known to be 
upregulated during ER stress, though the role of CMA during ER stress is yet to be defined. 
Considering CMA is increased in Bz resistance, we examined whether CMA was able to alleviate ER 
stress in MM, therefore establishing its possible role in Bz resistance. Under ER induced stress, 
LAMP2A protein expression and the number active lysosomes were shown to increase in response to 
increasing levels of ER stress. Increases in CMA activity in response to Bz treatment were shown to 
be a result of increased ER stress levels and not a proteasome inhibition. ER stress induced by an 
alternative ER stressor, dithiothreitol (DTT), resulted in an almost identical outcome as seen in 
previous experiments using Bz. These findings were the first to establish a relationship between CMA 
and the UPR, while also being the first to demonstrate that CMA is capable of being a compensatory 
stress mechanism during proteasome inhibition. 
CMA might be a potential therapeutic target in MM, and the inhibition of CMA could potentially 
sensitise Bz resistant cells to Bz. This was tested by LAMP2A knockdown and pharmacological 
inhibition of CMA. Initial attempts to knockdown LAMP2A by transducing Bz sensitive and resistant 
cells with shRNA were lethal to cells, therefore making it unfeasible to establish stable LAMP2A 
knockdown cell lines. To overcome difficulties associated with shRNA knockdowns, we used siRNA 
to achieve transient knockdown of LAMP2A. However, the level of LAMP2A knockdown was 
inadequate to effectively inhibit CMA. Consequently, the level of knockdown, coupled with the short-
lived knockdown effect of siRNA and the long half-life of LAMP2A resulted in little effect on the 
viability of Bz sensitive and Bz resistant cells. We alternatively chose to use a PHLPP1 inhibitor 
(PHLPPi) to inhibit CMA. Inhibition of CMA using the PHLPPi significantly reduced the viability of 
Bz sensitive and resistant cells. In combination with Bz, the PHLPPi inhibitor also enhanced the 
cytotoxic effects of Bz in both sensitive and resistant cells, but also enhanced the sensitivity of 
resistant cells to Bz. The combination of the PHLPPi with the lowest concentration of Bz had a more 
cytotoxic effect on resistant cells than the highest Bz concentration had alone. This supports the 
hypothesis that CMA is important in MM and Bz resistance, making further evaluation into its 
potential therapeutic use worthwhile.  
In summary, this project shows that reduced UPR activity is associated with Bz resistance, and can 
predict Bz resistance in MM. Decreases in ATF6 and XBP-1 expression reflected reduced UPR 
activity, which mirrors Bz resistance in MM. These findings are also further supported by decreases in 
ER morphology in Bz resistant cells, which reflect reduced UPR activity. As supported by the 
literature, the reduction in ER size morphology was a direct result of reduced ATF6 and XBP-1 
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expression levels, as ER expansion is dependent upon both XBP-1 and ATF6. This has demonstrated 
that Bz sensitivity is mediated by the dependence myeloma cells have on the UPR. Our findings have 
gone on to further show that upregulation of CMA is associated with Bz resistance. LAMP2A gene 
and protein expression levels are significantly increased in Bz resistance. Basal CMA levels are also 
noticeably higher in Bz resistant cells, compared to Bz sensitive cells, further confirming the 
importance of CMA in Bz resistance. CMA is also activated under ER stress, with CMA activity 
proportional to the level of ER stress. This illustrates the role of CMA in alleviating ER stress in MM, 
making it a favourable target in treating MM. Inhibition of the CMA pathway appears to reduce the 
viability of Bz sensitive and resistant myeloma cells and enhances the cytotoxic effects of Bz. CMA 
appears to play an important role in conferring Bz resistance and might be favourable target in the 
treatment of Bz resistant MM. Further investigation into CMA inhibition as a potential therapy to treat 




1.1 Multiple Myeloma  
1.1.1 Multiple myeloma the disease 
Multiple myeloma (MM) is a plasma cell malignancy, and is characterized by the proliferation of 
plasma cell clone/s and the infiltration of the bone marrow by malignant plasma cells, resulting in 
the formation of plasmacytomas (Kyle et al., 2003). Those diagnosed with the disease are further 
affected by the burden of the disease, which has implications on a number of the organs in those 
who are diagnosed with the malignancy. The disruption of the bone marrow and the normal 
functioning of the plasma cells eventually result in the development of anaemia, leukopenia, 
hypogammaglobulinemia, thrombocytopenia and peripheral neuropathy as a result (Blade et al., 
1998). Consequently, this contributes to patients becoming fatigued and increase the risk infection 
occurring within patients. Furthermore, 90% of patients with MM suffer from osteolytic lesions as 
a result of the disease, which cause fragile bones and bone pain (Roodman, 2010). Up to 60% of 
patients with osteolytic lesions develop bone fractures as a result of the disease (Terpos et al., 
2011). Additionally, increased levels of calcium released into the blood contributes to the 
development of hypercalcemia, causing kidney failure and other kidney disorders (Oyajobi, 2007). 
While the increase in calcium levels influence and contribute to kidney failure, monoclonal 
immunoglobulin (M-protein), also known as paraprotein, is another contributing factor that causes 
kidney failure. Misfolded immunoglobulin light chains form amyloids, which is deposited in the 
kidneys causing amyloidosis in the kidneys and renal failure. Excessive immunoglobulin light 
chains deposit in the kidney tubules causing cast nephropathy and typically acute kidney injury. 
Excessive production of monoclonal immunoglobulin can lead to hyperviscosity syndrome, which 
is characterised by bleeding, blurred vision, confusion, neurologic symptoms and thromboembolic 
disease. 
1.1.2 Epidemiology  
According to the Myeloma Foundation of Australia, 1200 new cases are diagnosed each year in 
Australia. The disease most commonly affects an aged population, with the chances of developing 
the disease increasing as age increases. The Leukaemia Foundation reported that 80% of newly 
diagnosed patients are diagnosed over the age of 60 and more frequently affects men than it does 
women. In 2008, 30% of all recorded deaths were attributed to cancer (Statistics, 2011). MM was 
found to be responsible for 0.6% of all recorded deaths in Australia (Statistics, 2011).  
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1.1.3 Genetics of the disease 
Like many other cancers, MM is characterised by heterogeneous genetic abnormalities. MM can 
be subdivided into two main groups based on chromosomal gains and losses (Hideshima et al., 
2007). The karyotypes of 55 – 60% of MM patients are seen to contain a hyperdiploid karyotype 
(total number of chromosomes of 48 to 74) (Hideshima et al., 2007). Chromosome trisomy 
appears to occur for the odd numbered chromosomes such as, 3, 5, 7, 9, 11, 15, 19 and 21 
(Hideshima et al., 2007, Rajkumar et al., 2013, Carballo-Zarate et al., 2017). The remaining cases 
are non-hyperdiploid. Within this group, chromosome karyotype numbers are below 48 
(hypodiploid) or over 74 (Rajkumar et al., 2013). The mechanism however that causes the 
alterations in the karyotype number of MM patients is yet to be found. 
Chromosome abnormalities’ are one of the most frequently occurring features identified in MM 
patients. Karyotype abnormalities have been observed to be most prevalent in highly proliferative 
clones (Debes-Marun et al., 2003). Nevertheless, a number of recurrent non-random abnormalities 
have been identified in MM such as translocations within the VDJ recombination region 
(Bergsagel and Kuehl, 2005) (Bolli et al., 2016). Chromosome translocations of the IgH 
(immunoglobulin heavy chain) locus (14q32 gene locus) are one of the most frequently occurring 
mutations identified in MM (Seidl et al., 2003). Translocation of the gene in MM is characterised 
by the juxtaposition of IgH gene sequences with non-immunoglobulin DNA sequences of gene 
loci from 11q13, 4p16.3, 16q23, or 6p21 (Seidl et al., 2003). Translocations of this locus is seen in 
60-75% of MM cases, as well present in almost all MM cell lines, which provides reason to 
believe that this mutation may have an important role in cell transformation (Seidl et al., 2003). 
The four-translocation variations are mediated by errors within the IgH switch recombination 
process and occur in 60% of IgH translocations (Seidl et al., 2003) (Debes-Marun et al., 2003) 
(Shi et al., 2016). The formation of the reciprocal translocates subsequently activate oncogenes as 
the oncogenes become located under the enhancer elements of the IgH gene locus. For this very 
reason, it is thought that chromosome translocations may cause the initial transformation of a 
plasma cell into a malignant cell.   
Further studies into MM have found that another prevalent chromosome translocation of the IgH 
locus is the translocation of the cyclin D1 gene at the 11q13 locus (Bergsagel and Kuehl, 2001). In 
15 – 20% of MM cases, the cyclin D1 protein is overexpressed as a result of the chromosomal 
translocation juxtaposed to the IgH 3' enhancer (Bergsagel and Kuehl, 2001) (Bustany et al., 2016). 
This overexpression of cyclin D1 is unique for MM and mantle cell lymphoma as the expression 
of cyclin D1 is not expressed in normal B cells (Aguilera et al., 1998, Bergsagel and Kuehl, 2001) 
(Bustany et al., 2016).  
While chromosome translocations have been identified in many instances of MM studies, other 
mutations have also been identified that contribute to the phenotype of myeloma cells.  For 
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instance, 54.5% of MM patients and 50% of the human myeloma cell lines have been shown to 
have NRAS and/or KRAS2 activating mutations (Bezieau et al., 2001). Mutations within the 
KRAS gene are more common than those identified in the NRAS gene and have been postulated 
that these early mutations might provide a significant role in the oncogenesis of MM (Bezieau et 
al., 2001, Smith et al., 2015). Furthermore, 39% of patients of newly diagnosed patients possess a 
RAS mutation on first analysis (Liu et al., 1996). However, one study had found that 12% of 
patients with no mutation of the RAS gene to begin with, have eventually developed a mutation 
within the gene following analysis of the disease progression (Liu et al., 1996).  
The sheer genetic complexity of MM is further demonstrated by identifying increased expression 
levels of the C-MYC gene in the early stages of MM (Jernberg-Wiklund and Nilsson, 2012). 
Expression of C-MYC is commonly increased in the later stages of MM pathogenesis, however 
the transcription factor (C-MYC) is found to be expressed during the transition from MGUS 
(monoclonal gammopathy of undetermined significance) to MM in two-thirds of MM patients 
studied (Chng et al., 2011). While the authors of the study still supported that C-MYC activation 
was a late event in the pathogenesis of MM, their study also provided evidence that C-MYC 
activation was likely to occur in the early stages of MM pathogenesis also. Additional studies have 
also found that the activation of a MYC transgene by somatic hypermutation induced MM in a 
conditional mouse model (Chesi et al., 2008). Nonetheless, the reasons causing C-MYC activation 
remain divided.  
While genetic changes are a large pathogenic driving factor in cell transformation and progression 
in MM, epigenetic factors are equally important as well. For instance a variety of P protein genes 
have been identified in myeloma cells to be silenced by epigenetic modifications. However, P16 
silencing appears to be the most prevalent in these cells. Important for the regulation of the cell 
cycle through the inhibition of cyclin-dependant kinases (CDKs) 4 and 6, P16 is methylated in 19 
– 53% of patient cases with MM (Sharma et al., 2010). Consequently, the hypermethylation of the 
P16 gene allows plasma cell proliferation and cell progression (Amodio et al., 2017). 
Hypermethylation of the P16 gene is a strong contributing factor, which causes the transformation 
from MGUS to MM (Galm et al., 2004) (Gonzalez-Paz et al., 2007). In addition, there is a 
substantial increase in the number of CpG islands in myeloma cells compared to MGUS cells 
(Gonzalez-Paz et al., 2007) (Galm et al., 2004).  
The significance of epigenetic modification in cells to drive tumour progression is further 
demonstrated in the methylation of the E-Cadherin gene. Evidence that methylation of the E-
Cadherin gene has an important role in contributing to the progression of MGUS to MM has been 
established in a number of studies (Seidl et al., 2004) (Chim et al., 2007). MGUS patients are seen 
to have no instances of E-Cadherin methylation, while MM patients appear to have high instances 
of its methylation (Seidl et al., 2004) (Chim et al., 2007) (Sharma et al., 2010). Furthermore, the 
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tumour suppressor gene (TSG) is an important gene that codes for a cell adhesion molecule 
(Sharma et al., 2010). Decreased or no expression of the gene is noted within cells that are likely 
to travel through out the body and establish a secondary tumour, a process called metastasis, 
although this is still to be proven (Sharma et al., 2010).  
The few genetic and epigenetic mutations outlined are only a number of the numerous mutations 
that contribute to cell transformation and progression in MM. This demonstrates the complexity of 
the disease and the difficulties in developing a further understanding. However, research is now 
enhancing our knowledge of MM and uncovering new possible targets for drug development to 
combat the disease.   
 1.2 The importance of the unfolded protein response to plasma 
cells and in MM 
Plasma cells are terminally differentiated B-lymphocytes of the adaptive immune system. The 
specialised function of plasma cells is to manufacture and secrete antibodies to a specific antigen. 
Both myeloma cells and plasma cells rely heavily on the unfolded protein response for post-
translational modifications, folding of antibodies and the regulation of the disposal of terminally 
misfolded/damaged proteins.  
1.2.1 Immunoglobulin folding and assembly 
Immunoglobulins (Igs) (antibodies) are polymeric structures that are composed of two identical 
light and heavy chains (Spiegelberg, 1974). These secreted proteins are folded and assembled 
within the lumen of the endoplasmic reticulum (ER) of plasma cells, following the translocation of 
both the light and heavy chains from the nucleus. Within the ER lumen, a series of modifications 
occur to both chains. Both the light and heavy chains are post-translational modified with 
oligosaccharides (Reddy et al., 1996) (Gass et al., 2002), before being assembled and then 
secreted. The assembly of the two light chains and two heavy chains are held together by 
hydrophobic interactions and stabilised by disulphide bonds (Reddy et al., 1996) (Lee et al., 1999). 
The assembly of immunoglobulins can be divided into five different isotypes (IgA, IgE, IgG, IgM 
and IgD), each displaying a unique conformation that performs a specialised function. The folding 
of all 5 Ig isotypes relies heavily upon the ER, the UPR and the ubiquitin-proteasome system for 
the correct quaternary structure. Any alteration to any of these mechanisms can have a negative 
impact on the production of functional immunoglobulins (Ling, 2009). At the same time, this 
pathway can be targeted or interrupted in those malignancies that are highly dependent on the 
functioning of the ER, such as MM (Ling, 2009). 
1.2.2 Endoplasmic reticulum  
The ER is an important organelle of most eukaryotic cells, characterised as being a network of 
interconnected internal membranes (Lodish et al., 2007). The ER serves multiple functions and is 
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essential in the synthesis of lipids, membrane proteins, and as well secreted proteins, such as 
antibodies. There are two types of ER, one of which is the rough endoplasmic reticulum (RER), 
named after its physical appearance and the other the smooth endoplasmic reticulum (SER) 
(Pluquet et al., 2015). The primary difference between the two is that the RER is studded with 
ribosomes, giving it a rough appearance, while the SER lacks ribosomes giving a smooth 
appearance under microscopic examination (Lodish et al., 2007).  
1.2.3 Unfolded Protein Response (UPR) 
The unfolded protein response (UPR) is an important cellular process that occurs in response to 
stress placed upon the endoplasmic reticulum (ER) of the cell (Schroder and Kaufman, 2005b). In 
such an instance, the ER has been seen to expand in volume by 5 fold in yeast models when 
subjected to UPR-inducing stimuli (Bernales et al., 2006). The pathways activation is a result of 
exceeded levels of unfolded and/or misfolded proteins within the ER, which surpass the 
endoplasmic reticulum’s ability to process (Xu et al., 2005) (Schroder and Kaufman, 2005b). 
Instances of such events occurring within the ER are referred to as ER stress. Causes for increased 
levels of unfolded and/or misfolded proteins are a result of a variety of contributing factors. The 
purpose of the UPR is to resolve ER stress and to restore homeostasis back to the cell. If this 
cannot be achieved, cells will enter apoptosis.  
Chaperones are critical molecular machinery used in normal cellular functioning and maintenance. 
Chaperones are proteins associated with assisting in the folding or unfolding, as well the assembly 
or disassembly of other proteins (Alberts et al., 1994). Within eukaryotic cells, chaperones are 
placed into two families, HSP60 and HSP70 (heat-shock protein) (Alberts et al., 1994). Within 
each family of chaperones are members that are distinct to specific organelles of the cell, however 
all share a characteristic affinity to exposed hydrophobic regions of misfolded/unfolded proteins 
(Alberts et al., 1994). The most understood molecular chaperone, capable of identifying and 
differentiating between proteins that are folded and unfolded (also misfolded) is the binding 
immunoglobulin protein (BiP) located within the ER. Not only a critical protein, BiP is also the 
most abundant ER chaperone (Maattanen et al., 2010). A part of the heat-shock protein 70 
(HSP70) chaperone family, BiP contains two important domains characteristic of the HSP70 
protein family necessary for the proteins functioning. The ATPase catalytic site located within the 
N-terminal domain, which controls the conformation of the protein (Maattanen et al., 2010). When 
the ATPase site is bound by ATP, BiP is in its open conformation, however if hydrolysed to ADP, 
causing BiP to then form a tighter affinity substrate binding conformation (Maattanen et al., 2010). 
The C-terminal domain consists of the substrate-binding site where peptides bind to the protein 
(Gething, 1999). When misfolded or unfolded proteins accumulate within the ER, BiP occupying 
transmembrane ER proteins (inactive state) dissociate from transmembrane proteins, and bind to 
the hydrophobic regions of the accumulating proteins via its substrate-binding site of the C-
terminal domain (Lai et al., 2007). This in turn activates the transmembrane ER proteins, enabling 
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them to transduce the stress signal across the ER to effector proteins. These effector proteins are 
then able to reprogram the transcriptome and activate various other genes to relieve ER stress 
(Hetz et al., 2011).  
To resolve the stress placed upon the ER as a result of the accumulation of unfolded and 
misfolded proteins, the activation of the UPR is critical to restore ER homeostasis. Stress signals 
activating the pathway are first transduced across the ER bilayer  activating the pathway. Stress 
signals are transduced via three ER transmembrane proteins PERK, ATF6, and IRE1α. This is 
enabled by the dissociation of the BiP chaperone from these three transmembrane ER proteins 
(PERK, ATF6, and IRE1α) leading to their activation. 
IRE1 is a type 1 transmembrane protein, which possesses a serine–threonine protein kinase 
domain and an endoribonuclease domain (Xu et al., 2005) (Schroder and Kaufman, 2005b) (Lin et 
al., 2007). In the absence of unfolded proteins, the IRE1 protein remains in an inactive state as a 
monomer bound by BiP (Hetz et al., 2011). As increased levels of unfolded protein rise in the ER, 
IRE1 becomes activated as the BiP chaperone dissociates from the protein; binding to exposed 
hydrophobic regions of unfolded proteins. As a result, within the membrane IRE1 oligomerizes 
into a dimeric protein by autophosphorylation of the juxtaposed kinase domains (Figure 1.1) (Ron 
and Walter, 2007) (Hetz et al., 2011). This in turn causes the activation of the cytoplasmic RNase 
domain enabling the protein to splice a 26 base pair intron from the XBP-1 (X-box Binding 
Protein - 1) mRNA (Ron and Walter, 2007, Schroder and Kaufman, 2005b). By cleaving the XBP-
1 mRNA, a shift in the open reading frame results, giving rise to a 371 amino acid spliced XBP-1 
peptide (Glimcher, 2010). In turn, the newly splice peptide codes for a basic leucine zipper 
transcription factor, containing a DNA binding domain in the N -terminal as well as a C -terminal 
transactivation domain, which are absent within unspliced forms of the gene (Glimcher, 2010). 
Translocating to the nucleus of the cell, XBP-1 binds to the promoter regions of target genes 
DnaJ/Hsp40-like genes, p58IPK, ERDj4, HEDJ, EDEM, protein disulfide isomerase-P5, RAMP4 
and ERDJ3 causing an upregulation in their expression (Hetz, 2012) (Ling, 2009). The 
upregulation of these genes enable the ER stress to be alleviated, restoring the ER to its normal 
state. 
The second ER transmembrane receptor is the PERK protein, whose main function is to modulate 
protein translation (Chakrabarti et al., 2011). PERK is a type I ER-resident transmembrane protein 
kinase (Harding et al., 2000). As elevated stress levels on the ER increase, caused by increasing 
levels of misfolded and unfolded proteins, the BiP chaperone dissociates from the N-terminus of 
the PERK protein. In doing so, the PERK protein oligomerizes into a dimeric protein and is 
activated by autophosphorylation (Hetz et al., 2011). In its active form, the PERK protein 
phosphorylates two target proteins, eIF2α and NRF2 (Figure 1.1). The eIF2α protein, essential for 
the initiation of protein translation in eukaryotic cells, is inactivated by PERK by the 
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phosphorylation of serine 51 within the α subunit of eIF2α (Schroder and Kaufman, 2005a). This 
as a result relieves ER stress by blocking the exchange of GDP bound to eIF2α, decreasing the 
influx of protein into the ER (Chakrabarti et al., 2011). Phosphorylation of NRF2, the NRF2 
protein bound to Keap1 (in unstressed cells) is segregated from each other, causing NRF2 to 
translocate to the nucleus (Ling, 2009). Within the nucleus; NRF2 binds to other bZIP proteins 
that activate transcription through the antioxidant response element (ARE) (Chakrabarti et al., 
2011) (Ling, 2009). This as a result causes an increase in the expression of genes that are involved 
within the phase II metabolism of xenobiotics such as A1 and A2 subunits of glutathione-S-
transferase, NAD(P)H quinone oxidoreductase, γ-glutamylcysteine synthetase, hemeoxygenase 1 
and UDP-glucuronosyl transferase (Ling, 2009).  
ATF6 is a 90kDa ER transmembrane transcription factor protein (Schroder and Kaufman, 2005a) 
(Walter and Ron, 2011), comprised of two separate homologs, ATF6α and ATF6β. Like XBP-1, 
ATF6 encodes a basic leucine zipper (bZiP) transcription factor in its cytosolic domain (Schroder 
and Kaufman, 2005b). In an inactive state, a BiP chaperone is bound to the N-terminal of ATF6 
(Ye et al., 2000). As ER stress increases, the BiP chaperone once again dissociates from the 
protein, resulting in ATF6 being pinched off the ER bilayer into transport vesicles, which travel to 
the golgi apparatus (Figure 1.1) (Walter and Ron, 2011). Unlike the activation pathway of IRE1 
and PERK, ATF6 does not become phosphorylated at its C-terminal domain (Chakrabarti et al., 
2011). Instead, once within the golgi, ATF6 is activated by two proteases. The first protease, site-1 
protease (S1P), is a serine protease that cleaves the luminal domain, before a second protease, 
metalloprotease site-2 protease (S2P), cleaves the membrane anchored N-terminal within the 
phospholipid bilayer (Ye et al., 2000) (Schroder and Kaufman, 2005b) (Ye et al., 2000). The 
cleaved N-terminal, releases the bZiP cytosolic domain, allowing it to translocate into the nucleus. 
Once within the nucleus, the bZiP transcription factor activates and upregulates UPR genes 
associated with endoplasmic-reticulum-associated protein degradation (ERAD) and protein 
folding to relieve ER stress (Meusser et al., 2005).  
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Figure 1.1: Regulators of the UPR. 
1.2.4 XBP-1 
As mentioned previously, the XBP-1 gene is a transcription factor that is activated during the UPR 
when a 26bp intron is spliced from XBP-1 mRNA. The spliced active transcript is then 
subsequently translocated to the nucleus to activate a variety of UPR target genes necessary to 
relieve the cell from ER stress. While the XBP-1 gene is critical in the UPR, its importance in the 
developing and differentiating a number of organs and cells has also been demonstrated in gene 
knockout mice (Acosta-Alvear et al., 2007). Mice with XBP-1 knockouts are found to exhibit 
abnormalities exclusively in secretory organs such as exocrine pancreas and salivary gland (Lee et 
al., 2005). These abnormalities as a result of the gene knockout, lead to early postnatal mortality 
(Lee et al., 2005). In addition, under close observation of the acinar cells from both the pancreatic 
and salivary glands in XBP-1 knockout mice, the ERs are noticeably underdeveloped, along with 
reduced expression of ER chaperone genes (Lee et al., 2005). Therefore, XBP-1 is a necessary 
gene required by exocrine cells for the full biogenesis of the secretory mechanisms within these 
cells.  
Not only is XBP-1 critical in secretory cells, its importance for cardiac myogenesis is equally as 
important. Lacking XBP-1 expression during embryonic development has been shown to be lethal 
in homogenous XBP-1-/- mouse embryos (Masaki et al., 1999). The cause of lethality is primarily 
due to cellular necrosis of cardiac myocytes of the atrium and the truncus arteriosus of the heart. 
 9 
However, mice embryos that are heterozygous XBP-1-/+ are non-lethal and have no noticeable 
necrosis to either the endocardial cushion or the conotruncal ridge (Masaki et al., 1999). This 
reiterated the importance of XBP-1, demonstrating its function in the maintenance and/or growth 
of cardiac myocytes during cardiogenesis.  
Mouse models have also further illustrated the importance of the XBP-1 gene during embryo 
development, as embryonic mice that lacked the gene are found to have hypoplastic foetal livers 
(Reimold et al., 2000). Mice with hypoplastic foetal livers are unable to survive as a result of 
anaemia. In addition to this, the development of the hepatocytes is impaired considerably, as 
reduced growth rates and prominent apoptosis result (Reimold et al., 2000). It is believed that 
downstream targets of the gene, which control the growth and development of hepatogenesis are 
highly dependent on XBP-1 and unable to be activated without it (Reimold et al., 2000). The 
importance of XBP-1 in development is further illustrated in B cell differentiation. The 
generation of plasma cells requires an upregulation of XBP-1, with XBP-1 mRNA levels 
upregulated as a result of plasma cell differentiation inducing stimuli in vitro (Reimold et al., 
2001). Furthermore, when XBP-1 was introduced to cells of the B cell lineage, XBP-1 initiated 
plasma cell differentiation (Reimold et al., 2001). 
While XBP-1 has been shown to be critical in a number of instances during organ development, 
as well necessary for the differentiation of some cells, its involvement in a variety of diseases is 
also frequently noted. Abnormalities in the gene and/or expression of XBP-1 have been identified 
to be a contributing factor in Crohn’s disease and ulcerative colitis (Kaser et al., 2008). Whilst 
important in these diseases, its involvement in MM is of greatest interest. Reason for this is that 
MM relies heavily upon the UPR, a complex quality control mechanism responsible for post-
translational modification, folding of proteins, and regulation of the disposal of terminally 
misfolded/damaged proteins. A critical component of the UPR, XBP-1, is a key regulator of this 
pathway. Without the gene, the UPR within myeloma cells would likely be impeded and have 
minimal function, due to regulatory role XBP-1 has within the pathway. The importance of the 
XBP-1 gene to myeloma cells has been further supported by a number of MM studies that were 
able to identify an increase in XBP-1 mRNA expression in myeloma cells relative to healthy 
control plasma cells (Davies et al., 2003) (Munshi et al., 2004) (Bagratuni et al., 2010). Protein 
expression levels were also increased; further supporting mRNA level findings (Carrasco et al., 
2007). The same study found that little or no expression was detected within the control samples, 
while 50% (10/20) of the MGUS samples and 70% (50/70) of the MM samples analysed 
displayed a strong and widespread expression of the XBP-1 protein. Expression patterns within 3 
tested myeloma cells lines also showed have increased protein expression, relative to the control 
plasma cells, with the spliced isoform being the most prevalently expressed. Within mice, the 
overexpression of XBP-1 has been shown lead to the development of MM (Carrasco et al., 2007). 
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While XBP-1 has been found to be highly expressed in myeloma cells in a number of studies, 
there are some instances where mRNA expression of XBP-1 is seen to be lowly expressed (Ling, 
2009) (Ling et al., 2012). Patients with low XBP-1 expression have been found to be resistant to 
bortezomib (Bz) treatment (Ling et al., 2012). Bz inhibits the proteasomes, which are responsible 
for the degradation of ubiquitinated misfolded or unfolded proteins. Early studies have shown that 
Bz increases the expression of spliced XBP-1 in vitro suggestive of a state of increased ER stress. 
Ling et al hypothesised that sensitivity to Bz treatment was associated with high XBP-1 mRNA 
levels, and that low levels of XBP-1 mRNA predicted poor responsiveness to Bz treatment. To 
determine if XBP-1 mRNA levels correlated with clinical responsiveness to Bz treatments, Ling et 
al (2012) analysed the expression levels of XBP-1 mRNA of myeloma cells obtained from bone 
marrow biopsies of 17 MM patients. The 17 patients underwent 2 treatment cycles with Bz alone 
or in combination with corticosteroids prior to analysis. Following treatment, patients were 
classified as having a complete response, partial response, minimal response and no response to 
bortezomib treatment. Of the 17 patients, 13 were considered responsive to Bz treatments and the 
remaining 4 patients resistant. XBP-1 mRNA levels were found to correlate with Bz response, 
with high levels of XBP-1 mRNA expression associated with sensitivity, and low expression 
levels of XBP-1 mRNA associated with resistance to the drug (Ling et al., 2012). In addition, Bz 
resistant cell line models also displayed lower XBP-1 expression compared to parent sensitive 
cells (Ling et al., 2012).  
It is evident that high XBP-1 expression is a commonly occurring feature in many MM cases, with 
its known role in the UPR a critical component necessary for the full functioning of the pathway. 
The importance of the UPR in MM is documented as being essential for managing cellular stress, 
as a result of increased paraprotein production (Michallet et al., 2011). However, emerging studies 
have now found that XBP-1 expression is largely decreased in bortezomib resistant (non-
responsive) myeloma cells, while still being highly expressed in bortezomib sensitive patients. 
With decreased expression in the UPR regulators, it is possible that an alternative mechanism is 
responsible in assisting myeloma cells in alleviating cellular stresses placed upon the cell, when 
the UPR is compromised. The goal of this project is to investigate the possible alternative 
mechanism for alleviation of the UPR in MM.  
1.2.5 SNPs in the XBP-1 gene  
A single nucleotide polymorphism (SNP) is a single nucleotide genetic variation that occurs 
within a genetic sequence and is found to occur within a proportion of the population of a species. 
These single nucleotide alterations may or my not have a direct impact upon the coding sequence 
of the gene. SNPs located within critical regions of a gene, such as a promoter or exon may alter 
the gene, losing its function. For instance, a SNP occurring within an exon could potentially cause 
a nonsense mutation, leading to a premature stop codon within the gene. This would subsequently 
prevent the full transcription of the gene, resulting in a truncated protein. As a result, the protein 
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would fail to carry out its function. However, if the SNP resulted in a missense mutation, 
depending on where it was located, it could potentially alter a codon from one amino acid to an 
alternative amino acid, affecting the genes overall coding sequence. In doing so, translated 
polypeptides would likely fold incorrectly, ultimately impeding upon the proteins function and 
rendering the protein useless.  Nonetheless, SNPs are capable of having these potential outcomes, 
though the frequency of these outcomes occurring is very small. Despite this though, SNPs have 
been shown to be the sole or contributing factor in developing some diseases (Cargill et al., 1999) 
(De Gobbi et al., 2006).  
SNPs identified within the XBP-1 gene have been found to be either the primary or contributing 
factor in a number of inflammatory diseases (Kaser et al., 2008). A study by Kaser et al (2008) 
identified a total of seven SNPs located throughout the XBP-1 gene, which presented risk for both 
types of inflammatory bowel disease, Crohn’s disease and ulcerative colitis (Kaser et al., 2008). 
Two different SNPs have been identified in the XBP-1 gene within myeloma cells (Hong and 
Hagen, 2013). One SNP was deemed insignificant, with the other affecting the transcriptional 
activity of the gene (Hong and Hagen, 2013). A c.499C>A mutation within the genes splicing 
region was found to prevent the splicing of XBP-1 (Hong and Hagen, 2013). HEK293T cells 
transfected with plasmids containing the wild type XBP-1 gene were seen to undergo splicing 
during ER induced stress, while cells transfected with plasmids containing the mutated XBP-1 
gene were seen to have no splicing of the gene during ER stress (Hong and Hagen, 2013). To 
further clarify that this mutation was the reason why the XBP-1 gene did not splice, Hong et al 
(2013) created a rescue mutant by mutating the complementary base of the mutant nucleotide to 
the original wild type. Upon ER stress by thapsigargin, the mutant XBP-1 was observed to be 
spliced (Hong and Hagen, 2013). This illustrated that this alteration prevented IRE1 dependant 
splicing of XBP-1. 
1.3 Autophagy 
1.3.1 Autophagy and the function of autophagy 
Autophagy is an evolutionarily conserved cellular mechanism important for maintaining cellular 
homeostasis in a number of cells (Yang et al., 2011b). The mechanism has the ability to degrade 
cellular organelles and proteins, as well maintain cellular biosynthesis during nutrient deprivation 
or metabolic stress (Yang et al., 2011b). The degradation of such cytoplasmic components occurs 
within the cells lysosomes, the organelles of the cell that are responsible for degrading waste 
materials and cellular debris, facilitated by hydrolase enzymes.  
The very diverse cellular pathway of autophagy can be divided into three pathways that have 
distinguishable characteristics. These three pathways are macroautophagy, microautophagy, and 
chaperone-mediated autophagy (CMA) (Figure 1.2). In the majority of cases, most of the literature 
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associates the name autophagy with macroautophagy. The primary function of macroautophagy is 
the elimination of damaged cell organelles or unused/damaged proteins (Mizushima et al., 2002, 
Mizushima, 2007). This is achieved by the formation of a double membrane around the organelle 
known as an autophagosome, before being degraded. Microautophagy however, is a non-selective 
lysosomal degradative process, which directly engulfs cytoplasmic material by autophagic tubes 
through both invagination and vesicle scission into the lumen (Li et al., 2012). Microautophagy 
has also been shown to coordinate with and complement the macroautophagy pathway, and CMA 
(Li et al., 2012). CMA is the most complex autophagic pathway of autophagy. Very specific, the 
CMA pathway degrades specific cytosolic proteins through a chaperone protein complex that 
delivers the protein substrates to a lysosomal membrane-bound protein (pathway discussed in 
further detail in a later section) (Bandyopadhyay et al., 2008). 
Through a number of studies, autophagy has been identified to have a variety of 
pathophysiological and physiological roles of importance. Instances of autophagy being involved 
in cellular responses are seen in starvation adaption, intracellular protein and organelle clearance, 
development, anti-ageing, microbial destruction, apoptosis, tumour suppression, and antigen 
presentation (Mizushima, 2007) (Chen et al., 2015) (Lapierre et al., 2015). The macroautophagic 
pathway is the most understood autophagic pathway of the three. Cytoplasmic components such as 
proteins and cellular organelles such as the mitochondria are degraded by macroautophagy that is 
first engulfed by an isolation membrane (Mizushima et al., 2002). The isolation membrane, 
resembling a membrane sac structure, surrounds the cytoplasmic debris to form an autophagosome, 
a double structured membrane enclosed structure (Lapierre et al., 2015). Once formed, the 
autophagosome fuses with endosomes that eventually results in the fusion between a lysosomes 
outer membrane with the autophagosome (Mizushima et al., 2002). Lysosomal hydrolase enzymes 
degrade the cytoplasmic contents, along with the inner membrane of the autophagosome (Perera 
and Zoncu, 2016). The degraded macromolecules are then released into the cytosol. 
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  Figure 1.2: The three types of autophagy.  
1.3.2 Regulation of autophagy  
Autophagy is activated by numerous cellular processes/events, as well divided into three 
distinctive pathways. Therefore, the regulation of autophagy is a complex process. Nonetheless, 
the pathways regulation for each cellular process/event appears to be linked to a variety of 
different proteins specific for each. This is why a large number of regulators have been identified 
and associated with regulating the pathway. For instance, amino acid depletion in mammals has 
been shown to have a strong influence on inducing macroautophagy (Mizushima, 2007). It is 
thought that a tRNA binding protein kinase, GCN2 (general control nonderepressible 2), is a 
possible sensor in detecting depleted amino acid levels (Mizushima, 2007). However, additional 
findings have also found that class III phosphatidylinositol 3 (PI3)-kinase  (PI3K) and Beclin 1 are 
capable of detecting changes in amino acid concentrations, also regulating the autophagy pathway 
(Nobukuni et al., 2005) (Byfield et al., 2005). Despite this however, autophagy regulation via 
amino acid regulation still remains to be clarified. Some evidence does support claims that the 
endocrine system is able to influence autophagy. For instance, the regulation of autophagy within 
the liver is seen to be regulated by insulin and glucagon levels, as it was identified that glucagon 
increased autophagy activity, while insulin resulted in autophagy suppression (Mizushima, 2007) 
(Tasset and Cuervo, 2016). Drosophila genetic studies have also been able to demonstrate the 
physiological importance of hormone signalling in autophagy regulation, with autophagy able to 
be hormonally induced through the PI3K pathway (Scott et al., 2004) (Rusten et al., 2004).  
While it is accepted that autophagy can be regulated through the endocrine system hormonally via 
the PI3K pathway, it still remains debated in which proteins are directly responsible for regulating 
autophagy in response to various other stimuli. However, it is widely accepted that the mammalian 
target of rapamycin (mTOR) is a key and central regulator in response to nutritional alterations 





















synthesis (Yang et al., 2005, Pattingre et al., 2008). The mTOR protein is a 280 kDa 
serine/threonine protein kinase, which is a part of the phosphatidylinositol-related kinases (PIKK) 
family (Pattingre et al., 2008). It is also composed of two signalling complexes, mTORC1 and 
mTORC2. The rapamycin sensitive protein also contains a catalytic carboxy-terminal domain that 
shares a resemblance with the catalytic domains of phosphatidylinositol-3 and 
phosphatidylinositol-4 (Pattingre et al., 2008). The protein is considered as a gate-keeping protein 
in autophagy regulation, through an inhibitory manner.  This is believed to be able to occur 
through two regulatory mechanisms. The first mechanism, mTOR performs in a signal 
transduction cascade through various downstream effectors to control transcription and translation 
(Cardenas et al., 1999). The second mechanism, through a direct or indirect interaction with 
autophagy related (Atg) proteins, causes an inhibitory effect, preventing autophagosome formation 
(Yang et al., 2005). Phosphorylation of the Atg13 protein reduces the interaction between it and 
serine/threonine protein kinase 1 (ULK1), preventing the formation of a trimeric complex, ULK 
kinase complex, which necessary for autophagosome formation (Yang et al., 2011b).  
1.3.3 Chaperone – mediated autophagy (CMA) 
As mentioned previously, the CMA pathway differs from macroautophagy and microautophagy, 
as CMA targets and degrades specific cytosolic proteins in a controlled manner by chaperoning 
single substrate molecules to the lysosome to be degraded (Bandyopadhyay and Cuervo, 2007). 
For proteins to be degraded, each protein must first be translocated across the lysosomal 
membrane into the lysosome by a chaperone complex (Kon and Cuervo, 2010). Once within the 
lysosome, a number of enzymes are able then to degrade the chaperoned substrate (Kon and 
Cuervo, 2010). Like other autophagic pathways, CMA is capable of degrading proteins in 
instances of nutrient deprivation, as well capable of degrading damaged proteins and providing 
protein quality control (Tasset and Cuervo, 2016). However, two distinctive features that 
distinguish it from the other two autophagic pathways is the ability to selectively and individually 
degrade proteins. The second characteristic is that all target proteins must first undergo complete 
unfolding prior to being translocated across the lysosomal membrane, which deviates from other 
autophagic pathways where proteins are engulfed in a phagophore, and is then fused with the 
lysosome, instead of being translocated (Kon and Cuervo, 2010). 
The pathways specificity to recognise and target specific substrates is achieved through its ability 
to recognise an amino acid motif within substrate proteins (Kon and Cuervo, 2010).  The motif is 
a peptide sequence, similar to the KFERQ motif, recognised by a cytoplasmic chaperone/co-
chaperone complex. Approximately 30% of cytoplasmic proteins are believed to contain this motif 
(Dice, 2007), however it has also been suggested that through posttranslational modification, some 
proteins can be modified to include this motif (Gracy et al., 1998) (Zuiderweg et al., 2017). 
Nonetheless, the CMA cytosolic chaperone complex identifies all substrates the CMA pathway 
degrades. The protein within this chaperone complex that is responsible for recognising such 
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substrates is the heat shock conjugate of 70 kDa (HSC70). It has already been established that the 
HSC70 protein is involved in other cellular processes, however its two primary functions within 
the cytoplasmic chaperone/co-chaperone complex is to firstly recognise the target substrate 
through the KFERQ motif and bind to the substrate, as well perform the translocation of proteins 
across membranes (Dice, 2007) (Kaushik et al., 2011b). For this to occur, the HSC70 chaperone 
must first be activated. Its activity is heavily dependant upon the heat shock protein of 40 kDa 
(HSC40). HSC40 regulates the ATPase activity of HSC70 by ATP hydrolysis within the N-
terminal domain (Dice, 2007). By hydrolysing ADP to ATP, a conformational change occurs in 
the C-terminal peptide-binding domain of HSC70 (Li et al., 2009). This conformational change 
results with the peptide-binding domain to develop an “open” conformation, allowing substrate 
binding (Li et al., 2009). To return HSC70 to its inactive state, the hydrolysis of ATP to ADP in 
the N-terminal domain results in a “closed” conformation of the protein (Li et al., 2009). The 
cytoplasmic chaperone/co-chaperone complex is also further composed of an HSC70 interacting 
protein (hip) that facilitates the formation of the two proteins HSC70 and HSC40, along with the 
protein substrate (Majeski and Dice, 2004). An additional protein, heat shock protein of 90 kDa 
(HSC90), is also responsible for preventing protein aggregation or refolding of unfolded proteins 
(Dice, 2007) (Cuervo, 2010). It is coupled to hsc70 by an hsc70-hsc 90-organiser protein (Hop) 
(Bandyopadhyay et al., 2010).  The final remaining protein within the complex is the Bcl2- 
associated athanogene-1 (bag-1). The function bag-1 is involved with, is uncoupling the binding 
of substrate proteins from the ATPase binding domain of hsc70 (Majeski and Dice, 2004) 
(Bandyopadhyay et al., 2010).   
As previously mentioned, the CMA pathway has the ability to rapidly degrade a number of 
proteins in response to an array of protein degrading stimuli. However, it still remains difficult to 
determine which stimuli takes precedence over other protein degrading stimuli when detected.  
While still not certain, there is growing evidence that suggests that cellular conditions may 
prioritize what protein degrading signals are acted upon first (Kon and Cuervo, 2010). 
Nonetheless, the binding of the substrate by the chaperone/co-chaperone complex is identical in 
all instances. As discussed earlier, a substrate target molecule is recognised by the chaperone/co-
chaperone complex. After the binding of the chaperone/co-chaperone complex to the substrate, the 
substrate is translocated to the lysosomal membrane. It is believed that certain factors within the 
chaperone/co-chaperone complex contribute to substrate unfolding (Agarraberes and Dice, 2001). 
Nonetheless, as the substrate protein is delivered to the lysosome membrane, the chaperoned 
substrate is presented to the lysosome-associated membrane protein variant 2A (LAMP2A).  One 
of three splice variants of the LAMP2 gene, LAMP2A facilitates not only substrate binding to the 
membrane, but it also enables the translocation of the substrates into the lumen of the lysosome 
for degradation (Kon and Cuervo, 2010) (Wang et al., 2015). Translocation is facilitated by the 
binding of the substrate to the small cytosolic tail of the LAMP2A protein, which is also 
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accompanied by an HSC70 protein (Kaushik et al., 2011a). The binding of substrates to the 
cytosolic tail of LAMP2A occurs through 4 basic amino acids (KRHH). Once in the lysosome, the 
HSC70 protein is referred to as the luminal form of HSC70 (lys-Hsc70), and results in substrates 
becoming degraded by various lysosomal proteases (Wang et al., 2015).  
1.3.4 LAMP2A and its importance to CMA 
LAMP2A protein is a lysosomal glycoprotein of 45 kDa that is located within the lysosomal 
membrane. The major domain of the protein within the lysosomal matrix is highly N- and O-
glycosylated (Majeski and Dice, 2004). As a result of being heavily glycosylated, the proteins 
molecular mass is increased to 96 - 120 kDa. The protein has also been characterised by having a 
short 12 amino cytosolic tail and is essential in the binding of substrates. This has been 
demonstrated through antibody binding inhibition of the cytosolic tail (Cuervo and Dice, 1996). 
The inhibition of CMA substrate binding using an antibody specific to the KRHH sequence 
prevented LAMP2A binding to the substrate (Cuervo and Dice, 1996).  In the absence of the 
antibody, protein substrates were seen to bind to the cytosolic tail (Cuervo and Dice, 1996). 
LAMP2A and HSC70 are both critical for CMA activity. Lysosomes without lys-hsc70 
(lysosomal residing HSC70), despite possessing LAMP2A are not capable of performing CMA 
(Kon and Cuervo, 2010). However, the importance of LAMP2A can’t be down played, as 
instances where lys-hsc70 is expressed and LAMP2A is knocked down, CMA activity is 
subsequently inhibited (Kon and Cuervo, 2010). In most cells the activity of CMA is directly 
proportional to the expression of LAMP2A, as its expression is the rate-limiting factor in the 
pathways activity (Dice, 2007) (Kon and Cuervo, 2010). LAMP2A expression levels are not fixed 
at a certain expression level, but instead change in expression to accommodate the cells needs, 
reflecting CMA activity (Kon and Cuervo, 2010). The expression and degradation of LAMP2A 
also fluctuates within cells according to the protein substrate levels (Cuervo and Dice, 2000). For 
example, instances where nutrient starvation occurs, levels of the LAMP2A protein in the 
lysosomal membrane are seen to increase by inhibiting LAMP2A protein degradation within the 
lysosomal membrane (Cuervo and Dice, 2000) (Kon and Cuervo, 2010). Instances of oxidative 
stress stimulating stimuli, LAMP2A expression is observed to increase through an alternative 
mechanism, whilst also being coupled with increased de novo synthesis (Kon and Cuervo, 2010). 
The signalling stimulus, which triggers the increase in de novo synthesis, is still undetermined, 
though is believed likely to occur through a different signalling cascade. This still remains to be 
proven, but it has been considered as a possible theory. 
Expression of the LAMP2A protein has been found to decline with age, with its expression found 
to decline in senescent fibroblasts and in livers of aged rats (Dice, 2007). Moreover, a decline in 
LAMP2A protein expression has also been identified within peripheral leukocytes isolated from a 
small ageing cohort of humans (Huang et al., 2012). Within ageing rat livers, mRNA levels of 
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LAMP2A remain unaffected by increasing age (Kiffin et al., 2007). The same study did however 
find that protein expression levels of lysosomal LAMP2A were substantially reduced within 
ageing rat livers (Kiffin et al., 2007). Further investigation has found that a defect in the 
reinsertion of LAMP2A into the lysosome was the reason for decreased levels of LAMP2A. Age-
related alterations to lysosomal membranes have been shown to be the direct cause for decreased 
CMA activity, though not through downregulation of LAMP2A transcription (Kon and Cuervo, 
2010). Nonetheless, during oxidative stress LAMP2A gene expression has been shown to increase 
(Dice, 2007), though the expression, or the role of CMA in plasma cell differentiation and MM 
still remains to be investigated. CMA has however, been shown to regulate T-cell responses 
through the targeted degradation proteins responsible for suppressing T-cell activation, 
maintaining activation-induced responses (Valdor et al., 2014).  
1.3.5 CMA regulation 
To date, we know that the regulation of the CMA pathway is facilitated through three lysosomal 
proteins, RAC-alpha serine/threonine-protein kinase (Akt), mammalian target of rapamycin 
complex 2 (mTORC2) and pleckstrin homology (PH) domain and leucine-rich repeat protein 
phosphatase 1 (PHLPP1). Akt is a serine/threonine-specific protein kinase shown to have a 
diverse number of roles such as, the metabolism of glucose, cell proliferation, transcription, 
apoptosis and cell migration to name a few (Datta et al., 1997, Sarbassov et al., 2005, Manning 
and Cantley, 2007), while mTORC2 has also known functions in cell growth and proliferation 
(Alessi et al., 2009). The mTORC2 complex is made up of a group of proteins comprised of 
mTOR, rapamycin-insensitive companion of mTOR (Rictor), stress-activated map kinase-
interacting protein 1 (Sin1), mammalian lethal with SEC13 protein 8 (mLST8) and protein 
associated with Rictor (Protor) (Alessi et al., 2009). Both mTORC2 and Akt kinases are known to 
regulate CMA activity by eliciting an inhibitory effect on CMA competent lysosomes, through 
the phosphorylation of the glial fibrillary acidic protein (GFAP) (Figure 1.3). This in turn disrupts 
the dynamics of the CMA translocation complex, which inhibits the pathways activity. Under 
such circumstances, GFAP loses its binding affinity to LAMP2A and consequently becomes 
associated with elongation factor 1 α (EF1α) in the lysosomal membrane (Bandyopadhyay et al., 
2010) (Arias et al., 2015). 
Activation of CMA is mediated through the recruitment of PHLPP1 to CMA competent 
lysosomes (Arias et al., 2015).  Once recruited to the lysosome, PHLPP1 counters the inhibitory 
effect of mTORC2 and Akt by the dephosphorylation of Akt (Arias et al., 2015). This results in 
GFAP no longer being phosphorylated by Akt, facilitating the activation of CMA by GFAP 
associating with LAMP2A, enhancing its stability in the translocation complex (Bandyopadhyay 
et al., 2010).  
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Figure 1.3: Regulation of the CMA pathway.  
Adaptation of the figure published by Arias et al (2015). 
1.3.6 CMA and its relationship with the UPR and cancer 
While links between the UPR and macroautophagy have already been well established (Ogata et 
al., 2006, Hoyer-Hansen and Jaattela, 2007, Verfaillie et al., 2010, Senft and Ronai, 2015, Shapiro 
et al., 2016), links between the CMA pathway and the UPR are yet to be made. Nevertheless, 
CMA has been shown to play an important role in modulating oxidative stress, nutrient starvation, 
eliminating damaged proteins and important in kidney growth (Kaushik and Cuervo, 2006) 
(Kaushik and Cuervo, 2012) (Tasset and Cuervo, 2016). While links between autophagy and 
cancer have been established, the activity and role of autophagy in a number of cancers is still 
widely debated. It is well debated that autophagy activity is decreased in many cancers, though 
many disagree with such claims and argue autophagic activity is increased. To argue either point 
is difficult, as autophagy consists of 3 different subgroups, with each found to have different basal 
levels in a variety of cancers. Macroautophagy has been identified as having tumour suppressor 
characteristics by maintaining genomic stability (Karantza-Wadsworth et al., 2007) (Mathew et al., 
2009). Within mouse models with compromised autophagy, spontaneous tumorigenesis is 
commonly observed, as reduced macroautophagy activity facilitates cell cycle progression, 
inhibits senescence, and supports the accumulation of proteins involved in oncogenesis (Kon et al., 
2011). With reduced macroautophagy activity, tumour cells still require a cellular mechanism, 
capable of managing cellular stress cells are subjected to as a result of high metabolic activity. 
Consequently, it is believed that CMA accommodates the cell, maintaining cellular homeostasis 
and specific metabolic requirements (Kon et al., 2011). Studies have shown that communication 
between the CMA pathway and macroautophagy exist, allowing one pathway to compensate for 
the other (Massey et al., 2006) (Kaushik et al., 2008a, Kon et al., 2011). While a number of 
mechanisms were identified in linking macroautophagy with CMA, the specific role of each 
mechanism in this process is still yet to be explored (Kaushik et al., 2008a). 
CMA activity has been shown to be upregulated in a variety of tumours relative to untransformed 
cells, while also promoting tumour proliferation (Kon et al., 2011, Saha, 2012) (Zhou et al., 2016). 
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Several cancer cell lines of different tissue origins have been shown to have consistently higher 
CMA activity compared to untransformed control cells, with approximately a 2.8-fold increase in 
the pathways activity (Kon et al., 2011). Within the same study, these results were also consistent 
within ex-vivo tumours of various tissues. Protein expression levels of LAMP2A varied 
throughout the various tumour types, however LAMP2A protein expression levels were 
significantly higher in all tumour tissues relative to the surrounding healthy tissue (Kon et al., 
2011). From this, it was concluded that CMA was upregulated in a number of cancer cell lines, as 
well in transformed cells; with the protein expression of LAMP2A increased in human tumours 
(Kon et al., 2011). Interestingly within the same study, normal healthy cells were found to respond 
to CMA blockades by upregulating macroautophagy, while within tumour cells, CMA inhibition 
was identified having no effect on the activity levels of macroautophagy (Kon et al., 2011). These 
results are also consistent with those found in pancreatic ductal adenocarcinomas (PDAC) with 
high autophagic activity (Yang et al., 2011a). Autophagy was also critical for continued malignant 
growth of PDAC in both in-vivo and in-vitro experiments (Yang et al., 2011a). 
It is likely that particular autophagic mechanisms, such as CMA, are possibly altered during the 
early stages or later stages of cancer development, acting as a protective mechanism against 
cellular stress. For instance, MM is a malignancy that characteristically produces excessive levels 
of paraprotein, which causes increased levels of ER stress upon the cell. In addition to this, MM 
patients that are resistant to Bz have been identified to have reduced UPR activity, a mechanism 
responsible for the management of unfolded and/or misfolded proteins, restoring cellular 
homeostasis (Ling, 2009) (Ling et al., 2012). Reduced UPR activity is known to result from low 
expression levels of XBP-1, a key regulator of the UPR (Ling et al., 2012). Consequently it is 
possible that CMA alleviates ER stress upon the cell caused by accumulating unfolded protein, as 
both the UPR and autophagy have been previously linked (Hoyer-Hansen and Jaattela, 2007). 
Evidence to suggest this is that CMA is commonly increased in a number of cancers (Kon et al., 
2011) and is responsible for the degradation of soluble proteins (Dice, 2007). Considering that 
paraprotein are immunoglobulin fragments, and immunoglobulins are a soluble protein (Alberts et 
al., 1994), it seems probable that CMA is an important stress mechanism in Bz resistance used to 
regulate paraprotein levels. Some evidence has suggested that myeloma cells rely on 
macroautophagy as a mechanism to modulate cellular stress (Hoang et al., 2009). Some studies 
have also demonstrated that autophagic inhibitors are effective against MM (Yang et al., 2011b) 
(Roy et al., 2016).  
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1.4 Drug therapies for MM 
1.4.1 Past, present and novel drug therapies 
As time has progressed, the treatment of MM has changed dramatically, as a result of advances 
made in the understanding of the malignancy, and development of new drug for the disease. As 
new therapeutic agents become available, they are used in combination with previous treatments 
in hope of better outcomes. Nevertheless, the disease still remains incurable, with current therapies 
only controlling the disease, minimizing its burden and slowing its progression. 
Upon the introduction of alkylating agents, the survival of patients diagnosed with MM was 
reported to be less than a year. Surprisingly survival periods were dramatically increased by up to 
60% of patients with the introduction alkylating agents in combination with steroids for treating 
MM. The median survival rates were seen to increase to 3 years; with high dose Melphalan still 
used an important treatment in MM patients. High dose Melphalan with autologous stem cell 
transplant rescue remains the standard of care in MM patients who are fit to undertake intensive 
chemotherapy. MM patients deemed suitable for such treatment usually have improved survival 
outcomes. However, like many other cancers treated using alkylating agents, resistance to this 
class of drug eventually develops. In such cases, DNA repair pathways are seen to evolve and 
enable cancers to become more tolerable to alkylation damage (Damia and D'Incalci, 1998). The 
development of drug resistance in tumour cells has lead to the development and use of alternative 
treatments to manage MM. One alternative class of drugs that have been and is still being used is 
anthracyclines. With up to seven cytotoxic properties, anthracyclines effectively bind to DNA, as 
well inhibit RNA and DNA synthesis (Rang et al., 2007). However, anthracyclines most notable 
cytotoxic characteristic is its ability to inhibit the progression of the topoisomerase II enzyme 
(Rang et al., 2007). The function of topoisomerase II enzyme is to relax the DNA double helix 
during replication, by nicking both strands to prevent the daughter strand from becoming 
entangled during mitotic segregation (Rang et al., 2007). Anthracyclines drugs prevent the enzyme 
from resealing the DNA double helix after DNA replication (Minotti et al., 2004). While effective 
in treating MM, drug resistance to anthracyclines eventually develop in MM patients treated with 
these drugs. In addition, the use of these types of drugs produce adverse side effects that make the 
use of anthracyclines less favourable. It is believed that increasing the dose concentrations of these 
drugs would over come drug resistance, however due to the toxicity of these drugs, increased 
concentration of the drug would cause more harm than benefit. The most adverse side effect for 
this class of drug is acute myelosuppression and cumulative dose-related cardiotoxicity, which can 
often cause irreversible cardiomyopathy and possible congestive heart failure (Hortobagyi, 1997). 
Even with recent improvements to the chemical structure of anthracyclines aromatic ring, 
derivatives still produce the same cardiotoxicity, despite improving the drugs therapeutic index 
and activity (Hortobagyi, 1997). For these reasons, this class of drug is not commonly used. 
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Bz was the first proteasome inhibitor approved for clinical use, which has improved the survival 
of MM patients (Chen et al., 2011). The effectiveness of Bz is further enhanced by the 
combination of Bz with other therapeutic agents. However, like many other drugs used, resistance 
develops in a significant number of MM patients. The boronic acid peptide of Bz interacts with 
the active threonine site of the 26S proteasome (Groll et al., 2006). This selectively and reversibly 
inhibits the chymotryptic protease activity of the 26S proteasome, an important organelle for the 
disposal of proteins in cells (Adams et al., 1999). It is thought that disruption of the homeostatic 
cellular environment within myeloma cells, leads to the accumulation of pro-apoptotic proteins 
within myeloma cells, causing the cell to enter apoptosis (Chen et al., 2011). However, like many 
other chemotherapy drugs, resistance develops in the majority of patients. This has led to the 
development of new PIs, such as Carfilzomib and Ixazomib to improve the efficiency of PIs and 
overcome resistance. Carfilzomib is a novel proteasome inhibitor that has a more potent effect 
than Bz, largely attributed to its irreversible inhibitory effect on the chymotrypsin-like activity of 
the proteasome (Ruschak et al., 2011). Promisingly, some Bz resistant MM patients and Bz 
resistant cell lines respond to Carfilzomib treatment (Kuhn et al., 2007). 
Immunomodulatory drugs are thalidomide analogues, which possess anti-myeloma properties to 
combat the disease (Corral and Kaplan, 1999). These classes of drugs modulate the immune 
system, as well are capable of anti-angiogenic, anti-inflammatory and anti-proliferative effects on 
myeloma cells (Dredge et al., 2002). In-vitro results using immunomodulatory drugs have shown 
that these cause the downregulation of important cytokines necessary for MM proliferation. They 
also produce co-stimulatory effects on Natural Killer (NK) and T cells that further aid in 
enhancing anti-MM immune activity (Quach et al., 2010). While both of these features are easily 
seen within in-vitro, this is yet to be completely verified within in-vivo studies (Quach et al., 2010). 
Lenalidomide, a thalidomide analogue, in combination with dexamethasone treatment lead to 
prolonged survival in newly diagnosed and relapsed MM patients (Weber et al., 2007). PIs and 
Immunomodulatory drugs have become the standard backbone for the treatment of MM patients. 
Other classes of anti-cancer drug have been explored in MM including monoclonal antibodies, 
Histone deacetylases (HDAC) inhibitors, checkpoint inhibitors, chimeric antigen receptor (CAR) 
T- cells, and B-cell lymphoma 2 (BCL-2) inhibitors, such as Venetoclax. 
Histone deacetylases are important enzymes necessary for the regulating of gene expression 
within eukaryotic cells epigenetically. Their most crucial role however, is to regulate genes 
associated with cell survival and proliferation. Preclinical trials have already revealed positive 
results using HDAC inhibitors. Hideshima et al (2013) found that not only do these types of drugs 
target their expected targets, but they also caused hyperacetylation of non-histone proteins 
involved in regulating cell growth and survival (Hideshima and Anderson, 2013). In addition, Cea 
et al (2012) reported that HDAC inhibitors could be used in combination with other anti-MM 
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agents, such as Bz, to further improve treatment effectiveness (Cea et al., 2013). The early results 
have lead to clinical trials using HDAC inhibitors in combination with Bz.  
While it appears that there is a noticeable trend occurring that once resistance to the latest 
therapeutic drug develops (in MM), an alternative therapeutic agent is developed to continue to 
fight the disease. However, now this trend appears to be broken, with research now investigating 
monoclonal antibodies to treat the disease and to also treat relapsed MM patients. Over the recent 
years, a total of seven monoclonal antibodies have been developed against MM (Yang and Yi, 
2011). These antibodies aim to target not only tumour cells but also tumour microenvironments. 
They further aim to target components of bone marrow milieu that support myeloma cell growth 
and survival also (Yang and Yi, 2011). Elotuzumab is a human immunoglobulin G1 
immunostimulatory monoclonal antibody, targeting the signalling lymphocytic activation 
molecule F7 (SLAM F7) (also known as CS-1). SLAM F7 is a glycoprotein expressed on the 
surface of NK cell and myeloma cells, though not expressed on any other healthy tissue, with 
reduced effect in surrounding tissue (Lonial et al., 2015). In one study, 97% of the MM patient 
cohort displayed high expression levels of SLAM F7 mRNA and protein (Tai et al., 2008). Within 
the sera of the MM patients analysed, very little SLAM F7 was detected, while also being 
undetectable within the healthy population (Tai et al., 2008). The antibody directed against SLAM 
F7, HuLuc63, was found to induce antibody-dependent cellular cytotoxicity (ADCC) against 
myeloma cells (Tai et al., 2008). Surprisingly, HuLuc63 triggered autologous ADCC against 
primary myeloma cells that had been resistant to conventional or novel therapies (Tai et al., 2008). 
In combination with conventional or novel anti-MM drugs, HuLuc63 was found to further 
enhance HuLuc63-induced MM cell lysis (Tai et al., 2008) (Yang and Yi, 2011). While these 
early results are promising, such treatments are still awaiting clinical trial.  
Daratumumab is another monoclonal therapeutic, targeting a unique CD38 epitope which is 
specific to lymphoma and myeloma cells (de Weers et al., 2011). CD38 is uniformly and highly 
expressed on myeloma cells, while having relatively low levels on healthy lymphoid and myeloid 
cells (Lokhorst et al., 2015). The targeting of CD38 positive tumour cells by Daratumumab 
promotes cell death through a number of different mechanisms. Such mechanisms include 
antibody dependant cell death, complement-mediated cell death, antibody mediated cellular 
phagocytosis, and the inhibition of the enzymatic activity of CD38 (Lokhorst et al., 2015). 
Daratumumab still remains in clinical trials (Sherbenou et al., 2017). 
The implementation of monoclonal antibodies to treat MM has lead to the development of a 
number of CAR T-cells. CAR T-cells are genetically modified T-cells that recognise and target a 
specific antigen. The chimeric antigen receptor is comprised of artificially fused proteins 
consisting of the antigen recognition domain and T-cell signalling domains (Mikkilineni and 
Kochenderfer, 2017). Different from conventional chemotherapies, this novel therapy is a cell 
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based therapy that targets a specific cell surface antigen, and have little to no off target side effects, 
unlike many chemotherapies. Currently, CAR T-cells targeting CD138, CD38, SLAM F7 and 
BCMA have entered preclinical and clinical trials to treat MM. The best response reported in a 
phase I clinical trial that used CD138 CAR T-cells was 4 patients having stable disease 
(Mikkilineni and Kochenderfer, 2017). Despite the expression of CD138 on salivary glands, liver 
and skin, the clinical trial found no epithelial toxicity, while CAR T-cells were detected for up to 4 
weeks (Mikkilineni and Kochenderfer, 2017).  
One other study has investigated the effects of CD19 CAR T-cells targeting proposed cancer stem 
cells in MM patients (Garfall et al., 2015). Myeloma cells are mostly CD19-, with very few cells 
expressing the surface marker (Garfall et al., 2015). However, it is believed that following 
autologous stem cell transplantation, infusion of CD19 CAR T-cells would eliminate residual 
cancer stem cells, as CD19+ cells have been detected amongst bone marrow plasma cells of 7 out 
of 9 MM patients analysed (Garfall et al., 2015). 
Preclinical trials using SLAM F7 CAR T-cells have successfully eradicated MM in mouse models 
(Hsi et al., 2008) (Chu et al., 2014), and are favourable over other MM CAR T-cells, as SLAM F7 
is only expressed on plasma cells and NK cells, whilst absent on non-haematological cells. 
However, the more favourable CAR T-cell to treat MM is the B-cell maturation antigen (BCMA) 
CAR T-cells. The BCMA antigen is only expressed on some B cells, normal plasma cells, and 
myeloma cells, whilst not being expressed by hematopoietic stem cells and non-haematological 
cells (Hsi et al., 2008) (Chu et al., 2014). BCMA CAR T-cells have successfully killed primary 
myeloma cells in vitro and in vivo mice models (Ali et al., 2016). In one clinical trial, the infusion 
of high dose BCMA CAR T-cells into one MM patient with an advance stage of the disease 
resulted in a significant reduction in bone marrow plasma cell numbers, from 90% to undetectable, 
while also entering complete remission for 17 weeks (Ali et al., 2016). 
Venetoclax, a Bcl-2 inhibitor, is being trialled as a MM therapy. Venetoclax works by inhibiting 
the Bcl-2 protein, which has an anti-apoptotic function in a number of haematological 
malignancies (Ashkenazi et al., 2017). The trial of venetoclax on 66 refractory MM patients 
resulted in an overall responsive rate of 21% (14/66), with an outcome of a very good partial 
response (VGPR) or better (Kumar et al., 2017).  
Research is still being conducted to further develop better and improved treatments against MM, 
as well further our understanding about the disease. With current advancements in both fields, 
researchers are now beginning to explore different methods in treating the disease, different to 
those of conventional methods, for example immune-based approaches, with promising results. It 
is hoped that in future these uprising treatments, coupled with current therapeutic agents and 
disease management therapies like stem cell therapy can finally defeat the MM malignancy. 
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Furthermore, understanding the mechanism of resistance and sensitivity enables design of therapy 
or targets that maximise efficacy and minimise the development of resistance.
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1.4.2 Bz resistance in MM 
Bz was the first PI to be approved for clinical use and has improved the survival of MM patients 
significantly by 4 - 6 years since its introduction (Chen et al., 2011). The effectiveness of Bz is further 
enhanced by its combination with a number of other therapies used to treat MM, with several 
combinations used within the clinic (Kapoor et al., 2012). Bz selectively and reversibly inhibits the 
chymotryptic protease activity of the 26S proteasome through the binding of the boronic acid peptide 
to the active threonine site within the 26S proteasome (Adams et al., 1999, Groll et al., 2006). 
However, like many other chemotherapy drugs, resistance develops in the majority of patients. 
The cause of Bz resistance is still poorly understood, however there are a number of mechanism, 
which have been found to contribute to Bz resistance. Acquired Bz resistance has been linked to a 
point mutation within the gene encoding the proteasome b5 subunit (PSMB5), leading to a 
conformational change within the bortezomib-binding pocket (Ri et al., 2010). Cells with the mutated 
PSMB5 subunit display greater resilience against apoptosis induced by Bz, while cells which contain 
the wild-type PSMB5 subunit are more susceptible to Bz induced apoptosis (Ri et al., 2010). 
Resistance could be further attributed to an upregulation of the mutant β5 subunit as identified in 
various Bz resistant cells (Franke et al., 2012). However, in two independent studies, this mutation 
was not identified in patients with refectory or relapsed myeloma (Politou et al., 2006) (Shuqing et al., 
2011). Instead, resistant myeloma cells have been found to possess a higher numbers of active 
proteasomes (Oliva and Cenci, 2014). Sensitive cells on the other hand, having the highest degradative 
workload, displayed the greatest sensitivity to proteasome inhibitors (Oliva and Cenci, 2014). This is 
largely attributed to cells expressing fewer active proteasomes (Oliva and Cenci, 2014). This 
consequently leads to increased vulnerability to proteasome inhibitors. 
Deubiquitinating enzymes (DUBs) are a class of enzymes responsible for the removal of ubiquitin 
labelling from cellular components marked for degradation (Reyes-Turcu et al., 2009). Their role and 
importance has been illustrated in MM, particularly in Bz resistant MM. The DUBs, USP14 and 
UCHL5, promote MM survival and possibly cause Bz resistance by reducing ubiquitinated protein 
levels in myeloma cells (Tian et al., 2014) (Wang et al., 2016). Plasma cells isolated from MM 
patients exhibit high expression levels of both USP14 and UCHL5, while there is no detectable 
expression of these proteins in normal plasma cells (Tian et al., 2014). Inhibiting the deubiquitinating 
activity by a novel 19S regulatory particle inhibitor, b-AP15, in combination with knockdowns of 
USP14 and UCHL5 resulted in a reduction in cell viability and proliferation (Feng et al., 2014). Other 
studies have also found that b-AP15 inhibiting the deubiquitylating activity of USP14 and UCHL5 
triggers apoptosis in MM cell lines in a time-dependent and dose-dependent manner (Liu et al., 2014). 
Similar cytotoxic effects to b-AP15 occur within myeloma cells when treated with an alternative DUB 
inhibitor, Copper pyrithione (CuPT)(Liu et al., 2014).  
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Bz resistance remains to be a complex involvement of a number of pathways responsible for 
manageing ER stress levels attributed to increased paraprotein levels. Therefore, it seems likely that 
there are additional stress mechanisms that could be responsible in contributing to Bz resistance. In 
order to treat MM patients with Bz resistance in in the future, the molecular mechanisms responsible 
in conferring Bz resistance must first be identified and their role in Bz resistant MM understood. In 
doing so, new or improved therapeutic approaches can be developed and subsequently implemented in 
the treatment Bz resistance. 
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Hypotheses and Aims 
The purpose of this project is to improve the current understanding surrounding the molecular 
mechanisms that are responsible for mediating Bz sensitivity and resistance in MM. This project 
specifically aims to further characterise the role of the UPR in mediating Bz sensitivity. This project 
further aims to determine the importance of CMA in Bz resistance, whilst also investigating whether 
CMA compensates the UPR in Bz resistant myeloma cells, conferring resistance.  
Hypotheses  
1) Reduced dependence on the UPR, reflected by decreased UPR activity, mediates Bz resistance 
in myeloma cells. 
2) Polymorphisms within or upstream of the splice site of the XBP-1 gene that prevent XBP-1 
splicing are associated with primary Bz resistance.  
3) CMA compensates the UPR in Bz resistance, by acting as compensatory stress mechanism 
responsible for alleviating ER stress. 
4) The inhibition of CMA will reduce the viability of myeloma cells, while also sensitising 
resistant cells to Bz. 
Aims 
1. Profile ATF6 mRNA expression in ex-vivo MM patient samples and in an in-vitro Bz resistant 
cell line model, and correlate findings to Bz sensitivity and clinical responses. 
2. Investigate ER size morphology within an in-vitro Bz resistant cell line model to study UPR 
activity in Bz resistance using electron microscopy and live cell imaging. 
3. Perform Sanger sequencing on ex-vivo patient samples to determine if SNPs occurring 
upstream of or within the splice site of the XBP-1 gene is associated with Bz resistance in 
MM.  
4. Analyse CMA activity in ex-vivo MM patient samples and in an in-vitro Bz resistant cell line 
model, and determine if CMA is increased in Bz resistant MM. 
5. Determine the effect of CMA inhibition on the viability of myeloma cells. Further characterise 
the effects of CMA inhibition on sensitising resistant cells to Bz. 
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2. Methods and Materials  
2.1 Cell line culturing and storage 
Myeloma cell lines, KMS-11, U266, RPMI 8226 and OPM-2 were provided by Dr Silvia Ling and 
were cultured using RPMI - 1640 culture medium (Sigma) supplemented with 10% foetal bovine 
serum (FBS) (Gibco), 5% L-Glutamine (Sigma) and 1% penicillin streptomycin (PenStrep) (Sigma) 
(referred to as media, unless stated otherwise) and were cultured at 37°C in a 5% CO2 atmosphere. 
KMS11 bortezomib resistant cells had been developed by Dr Silvia Ling and were cultured in the 
presence of bortezomib (Selleckchem PS-341) as previously described (Ling et al., 2012). In brief, Bz 
resistant KMS11 cells were developed by exposing KMS11 cells to Bz continuously in culture, with 
fresh Bz added to RPMI-1640 medium following passaging (Ling, 2009). The concentration of Bz 
was increased by 2-fold until thoroughly adapted and tested by cytotoxicity assays (Ling, 2009). It 
typically required 3-5 passages at each concentration before increasing Bz concentrations. Stability of 
resistance was also tested by passaging resistant cell lines without bortezomib for 4 to 5 passages 
(Ling, 2009). Adherent cells were harvested with a 0.25% Trypsin/EDTA solution (Sigma) following 
a PBS wash.  
Harvested cell pellets were split and cryopreserved in storage medium to maintain a low passage 
number. Storage medium was composed of 70% culture medium, 20% FBS and 10% 
dimethylsulfoxide (DMSO). Cyropreserved cells were stored overnight at - 80°C, then transferred to 
liquid nitrogen for long-term storage. Remaining cell pellets were either re-cultured in culture media 
or processed for downstream applications. 
2.2 Collection and processing of multiple myeloma patient 
samples  
Forty-nine bone marrow aspirate samples were collected from MM patients prior to the treatment with 
Bz. Written and informed consent was obtained and approved by South Western Sydney Local Health 
District Human Research Ethics Committee (project number 12/151). Bone marrow mononuclear cells 
were isolated by density centrifugation using Ficoll-Paque Plus (GE Healthcare) at 400 g for 35 min at 
20°C, washed twice with PBS containing 2 mM EDTA (centrifugation at 300 g for 10 min at 20°C) 
and cryopreserved at -180°C for cell sorting. Myeloma cells from patient samples were isolated by 
flow cytometry using APC-conjugated CD38 antibody and PE-conjugated CD138 antibody. Myeloma 
cells were isolated using a two laser fluorescence-activated FACSAria III cell sorting system (BD 
Biosciences). Prior to sorting, all samples were thawed and washed with 3 ml PBS and centrifuged at 
1500 rpm for 5min. Cells in 60 µl of suspension (1x105 - 1x106) were then incubated with 15 µl of PE-
conjugated CD138 antibody (A40316, Beckman) and 15 µl of APC-conjugated CD38 antibody 
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(340439, BD Biosciences) on ice (protected from light) for 30 minutes. Following incubation, samples 
were washed with 3 ml of PBS and centrifuged at 1500 rpm for 5 minutes.  For each sample, 15 µl of 
7AAD solution (555816, BD Biosciences) was added into 60 µl cells on ice and incubated for 10 
minutes, then washed by PBS twice. Cell pellets were suspended in 500 µl of PBS for cell sorting at 
the Flow Cytometry Core Facility of the Westmead Millennium Institute, N.S.W, Australia. Myeloma 
cells that co-expressed CD138 and CD38 were collected. Patient clinical responses to Bz were 
determined by a haematologist following the IMWG uniform response criteria (Appendix I) 
(Rajkumar et al., 2011). 
A total of 66 MM patient bone marrow trephines were obtained from Monash University (kindly 
provided by Professor Andrew Spencer). Of the 66 patients, the cohort consisted of CR/VGPR (n=20), 
PR (n=22), MR (n=11), SD (n=6), and PD (n=7). Trephines samples were collected prior to patients 
undergoing any proteasome inhibitor treatment. Patient clinical responses to Bz were determined 
according to the IMWG uniform response criteria by haematologists following Bz treatment. The 
collection and use of bone marrow trephines were authorised by ethics approval (as mentioned above).  
2.3 Live cell imaging  
KMS11 Bz sensitive and resistant cells were cultured under previously mentioned conditions in 35 mm 
glass bottom culture dishes (Greiner Bio-One) for 24 hours. After 24 hours, the media was aspirated off and 
replaced with fresh culture media without FCS, and incubated with 100 nM of ER-trackerTM Green (Life 
Technologies) at 37°C for 40 minutes. This is a cell permeable stain consistent of a green fluorescent dye 
and glibenclamide that binds to the sulphonylurea receptors of ATP-sensitive K+ channels, which are 
prominent on ER. After incubation, media was aspirated and replaced with regular culture media for 
imaging. Images were captured using the BioStation IM-Q (Nikon Corporation) Time Lapse Imaging 
System. Image analysis was performed using ImageJ 1.46r software to calculate the corrected total cell 
fluorescence (CTCF) Bz sensitive and resistant myeloma cell lines. Mean fluorescent intensity was 
corrected to the area on interest. 
2.4 Electron microscopy  
Using a Morgagni transmission electron microscope (TEM) (FEI, Eindhoven, The Netherlands), rough 
endoplasmic reticulum (ER) luminal widths were measured in KMS11 Bz sensitive and resistant cells at a 
magnification of 40,000x. For each cell type, 10 images of the ER were acquired and the luminal width 
measured at 4 points (widest points) in each image using online calibrated software (AnalySIS v3.0, Soft 
Imaging System GmbH, Germany). The mean of the 40 measurements was then calculated for each sample. 
2.5 RNA extraction and cDNA synthesis 
Total RNA was extracted using TRIzol reagent (Invitrogen), followed by further RNA purification 
using the RNeasy Mini kit (Qiagen) following the manufactures instructions. The quantity of RNA 
 30 
was determined using the Nanodrop 2000C spectrophotometer (Thermo Scientific) at a UV 
absorbance of 260 nm. RNA was synthesised into cDNA using a SuperScript™ III Reverse 
Transcriptase (Invitrogen) kit and random hexamer primers (Invitrogen) following the manufacturers 
instructions. Due to low amounts from cell sorted patient samples, a total of 11 µl of RNA was used 
for cDNA synthesis. 
2.6 XBP-1 sequencing and SNP analysis 
The XBP-1 sequencing primers was designed using NCBI Primer-BLAST software targeting the 
XBP-1 mRNA sequence (NM_001079539.1). Two primer sets were designed to span within the 
coding region of the XBP-1 mRNA for sequencing (Appendix II). Primers 40F and 460R (Primer Set 
1) targeted the first half of the transcript, while primers 441F and 936R (Primer Set 2) targeted the 
remaining section of the XBP-1 transcript. XBP-1 was amplified using the following thermal profile of 
95°C (5 min), 40 cycles of 95°C (20 sec), 62°C (20 sec), 72°C (20 sec), and followed by a final 
extension of 72°C (5 min).  Reactions for both primer sets were composed of 10 µl of KAPA2G 
Robust HotStart ReadyMix (2x) (KAPA Biosystems), 1 µl of forward (40 µM), 1 µl reverse primer 
(40 µM), 1 µl of cDNA, and 7 µl of RNase free water. All reactions were run on a C1000 Thermal 
Cycler (BIORAD). PCR products were loaded (2.5 µl) onto 1.5% agarose gels (Promega) containing 
GelRed (Biotium), along with 2 µl of pUC19/HpaII DNA Molecular Weight Marker (GeneWorks). 
The running of gel electrophoresis was performed in 1x TBE buffer (Amresco) for 45 minutes at 90 
volts. Gels were imaged using GelDoc-It™ TS310 Imaging system (UVP).  
Prior to sequencing, PCR reactions were subjected to a DNA clean up using a DNA clean and 
concentrator™ kit (Zymo Research) following the manufactures instructions and eluted with RNase 
free water. Samples were sent to Australian research genome facility (AGRF) at the Westmead 
Millennium Institute, N.S.W, Australia.  Sequences were analysed using Sequence Scanner Software 2 
(Applied Biosystems), and SNPs analysis was performed using Sequence Scanner Software 2.0 
(Applied Biosystems). 
2.7 Amplicon extraction and purification from agarose gels 
PCR amplicon fragments were excised from 1.5% agarose gels under UV light and purified using the 
GenElute Gel Extraction kit (Sigma) following the manufactures instructions. Amplicons were eluted 
into TE Buffer (provided). 
2.8 Quantitation of ATF6 gene expression by Real-time PCR 
ATF6 gene expression was quantified on the Rotor-Gene Q (Qiagen), using the standard curve method. 
ATF6 was normalised to the house keeping gene β-actin for each sample. The following primer 
sequences were used to target each transcript; ATF6 Forward: AATCCGCTTGTCAGTCTCGC (exon 
8) and Reverse: GCCTCTGGTTCTCTGACACA (exon 8/9 boundary), β-actin Forward: 
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AATCTGGCACCACACCTTCTAC (exon 3) and Reverse: ATAGCACAGCCTGGATAGCAAC 
(exon 4). All samples were run in triplicate and with each reaction consisting of 10 µl of KAPA 
SYBR® FAST qPCR Kit Master Mix (2X) Universal (KAPA Biosystems), 1 µl of forward and 1 µl 
reverse primer, 1 µl cDNA, 7 µl of nuclease free water (Geneworks). The following thermal profile 
was used: after an initial activation step of 95°C (5 min), reactions were amplified over 40 cycles for 
95°C (10 sec), 63 °C (15 sec) and 72°C (15 sec). A serial dilution of control cDNA was used as the 
template for each standard curve. Melt curve analysis was performed on all samples to confirm 
product specificity. The copy number for ATF6 and β-actin was calculated for each sample using the 
URI Genomics & Sequencing Centre copy number formula. For each sample, ATF6 was normalised 
to β-actin. Each run included no template controls in duplicate. 
2.9 Quantitation of LAMP2A gene expression by Real-time PCR 
LAMP2A gene expression was quantitated by Real-time PCR on the Rotor-Gene Q (Qiagen) using 
gene specific primers as used by Cacciottolo et al (2013); Forward: CAGCTCAAGACTGCAGTGC 
and Reverse: ATGATGGTGCTTGAGACCA. LAMP2A was normalised against the GAPDH 
housekeeping control for each sample, and the relative gene expression calculated using the ΔΔCt 
Method (Livak and Schmittgen, 2001). Reactions comprised of 10 µl of KAPA SYBR® FAST qPCR 
Kit Master Mix (2X) Universal (KAPA Biosystems), 1.5 µl cDNA, 0.6 µl forward and 0.6 µl reverse 
primer (4 µM) for LAMP2A or 0.4 µl GAPDH QuantiTect Primer Assay (Qiagen - QT01192646) and 
made to reaction volumes of 20 µl with nuclease free water (Geneworks). Reactions were prepared in 
triplicate and amplified using a thermal cycling profile of 95°C (5 min), followed by 40 cycles of 95°C 
(10 sec), 61°C (30 sec). Melt curve analysis was performed on all samples to confirm product 
specificity. Each run included no template controls in duplicate. 
2.10 Western blotting  
Suspension cells were harvested and pelleted as previously mentioned. Cell pellets were then 
subsequently washed with PBS, and pelleted at 500 x g for 5 minutes. Cell pellets were lysed with 
RIPA buffer (Sigma), containing protease inhibitor cocktail (Sigma) following the manufacturers 
instructions. Cells were left to lyse for 5 minutes on ice, then centrifuged at 8000 x g for 10 minutes at 
4°C. Adherent cells were lysed with RIPA buffer in their culture vessel following the removal of 
culture media and washing with PBS. Protein concentrations of samples were determined using a 
Pierce Coomassie Protein Assay Kit (Thermo Scientific), following the manufactures instructions. For 
each sample, 30 µg of protein was denatured at 95°C for 5 minutes in 4x Laemmli sample buffer 
(BIORAD). Samples were then separated by SDS-PAGE on 4-20% Mini-PROTEAN TGX Precast 
Gels (BIORAD) for 80 minutes at 100 V in 1x Running buffer (25 mM Tris-base, 0.1% SDS, 192 mM 
Glycine). Each gel was run with a Precision Plus Protein Standard (BIORAD). Samples were then 
transferred to Immobilon-P 0.2 µm PVDF membrane (EMD Millpore) for 60 minutes in 1x Transfer 
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buffer (20% methanol (v/v), 2.5 mM Tris-base, 19.2 mM glycine) at 100 volts. Membranes were 
blocked in a 5% (w/v) skim milk in 1x TBST (0.5 M Tris-base, 1.5 M NaCl, pH 7.6, 0.1% Tween20) 
for 60 minutes. Primary blotting was performed overnight at 4°C in 5% (w/v) skim milk in TBS 
(Appendix III). Membranes were washed for 5 minutes (x3) in 0.1% TBST, followed by secondary 
blotting for 60 minutes at 4°C (Appendix III), and subsequently washed for 5 minute in 0.1% TBST 
(x3), and once with TBS for 5 minutes. Membranes were treated with Clarity Western ECL Substrate 
solution (BIORAD) for 5 minute prior to imaging using a VersaDoc Imageing System (BIORAD) or 
Licor Odyssey Fc Imageing System (Li-COR) where specified. Protein expression was quantified 
using ImageJ 1.46r software.  
2.11 Immunofluorescence/confocal microscopy of CMA activity 
For each sample, a serum-starved control (18 – 24 hours) was cultured for each experiment to 
maximally activate CMA (Kaushik et al., 2008b). Following the harvesting of cells, cells were washed 
with PBS and pelleted at 500 xg for 5 minutes. Cell pellets were resuspended in PBS, with 10,000 – 
20,000 cells cytospun onto glass coverslips (Thermo Scientific) using a Cytospin 4 (Thermo 
Scientific) at 1500 rpm for 3 minutes. Cells were allowed to air dry briefly before fixing with 50% 
methanol for 2 minutes, then 100% methanol (-20°C) overnight. Upon staining, samples were gradual 
rehydrated with PBS by adding 1:1 volume of PBS:methanol (x3). The fixative was then aspirated and 
coverslips were extensively rinsed with PBS and then washed for 5 minutes with fresh PBS. Blocking 
solution (2% FCS, 0.3 M glycine, 1% BSA, and 0.01% Triton X-100 in PBS) was added to each 
coverslip for 30 minutes, and then briefly rinsed with PBS. Each coverslip was then incubated with 
primary antibodies LAMP2A (1/500) (Abcam) and HSC70 (1/200) (Novus) for 90 minutes diluted in 
1% BSA. No primary antibody negative controls were included for each experiment. Coverslips were 
then subsequently rinsed in PBS and then washed with 0.2% PBST for 5 minutes. Incubation with 
secondary antibodies was performed using anti-Mouse Alexa 488 (Life Technologies) and anti-Rabbit 
Alexa 555 at 1/1000 (Abcam) in 1% BSA for 60 minutes. Coverslips were then rinsed in PBS, and 
then subsequently washed with 0.2% PBST for 5 minute, rinsed with MilliQ water and mounted with 
Prolong Gold Antifade Mountant with DAPI (Applied Biosystems). Slides were sealed and left to cure 
for 24 hours protected from light. Images were captured by confocal microscopy using a Leica SP5 
confocal microscope (Leica Biosystems). Quantification of LAMP2A/HSC70 co-localised puncta 
(CMA active lysosomes) was performed on Z-stack images using ImageJ software (NIH). Co-
localisation analysis and the number of co-localised puncta were performed using the ImageJ JACoP 
Plugin (Bolte and Cordelieres, 2006). Pearson coefficients (r) for the co-localisation of LAMP2A and 
HSC70 on lysosomes were automatically generated using the ImageJ JACoP Plugin. 
2.12 Immunohistochemistry for bone marrow trephines 
Bone marrow trephines were cut at 4 µm sections and mounted on Superfrost Plus slides (Thermo 
Scientific). All immunohistochemical staining was performed using the EnVision FLEX High pH kit 
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(Dako), following the manufacturers protocol with minor modification, unless stated otherwise. All 
sections were preheated at 60°C for 60 minutes, then deparaffinised in xylene for 6 minutes (x3), 
followed by rehydration with 100% (x2), 70% and 50% ethanol, for 6 minutes each, before rinsing 
with water. Antigen retrieval was performed in a water bath set at 98°C for 15 minutes, with sections 
subsequently blocked for 5 minutes, and incubated with primary antibodies. Primary antibodies 
LAMP2A (Abcam) was diluted 1/1000 and CD138 (Thermo Scientific) diluted at 1/50, and allowed to 
incubate for 60 minutes. Secondary antibodies (included in the kit) were incubated for 30 minutes, and 
then incubated with DAB/Chromogen (included in the kit) for 1 minute. Sections were stained with 
haematoxylin solution (Thermo Scientific), washed with water and then treated with Scott bluing 
solution (Thermo Scientific). Slides were then dehydrated with 50%, 70%, 100% (x2) ethanol and 
xylene before mounting with ultra mounting oil (Fronine). Slides were scanned at x40 magnification 
and converted into digital images using the Aperio AT Turbo Pathology Digital Scanner (Leica 
Biosystems). The staining intensity and extent of staining of LAMP2A was scored in CD138 positive 
stained cells of superimposed images for each bone marrow trephine. Scoring was performed blinded 
by 3 independent scorers, 2 of which were haematopathologists. Staining intensity was scored on a 1-3 
scale, 1 = low intensity, 2 = medium intensity, and 3 = high staining intensity. The extent of staining 
was scored on as follows, 1 = 0-25%, 2 = 26-50%, 3 = 51-75%, and 4 = 76-100%.  
2.13 Lentiviral transduction of cells with LAMP2A shRNA 
KMS11 sensitive and resistant cells were cultured following the protocol previously mentioned. On 
day zero, 1 x 105 cells were seeded into 24 well plates and cultured overnight. Cells were transduced 
using MISSION lentiviral transduction particles (Sigma) containing shRNA against LAMP2A, and 
control wells with MISSION shRNA control transduction particles (Sigma – SHC001V) in complete 
culture media containing Hexadimethrine bromide (Sigma) at a final concentration of 8 µg/ml. For 
each cell type, an untreated control well was cultured with culture media without any lentiviral 
particles as a control for puromycin screening.  Target sequences of the shRNA used were LAMP2A-
1: 5’-GACTGCAGTGCAGATGA-3’ (sense) and LAMP2A-2: 5’-
AAGCACCATCATGCTGGATAT-3’ (antisense) as used by Kon et al (2011) (Kon et al., 2011). 
Further information on the construct can be found in Appendix IV. For each well, 3.0 x105 TU 
lentiviral particles were added for each construct. Plates were centrifuged at 2000 rpm for 30 minutes 
at 37°, then cultured for 24 hours. Viral supernatants were aspirated after 24 hours and replaced with 
fresh culture media and cultured overnight to enable the expression of constructs. All cells were then 
cultured in media containing puromycin (Sigma) at a concentration of 3 µg/ml, and screened for 14 
days, replacing media containing puromycin every 3 days. Cells were transferred to T75 flasks once 
confluence was reached in 24 well plates, and cultured to increase cell numbers for downstream 
experiments.  
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2.14 Transfection of cells with siRNA 
Custom designed Stealth siRNA were designed for the knockdown of LAMP2A targeting the isoform 
specific region of the LAMP2A isoform in exon 9. Sequences targeted were as follows 
LAMP2A_Stealth 1: GACTGCAGTGCAGATGACGACAACT (Invitrogen). KMS11 Bz sensitive 
and resistant cells were harvested and pelleted at 200 x g for 5 minutes at room temperature. Pellets 
were suspended in PBS and viable cell numbers counted using trypan-blue exclusion. For each cell 
type, 5.0 x 106  cells were pelleted at 200 x g for 5 minutes and suspended in 400 µl of RPMI media 
containing 10 mM HEPES (Invitrogen) without media supplements and 300 nM of Stealth siRNA. 
Cells were exponentially electroporated in 0.4 cm cuvettes (BIORAD) at 240 volts (960 µF) using a 
Gene Pulser Xcell (BIORAD). Cells were immediately transferred to pre-warmed media before being 
seeded in culture vessels and cultured. Experiments were run in triplicates, with an appropriate Stealth 
RNAi negative control medium GC duplex (Invitrogen) and mock electroporation control.  
2.15 MTS assays 
Cell suspensions were adjusted to 100,000 cells/ml in RPMI culture media without phenol red (Sigma), 
supplemented with 10% FCS, 5% P/S and 5% L-Glutamine. Each well was seeded with 100 µl of the 
cell suspension and cultured overnight. Following the overnight culturing, cells were treated with 
freshly prepared Bz and left to culture for specified time under regular culture conditions. Each assay 
comprised of 3 replicates for each Bz concentration, with each plate also containing 3 blank wells 
without cells. Following the manufacturers instructions, CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay reagent (Promega) was added to each well as instructed by the protocol and 
incubated in a CO2 incubator for 4 hours. Absorbance readings were measured at 490 nm using a 
SpectraMax M2 (Bio-Strategy). Absorbance values were subtracted from designated blank wells. Cell 
viability was calculated as follows: Abs treated samples/Abs untreated control samples x 100.  
2.16 Annexin V apoptosis assays  
Apoptosis was assessed using a PE Annexin V Apoptosis Detection kit (BioLegend). Cell suspensions 
were collected and cells were subsequently rinsed with PBS. The adherent cells were then harvested 
using 2 mM EDTA and then pelleted at 350 x g for 5 minutes. Supernant were aspirated and pellets 
washed with 1000 µl of PBS and centrifuged as previous. After aspirating the PBS, each pellet was 
suspended in 100 µl of Annexin V binding buffer, and 5 µl of both 7-AAD and PE Annexin V. 
Samples were gently vortexed and incubated at room temperature in the dark for 15 minutes. 
Following the incubation period, 400 µl of Annexin V binding buffer was added to each sample and 
then analysed by flow cytometry using a BD FACSCanto II (BD Biosciences). For each experiment, 
the following controls were included in order to identify each cell population, which included an 
unstained control (live population), 7AAD control (necrotic population) and Annexin V control 
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(apoptotic population). Cells used for the 7AAD control were combined with 0.1% saponin in order to 
permeablise the cells. Data was analysed using the BD FACSDiva™ software. 
2.16 Statistics 
All graphs were generated using GraphPad Prism (GraphPad Software, CA, U.S.A) and statistical 
analysis was performed by either an unpaired t test with Welch’s correction student t-test or a one-way 
ANOVA.  
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3. Reduced UPR activity in MM reflects a 
decrease in Bz sensitivity. 
3.1 Introduction 
Highly conserved within eukaryotic cells, the UPR is a cellular response that is critical in restoring 
cellular homeostasis in instances of ER stress. The UPR is activated through any of three 
transmembrane proteins within the ER lumen (Lee and Ozcan, 2014). These proteins, IRE1, PERK 
and ATF6, remain bound in their inactive isoform to the BiP chaperone. It is during the presence of 
unfolded or misfolded protein at levels exceeding the manageable threshold, the BiP chaperone 
dissociates from these proteins and binds to the unfolded and misfolded protein (Lee and Ozcan, 2014). 
In turn, each regulatory protein undergoes a conformational change into their active isoform resulting 
in the activation of the pathway. This subsequently results in the activation of a series of downstream 
protein chaperones and transcription factors responsible for restoring homeostasis (Hetz, 2012). In 
doing so, general gene transcription is reduced, while the transcription of protein folding chaperones 
are increased (Rozpedek et al., 2016).  
One of the most important regulators of the UPR, XBP-1 is a transcription factor that is activated by 
the splicing of a 26 bp intron from XBP-1 mRNA. The splicing of XBP-1 mRNA is predominately 
performed by IRE1, however splicing can be facilitated by ATF6 (Yoshida et al., 2001). Plasma cell 
differentiation is heavily dependent on the expression of XBP-1, and is upregulated during the 
differentiation of plasma cells (Reimold et al., 2001). Abnormalities in the gene and/or expression are 
characteristically identified within a number of diseases, such as Crohn’s disease, inflammatory bowel 
disease and ulcerative colitis (Kaser et al., 2008). Within MM, XBP-1 expression is significantly 
increase in myeloma cells relative to healthy control plasma cells (Davies et al., 2003, Munshi et al., 
2004, Bagratuni et al., 2010), and shown to promote the development of MM in mice when 
overexpressed (Carrasco et al., 2007). The decreased expression of XBP-1 mRNA has also been found 
to mirror Bz resistance, while increased expression is associated with sensitivity to Bz (Ling et al., 
2012).  
Even though XBP-1 expression has been well characterised in MM and Bz resistance, current 
understanding surrounding the UPR in Bz resistance is still poorly understood. ATF6 shares a similar 
function to XBP-1 during UPR activation, and has the ability to splice XBP-1 into its active isoform 
(Yoshida et al., 2001). It is possible that ATF6 expression has similar expression levels as XBP-1. 
Therefore, this chapter aims to improve the current understanding associated with the role of the UPR 
in predicting Bz sensitivity in MM by profiling ATF6 expression in Bz sensitive and resistant MM. It 
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will further determine the significance of ATF6 expression in predicting sensitivity to Bz, by 
correlating these findings with ER size morphology in Bz sensitive and resistance myeloma cells.  
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3.2 ATF6 expression decreases with increasing Bz resistance  
The UPR, in particular the XBP-1 pathway, has been shown to be critical for the functioning and 
survival of myeloma cells (Nakamura et al., 2006) (Carrasco et al., 2007) (Bagratuni et al., 2010) 
(Ling et al., 2012). With the exception of a small subset of patients (1 - 5%), most secrete large 
amounts of paraprotein (Prasad et al., 2009). Due to the excessive paraprotein levels, myeloma cells 
rely heavily on the UPR pathway to manage ER stress. XBP-1 expression has been previously shown 
to be able to predict PI sensitivity in MM patients (Ling et al., 2012). The mRNA levels of both the 
total amount and active spliced isoform of XBP-1 are substantially reduced under increasing Bz 
resistance (Ling et al., 2012) (Leung-Hagesteijn et al., 2013) (Gambella et al., 2014). This inverse 
relationship between XBP-1 expression and Bz resistance levels has been further supported by similar 
results seen in MM cell lines resistant to Bz (Ling et al., 2012). However, XBP-1 is not a direct target 
of Bz, though its expression is possibly a surrogate marker for dependence on the UPR in myeloma 
cells. We therefore aimed to further investigate if other important regulators of the UPR displayed a 
similar trend in expression levels within Bz resistant MM. 
We aimed to investigate the expression of ATF6 mRNA in a Bz sensitive and resistant cell line model, 
and ex-vivo MM patient samples. ATF6 can activate XBP-1 through the mRNA splicing of a 26 bp 
intron from the unspliced isoform into its actively spliced isoform during UPR activation (Shoulders et 
al., 2013). ATF6 mRNA expression has yet to be explored in Bz resistant cell line models or MM 
patients, this is despite protein expression levels of ATF6 being previously shown to decrease as Bz 
resistance increased in MM cell lines (Ling et al., 2012). It is therefore suggestive that decreases in the 
expression of critical regulators of the UPR reflect a decrease in UPR activity and might be able to 
predict Bz sensitivity.  
We assessed ATF6 mRNA levels in a KMS11 Bz resistant cell line model hypothesising that ATF6 
gene expression would predict sensitivity to Bz, with reduced ATF6 expression reflecting decreased 
sensitivity to Bz. ATF6 mRNA levels were quantified by Real-time PCR using a standard curve 
method. ATF6 primers were designed to span exon-exon boundaries to specifically target ATF6 
mRNA transcripts, with ATF6 expression normalised to the house keeping gene β-actin for each 
sample. We found that KMS11 cells resistant to Bz had a trend towards a reduction in ATF6 mRNA 
levels, compared to Bz sensitive cells (Figure 3.1a; p=0.06). Relative to the sensitive cells, ATF6 
mRNA levels were found to decline by 38% in resistant cells. These results support and coincide with 
ATF6 protein levels in Bz resistant cell lines published previously (Ling et al., 2012). Under 
increasing Bz resistance, myeloma cell lines possessed decreasing protein expression levels of ATF6.  
We continued to explore expression levels of ATF6 mRNA within MM patients of varying levels of 
Bz resistance. We hypothesized that the gene expression of ATF6 would substantially decrease in MM 
patients who developed progressive resistance to Bz. ATF6 mRNA levels were quantified in myeloma 
cells purified from 45 patient bone marrow aspirates by Real-time PCR. Bz sensitivity of MM patients 
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following cycle 2 Bz therapy was determined according to the IMWG uniform response criteria by 
haematologists blinded to this study (as described in Appendix I) (Rajkumar et al., 2011). Patients 
classified as having CR/VGPR (n=5) to Bz were the most sensitive to Bz and were assigned to a single 
cohort. Patients that were considered having a PR (n=28) were assigned to the second patient cohort. 
The remaining two patient groups, SD (n=9) and PD (n=3), were resistant to Bz, with PD patients 
classified as having the most resistant phenotype.  
Patients with CR/VGPR (n=5) + PR (n=28) that were sensitive to Bz had significantly higher levels of 
ATF6 mRNA compared to patients with SD (n=9) + PD (n=3), who were resistant to Bz (Figure 3.1b; 
p=0.007). ATF6 mRNA levels were identified being 3.92 fold higher in CR + VGPR + PR patients 
compared to SD + PD patients. On an individual group basis, ATF6 mRNA levels were seen to 
decrease as Bz resistance increased, however the differences between each patient group were of no 
significance. However, we did identify there to be a significant difference between PR patients vs SD 
+ PD patients (p=0.01). ATF6 mRNA levels were 3.1 fold higher in the PR patients than in SD + PD 
patients. We also observed increased variation in the expression of ATF6 mRNA within CR/VGPR 
patients, which was reflected by the increased variation of the S.E.M within CR/VGPR cohort. As 
resistance to Bz increased, variation in the S.E.M appeared to become substantially less, which further 
coincided with reduced ATF6 mRNA levels. This indicated that the variable ATF6 expression 
observed in the Bz sensitive patients reflected a broader UPR activity, suggesting a more functional 
UPR. As Bz resistance increased, ATF6 mRNA expression appeared to be more narrowly distributed 
among the Bz resistant patients, which reflected lower UPR activity. This therefore suggested that 
resistant patients possessed lower UPR activity and that the UPR pathway was less functional in Bz 
resistance. These results further confirmed and supported our findings seen within the KMS11 Bz 
resistant cell line model that ATF6 gene expression decreases as Bz resistance increases, reflecting 
reduced UPR activity. They further strengthen previous findings by Ling et al (2012) that found Bz 
sensitivity is mediated by the dependence myeloma cells have on the UPR (Ling et al., 2012). 
Myeloma cells that have high expression of ATF6 and XBP-1 are more sensitive to Bz, while cells 





Figure 3.1: Real-time PCR quantification of ATF6 mRNA expression in a bortezomib sensitive 
and resistant cell line model and patient samples.  
a) Reduced ATF6 mRNA expression in KMS11 cells resistant (black bar) to bortezomib relative to the 
control bortezomib sensitive cells (white bar). Data are shown as mean ± SEM (n=5; p=0.06, t test). b) 
ATF6 mRNA expression in Multiple Myeloma patients with increasing bortezomib resistance 
according to the IMWG Patient Response Criteria. Complete response (CR) and very good partial 
response (VGPR) patients (n=5) are the most sensitive to bortezomib, followed by partial response 
(PR) patients (n=28). Patients with stable disease (SD) (n=9) or progressive disease (PD) (n=3) were 
relatively resistant to bortezomib. ATF6 mRNA levels decreased with increasing bortezomib 
resistance in Multiple Myeloma patients. Data is shown as mean values ± SEM (n=45). Statistical 
analysis was performed on sensitive patients (groups CR+VGPR and PR) vs resistant patients (groups 
SD and PD) **(p=0.007, t test). There is a statistical difference between PR (n=28) and SD + PD 
patients (n=12) *(p=0.0107; t test). 
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3.3 UPR activity decreases with Bz resistance, reflected by 
reduced ER morphology  
The ER is the organelle which is responsible for the synthesis, folding, modification and quality 
control of most secretory and membrane proteins (Oyadomari and Mori, 2004). The UPR is an 
adaptive cellular and signalling response that enables the cell to manage ER stress levels attributed to 
unfolded and misfolded protein. Therefore, it is possible that the morphological expansion of the ER 
represents increased UPR or dependence on the UPR. Observed in yeast models, ER expansion is a 
contributing factor in ER stress management (Schuck et al., 2009). Under UPR-inducing stimuli, the 
size of the ER is seen to increase by up to 5 fold, in order to accommodate and rectify accumulating 
protein levels within the ER (Bernales et al., 2006). Furthermore, within mammalian secretory cells, 
the expansion of the ER is required for the production and secretion of large protein quantities 
(Capoccia et al., 2011), suggesting that UPR activity is upregulated in myeloma cells through the 
expansion of the ER. XBP-1 and ATF6 have been shown to directly mediate ER expansion (Shaffer et 
al., 2004, Aragon et al., 2012, Kim et al., 2015), with the overexpression of spliced XBP-1 shown to 
increase the production of phospholipids and the expansion of the RER (Sriburi et al., 2004). ATF6 
induces the production of phospholipids and ER membrane expansion, independent of XBP-1 
(Bommiasamy et al., 2009). Therefore, in Bz resistance where ATF6 (shown in this project) and XBP-
1 are downregulated (Ling et al., 2012), it is likely that the ER is smaller and restricted. Through live 
cell imaging using an ER tracker dye and electron microscopy, we examined ER morphology in a 
KMS11 Bz sensitive and resistant cell line model to determine if the size of the ER supported 
molecular findings associated with drug resistance and UPR activity. We hypothesised that cells with 
a high dependence on the UPR would possess a larger ER size, reflecting increased UPR activity 
compared to cells that were less dependent on the UPR and more resistant to Bz.  
We first assessed ER morphology within a KMS11 Bz sensitive and resistant cell line model by live 
cell imaging using an ER tracker dye and a BioStation IM-Q Time Lapse Imaging System. Both the 
sensitive and resistant cells were cultured for 24 hours in 35 mm glass bottom dishes. Cells were then 
incubated with 100 nM of ER-trackerTM Green for 40 minutes in fresh media without FCS under 
standard culture conditions. Following the incubation period, the media containing the ER tracker was 
aspirated and replaced by fresh media for imaging. The ER of cells were visualised by fluorescent 
time-lapse imaging through the binding of glibenclamide (glyburide) to the sulphonylurea receptors of 
ATP-sensitive K+ channels located on the ER. Fluorescent measurements for each cell were 
normalised to the area of fluorescence measured. 
The mean fluorescent intensity of the ER in the resistant cells was found to decrease by 35% (1.35 
fold decrease) relative to sensitive cells (Figure 3.2; p=0.02352). The decrease in fluorescence 
reflected a reduction in ER size within resistant cells. Within sensitive cells, the fluorescent 
measurement range was more widely distributed (range of 144,037 CTCF/U) compared to the resistant 
 42 
cells, which had a tighter distribution in fluorescence measurements (44,856 CTCF/U). The greater 
distribution in ER sizes seen in sensitive cells reflected the increased ability of the ER to expand in 
response to varying protein levels. Resistant cells however, appeared to have a narrower range in 
which the size of the ER could expand. This suggested that the ER expansion capabilities of resistant 
cells were substantially less than the ER seen with the sensitive cells. This indicated that sensitive cells 
had a more functional UPR pathway, while resistant cells had limited functioning or compromised 
UPR.  
To further strengthen and support our findings associated to the size of the ER in Bz sensitive and 
resistant cells, we assessed rough ER (RER) morphology and lumen size by transmission electron 
microscopy. This part of the work was performed with the assistance and supervision of Associate 
Professor Murray Killingsworth and Dr Ken Lai. The RER is responsible for protein translation and 
protein secretion (Mandon et al., 2013). For both the KMS11 Bz sensitive and resistant cells, up to 10 
images of the RER were taken at 40,000x magnification. The RER lumen of each cell was measured at 
the 4 widest points, totalling 40 measurements. Compared to the sensitive cells, the RER lumen widths 
of the resistant cells were significantly narrower (Figure 3.3; p=<0.0001). On average, the RER lumen 
width of resistant cells was 10 nm smaller (24%) than the average lumen width of the sensitive cells, 
reflecting a reduction in the RER lumen size in instances of Bz resistance. Once more, we found that 
the RER measurements of the sensitive cells were broadly distributed (range of 36 nm), with the range 
being substantially greater than those seen in the resistant cells (range of 23 nm). This indicated that 
the expanding capacity of the RER in Bz resistant cells was substantially less than that of sensitive 
cells, reflecting decreased UPR functioning and limited ER expansion. These results further supported 
similar results observed in ER tracker experiments, which suggested reduced UPR function in Bz 
resistant MM which possessed reduced ER size morphology. 
In summary, we can confirm that UPR activity is reduced in Bz resistant MM. Reduced ATF6 
expression was associated with Bz resistance, as seen in Bz resistant cell lines and MM patients, 
which further coincided with the reduction in the size of the ER within in-vitro modelling. This 
supports the hypothesis that Bz resistance is associated with downregulation of the UPR. Together 
with existing knowledge of the UPR and ER biology, it is likely that Bz resistance is associated with 
the downregulation of the UPR, which is regulated by XBP-1 and ATF6. Due to the downregulation 





Figure 3.2: Live cell imaging of KMS11 bortezomib sensitive and resistant cells. 
Representative images of live cell staining of the ER in KMS11 bortezomib sensitive and resistant 
cells (left panel), incubated with 100 nM of ER tracker dye (green). Images were captured at 80x 
magnification. ER fluorescence/area of KMS11 sensitive (n=16) and resistant (n=16) cells (right 
panel) using an ER tracker dye. Data shown as mean of values (centre bar) ± SEM (error bars) *(n=16; 




Figure 3.3: Electron microscopy of ER lumen widths in KMS11 bortezomib sensitive and 
resistant cells.  
Electron microscopy of the ER lumen (shown by arrows) in KMS11 bortezomib sensitive (left panel) 
and resistant cells (right panel). Mean RER lumen widths of KMS11 bortezomib sensitive cells (n 
=10) and KMS11 bortezomib resistant cells (n=10) at 40,000x magnification as measured by electron 
microscopy. Data is shown as mean measurement values ± SEM **(p=<0.0001, t test) (bar and error 
bar). Each dot plot point represents the average of the 4 broadest points measured for each RER lumen. 
Top row scale bar is 500 nm and the bottom panel scale bar is 200 nm. 
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3.4 SNP variations within the XBP-1 gene of multiple myeloma 
patients 
There is a direct correlation between the expression of XBP-1 and Bz sensitivity in MM, as high 
expression levels of XBP-1 are associated with increased Bz sensitivity (Ling et al., 2012). This 
important transcription factor is responsible for the activation of the UPR in response to ER stress, but 
also serves as a very important factor in a variety of other roles, such as plasma cell differentiation and 
organ development (Reimold et al., 2001, Lee et al., 2005). The unspliced XBP-1 mRNA translates 
into an inactive truncated protein, whereas spliced XBP-1 mRNA is translated into an active XBP-1 
transcription factor with a strong transactivation domain (Chakrabarti et al., 2011). Splicing of the 26 
bp intron is mediated by the ER transmembrane endoribonuclease, IRE1 (Shen et al., 2001) (Yoshida 
et al., 2001). Therefore, any compromise to the splicing of XBP-1 could potentially compromise the 
ability of the UPR to deal with ER stress. This is illustrated in a number of diseases where SNPs that 
occur within the gene contribute the diseases phenotype, such as Crohn’s disease, inflammatory bowel 
disease and ulcerative colitis (Kaser et al., 2008). In MM, SNPs have also been found to occur within 
the XBP-1 gene and have also been linked to reduced levels of the spliced XBP-1 isoform (Leung-
Hagesteijn et al., 2013) (Hong and Hagen, 2013). One of two SNPs has been found to occur within the 
splice site of XBP-1, preventing the splicing of unspliced XBP-1 (Leung-Hagesteijn et al., 2013). The 
other occurred within the trans-activating domain of the spliced XBP-1 isoform, which affected the 
tertiary structure, altering transcriptional activity (Leung-Hagesteijn et al., 2013).  
We therefore aimed to assess if SNPs occurring upstream of or within the splice site of XBP-1 is the 
underlining cause of a mutation that might be contributing or causing Bz resistance. We hypothesised 
that SNPs within XBP-1 would occur more frequently in resistant patients with SD or PD, than within 
sensitive patients of CR, VGPR or PR, explaining in particular primary resistance in MM patients. We 
further hypothesised that SNPs within the splice site of the XBP-1 gene would prevent XBP-1 splicing, 
leading to reduced XBP-1 expression and activity seen in resistant patients.  
Using two primer sets spanning the entire CDS (coding DNA sequence) region of XBP-1 mRNA, we 
attempted to amplify and sequence XBP-1 in 49 MM patients. We initially were unable to amplify 
XBP-1 in 32/49 patient samples with either the first or second primer set, despite working positive 
controls. To eliminate the possibility of template degradation within samples, new cDNA was 
synthesised from the remaining RNA stocks of these patient samples. XBP-1 was re-amplified for 
each of the 32 samples, along with β-actin as a positive amplification control. While β-actin and the 
XBP-1 positive control did amplify, no amplification was detected for XBP-1 within any of the 
samples (not shown). As a result, we then attempted to use the 40F/936R primers, spanning the entire 
CDS region to amplify XBP-1. From the 32 samples, 16 failed to yield any product, with the 
remaining 16 samples (50%) yielding an amplicon of ~ 890 bp. Each patient ~ 890 bp product was 
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excised from agarose gels and purified using a gel purification kit. Purified PCR products were then 
re-amplified by PCR using the first and second primer sets. PCR products of both primer sets were run 
on agarose gels, before the products were cut from the agarose gels and purified for Sanger sequencing. 
In total 34/49 samples were sequenced, with XBP-1 unable to be amplified in the remaining 15 patient 
samples.  
From the 34 patients sequenced, only 3/34 patients (6%) were identified in having a SNP within the 
XBP-1 gene (Table 1). Of the 3, none were considered having SD or PD; instead 2/3 was considered 
as having PR to Bz. The response to Bz for the third patient was not evaluable, as the patient was 
deceased prior to receiving a second cycle of therapy (with Bz). Amongst the 3 patients, we identified 
3 different SNPs, all of which were located within different loci of the gene. Each mutation resulted in 
a different phenotypic outcome, ranging from nonsense to a synonymous mutation. The only SNP that 
caused a nonsense mutation, resulting in a premature stop codon, was identified in the patient who was 
deceased prior to receiving the 2nd cycle of Bz. Occurring upstream of the XBP-1 splice site, this 
mutation resulted in a truncated isoform as a result of a nonsense mutation (premature stop codon).  
In summary, we found no correlation between SNPs or mutations occurring within the splicing site of 
XBP-1 and Bz resistance. Although, SNPs that occurred within the splice site of XBP-1 resulted in a 
poor prognosis, the occurrence within the patient cohort was low. The one patient who did possess a 
SNP within the splice site of XBP-1 died prior to undergoing the second cycle Bz therapy. These 
findings coincide and support one previous study, which found that SNPs occurring within the splice 









Table 1: SNPs detected within the XBP-1 CDS region of Multiple Myeloma patients. 
 
Patient Exon Position SNP Amino Acid Outcome 
Patient 8 Exon 3 of CDS 465 ATG à ATA Metà Ile Missense Mutation 
Patient 23 Exon 1 of CDS 255 CCC à CCT Pro à Pro Synonymous Mutation 
Patient 42 Exon 3 of CDS 487 GAG à TAG Glu à Stop Codon Nonsense Mutation 
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3.5 Discussion  
Through Bz sensitive and resistant MM cell line modelling, and the analysis of ex-vivo patient samples 
we were able to identify and show that reduced UPR activity is associated with Bz resistance, and can 
predict Bz sensitivity in MM. Reduced ATF6 expression was shown to mirror Bz resistance in MM, 
and were consistent with reduced ER size morphology findings using live cell imaging and electron 
microscopy. Cells with a high dependence on the UPR were found to possess a larger ER morphology 
reflecting increased UPR activity, compared to cells that were less dependant on the UPR pathway and 
more resistant to Bz.  
Even with the improved understanding of MM and the use of the proteasome inhibitor Bz in the clinic, 
MM still remains an incurable disease. The dependence myeloma cells have on the UPR and the 
proteasome has resulted in Bz becoming an effective method in treating the disease by clinicians. 
While the implementation Bz has increased the life expectancy considerably within patients diagnosed 
with MM, however relapsed refractory MM still remains the biggest hurdle in treating the disease 
(Chen et al., 2011). This is made even more difficult in a small subset of patients who possess primary 
resistance to Bz prior to undergoing any treatment with Bz. Currently, the understanding surrounding 
the development Bz resistance and the cause of primary resistance in MM still remains largely 
unknown. This is made more difficult, as there is no way to ascertain whether or not a patient has 
become resistant or is resistant to Bz prior to undergoing treatment with Bz. This therefore has a 
substantial negative effect on the health and management of patients, leading to lost time and 
opportunity, as well resulting in unnecessary side effects caused by ineffective therapy.  
XBP-1 is a critical regulator of the UPR and is important in the development and differentiation of a 
number of organs and cells (Acosta-Alvear et al., 2007). XBP-1 mice knockouts exhibit abnormalities 
exclusively in secretory organs such as exocrine pancreas and salivary gland, which lead to early 
postnatal mortality (Lee et al., 2005). The ER of acinar cells from both the pancreatic and salivary 
glands in XBP-1 knockout mice are noticeably underdeveloped, along with reduced expression of ER 
chaperone genes (Lee et al., 2003) (Lee et al., 2005). The importance of XBP-1 in the generation of 
plasma cells is well published, with an upregulation in XBP-1 mRNA levels as a result of plasma cell 
differentiation inducing stimuli, and able to initiate plasma cell differentiation (Reimold et al., 2001). 
Furthermore, both mRNA and protein expression of XBP-1 are well reported as being highly 
expressed in myeloma cells relative to healthy control plasma cells. (Davies et al., 2003, Munshi et al., 
2004, Carrasco et al., 2007, Bagratuni et al., 2010, Gambella et al., 2014). However, within Bz 
resistance, the expression of XBP-1 has been found to coincide with reduced sensitivity to Bz 
treatment in MM patients (Ling et al., 2012) (Orlowski, 2013).  
In this study, we found that the expression of ATF6 shared the same trend as that of XBP-1 expression 
relative to Bz sensitivity in both ex-vivo patient samples and a Bz resistant cell line model published in 
a previous study (Ling et al., 2012). As many studies have reported previously, the splicing of XBP-1 
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from its unspliced (inactive) isoform to its spliced (active) isoform can be facilitated through ATF6 
(Adachi et al., 2008) (Shoulders et al., 2013). The decrease in ATF6 expression is likely a contributing 
factor in reduced XBP-1 expression, though it is highly doubtful that it is the primary cause. The direct 
relationship between the two however is difficult to establish, considering our knowledge and 
understanding surrounding ATF6 in MM and Bz resistance is still largely unknown. Prior to this 
study, ATF6 had been briefly investigated in one previous MM study. Bz resistant cell lines were 
found to have lower protein expression levels of ATF6 compared to cells that were more sensitive to 
Bz (Ling et al., 2012). In this study, a similar trend was seen in 45 MM patients. High ATF6 mRNA 
expression was associated with a clinical response to Bz, and low ATF6 expression was associated 
with resistance to Bz. ATF6 is known to have a redundant function as XBP-1, and aids in the secretory 
function of the cell by assisting in expanding the ER through ER biogenesis (Aragon et al., 2012, Fox 
and Andrew, 2015). Therefore this finding is consistent with the hypothesis that ATF6 expression is a 
reflection of UPR activity; reduced ATF6 is associated with reduced UPR activity, which is associated 
with reduced Bz sensitivity. 
Our assessment of ER size morphology showed that Bz resistant cells have reduced dependence on the 
UPR, possessing a reduction in the overall ER size, and a decrease in the ER lumen width, leading to 
limited ER expansion. The expansion of the ER as a mechanism to modulate ER stress is dependent 
upon the activation of the UPR in response to an influx of misfolded and unfolded protein (Walter and 
Ron, 2011, Hetz, 2012) (Gardner et al., 2013). Our findings support previous studies (Davies et al., 
2003, Munshi et al., 2004, Carrasco et al., 2007, Bagratuni et al., 2010, Gambella et al., 2014) that 
decreased XBP-1 and ATF6 expression, is likely to mediate the reduction in UPR activity and reduced 
ER size (Shaffer et al., 2004) (Huh et al., 2010) (Kim et al., 2015). XBP-1 has been shown to regulate 
ER expansion (Shaffer et al., 2004) (Huh et al., 2010) (Kim et al., 2015), and directly expand the ER 
through MIST1 (Huh et al., 2010) (Direnzo et al., 2012). ER expansion is also dependant on increased 
ER biogenesis and phosphatidylcholine synthesis, which is enhanced by ATF6 (Aragon et al., 2012). 
Therefore, it seems likely that the downregulation of ATF6 in Bz resistant MM contributes to reduced 
UPR function by subsequently reducing ER biogenesis signalling, which further amplified by reduced 
phosphatidylcholine synthesis. This in turn, limits the ERs ability to expand under ER stress, 
compromising/impairing the UPRs function in Bz resistant cells. The negative effect this has on the 
functioning of the UPR is further amplified by reduced XBP-1 expression in Bz resistant MM (Ling et 
al., 2012), as XBP-1 is responsible for directly regulating ER expansion (Shaffer et al., 2004) (Huh et 
al., 2010) (Kim et al., 2015). The reduced UPR activity in Bz resistant cells thus demonstrates the 
limited dependence resistant cells have on the UPR, explaining in part, why Bz is ineffective against 
resistant myeloma cells. Additional reasons that may also explain the reduction in ER size could 
include reduced protein synthesis and/or an alternative pathway assisting in the management of ER 
stress. It still remains unclear what causes reduced XBP-1 and ATF6 expression, though has 
considerable consequences on the functioning of the UPR.  
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The XBP-1 sequencing study was too small to be conclusive. However, there were a number of 
important findings. SNPs occurring within the coding region of XBP-1 were rare, and did coincide 
with findings of a previous study (Chapman et al., 2011). SNPs occurring before or within the splice 
site of XBP-1 that resulted in a stop codon were found to occur in 1 out of 34 patients studied. The one 
patient who possessed this SNP was found to have a poor prognosis, which resulted in the patient 
becoming deceased prior to undergoing the second cycle Bz therapy. SNPs occurring within the splice 
site of XBP-1 has been shown to prevent the splicing of the XBP-1 mRNA transcript, and hence 
prevented the activation of the UPR (Leung-Hagesteijn et al., 2013) (Hong and Hagen, 2013). XBP-1 
splicing has been shown to be essential in mediating Bz sensitivity in primary MM samples and in cell 
lines (Leung-Hagesteijn et al., 2013). Mutations occurring in the splice site of XBP-1 have also been 
found to be associated with PD and poor prognosis (Chapman et al., 2011). Both the previously 
published work and our data suggest the relative poor prognosis of such mutations, although this has 
only been found to occur in a small number of patients. XBP-1 splicing is important in plasma cell 
differentiation and antibody secretion (Reimold et al., 2001) (Lee et al., 2005). The defect in XBP-1 
splicing in MM may potentially lead to dedifferentiation of myeloma cells (Gu et al., 2012), resulting 
in a more proliferative phenotype and hence a more aggressive stage of the malignancy. This may 
explain the poor outcome of the reported cases. This needs further validation, because if this is 
confirmed, patients with mutations within the splice site should be treated with an alternative agent. 
This approach should also be applied to patients who possess a nonsense mutation upstream of the 
XBP-1 splice site.  
We remain speculative to the reasons why we were unable to amplify XBP-1 in 15 MM patients. 
Firstly, it is possible that a SNP or mutation within the promoter of the XBP-1 gene could be affecting 
the expression of the XBP-1 gene. By altering the binding site of the promoter, this could have 
affected the XBP-1 promoter. In turn, this would have subsequently resulted in XBP-1 not being 
expressed in these patients, explaining why were unable to amplify XBP-1 mRNA. SNPs have been 
previously identified in the XBP-1 promoter and found to regulate XBP-1 expression within vertigo 
patient patients (Ren et al., 2009). However, this is yet to be explored within MM patients. To 
determine if this were the case in the 15 patient samples, XBP-1 sequencing of the gDNA would be 
required, however patient gDNA was not isolated and stored for this project. Alternatively, these 15 
patients might have had high expression levels of paired box protein 5 (PAX5). PAX5 is known to 
have a strong binding association to the promoter of XBP-1, and has been shown to be heavily 
downregulated in XBP-1 transient expression studies (Reimold et al., 1996) (Iwakoshi et al., 2003). 
This is believed to be one of most likely explanations as to why these patients didn’t express XBP-1, 
considering PAX5 is highly expressed in a number of plasma cell lines (Iwakoshi et al., 2003). 
In summary, we were able to identify and show that heightened UPR activity is a predetermining 
factor for Bz sensitivity in MM. We identified that the expression of ATF6 and the expansion of the 
ER mirrors Bz sensitivity, which coincides with XBP-1 expression profiles in Bz sensitivity as 
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previously published (Ling et al., 2012). We were able to further conclude that myeloma cells resistant 
to Bz have a decreased dependence on the UPR as reflected by the reduction in the size of the ER and 
reduced ATF6 expression. We can further confirm that the reduction in ER size morphology is a 
downstream effect of reduced expression of ATF6 and XBP-1. We found no evidence to prove that Bz 
resistance was mediated by a SNP occurring within the XBP-1 splice site. Instead, we did however 
find that SNPs within the XBP-1 gene that resulted in a nonsense mutation upstream of the splice site 




4. Increased Expression of LAMP2A in Bz 
Resistance  
4.1 Introduction 
CMA is a highly specific pathway responsible for the targeting and degradation of soluble cytosolic 
proteins. In order for CMA substrates to be degraded by the CMA pathway, they first must be 
recognised and bound to by the CMA chaperone complex (Dice, 2007) (Cuervo, 2010). Within the 
CMA chaperone complex, HSC70 recognises and binds to the KFERQ motif sequence located within 
targeted substrates (Kon and Cuervo, 2010). Once bound to HSC70, the substrate is then chaperoned 
to the lysosome where it binds to LAMP2A, the ‘gateway’ protein of the lysosome (Orenstein and 
Cuervo, 2010). Upon binding, LAMP2A undergoes multimerisation, followed by the HSC70 protein 
and bound substrate being translocated into the lysosome and degraded (Kaushik et al., 2011b). 
Following this process, the LAMP2A multimer is either disassembled in the lysosomal membrane 
lipid microdomain by Cathepsin A, leading to reduced CMA activity, or reinserted into the lysosomal 
membrane (Cuervo et al., 2003). 
LAMP2A expression levels are not fixed but instead change in expression to accommodate the cells 
needs and in response to CMA substrate levels (Cuervo and Dice, 2000, Kon and Cuervo, 2010). 
LAMP2A is the rate-limiting factor for CMA, with CMA activity being directly proportional to the 
expression of LAMP2A (Dice, 2007) (Kon and Cuervo, 2010). Expression levels of LAMP2A are 
upregulated in a number of tumour tissues relative to surrounding healthy tissue (Kon et al., 2011). 
Breast cancer cells deficient of LAMP2A also display increased sensitivity to the drug Doxorubicin 
(Saha, 2012). Therefore, CMA appears to have an important role in cancer, with links to 
chemotherapy resistance. This chapter aims to investigate CMA levels in Bz resistance through the 
analysis of CMA active lysosomes and the profiling LAMP2A expression. 
4.2 LAMP2A expression and CMA activity profiling in KMS11 Bz 
sensitive and resistant cells 
Our previous work showed that important regulators of the UPR decreased in expression with 
increasing Bz resistance in MM (Ling et al., 2012) (Niewerth et al., 2015) (Soriano et al., 2016). We 
therefore hypothesised that an alternative pathway is likely responsible for the alleviation of ER stress 
in cells with reduced UPR activity, and hence contributing to Bz resistance. We examined CMA 
activity as an alternative mechanism for modulating ER stress. CMA is upregulated in a number of 
cancers and has a well-documented role in regulating oxidative stress and nutrient starvation (Majeski 
and Dice, 2004) (Wang et al., 2010) (Kon et al., 2011). We first aimed to measure LAMP2A gene 
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expression within Bz sensitive and resistant KMS11 cell lines. Since only the splice variant LAMP2A 
is associated with CMA, primers used specifically targeted only the LAMP2A splice variant. To 
ensure only LAMP2A mRNA levels were quantified, the forward primer of LAMP2A crossed the 
boundary of exons 6 and exon 7. 
Real-time PCR data of LAMP2A revealed significantly higher mRNA levels in KMS11 resistant cells 
compared to sensitive cells (Figure 4.1a; p=0.0002). We went on to further examine protein expression 
levels within the sensitive and resistant cells by western blot analysis, to do so, we examined the 
heavily glycosylated 110 - 120 kDa LAMP2A isoform, instead of the 45 kDa variant. The reason in 
doing so is that glycosylated LAMP2A proteins reside within the membrane of the lysosome, where 
they are the rate-limiting factor in CMA activity (Majeski and Dice, 2004). LAMP2A expression was 
normalised to β-actin. LAMP2A protein expression was increased in KMS11 resistant cells relative to 
KMS11 sensitive cells (Figure 4.1b; p=0.0329). The increase in glycosylated LAMP2A levels in the 
resistant cells indicated that CMA activity was upregulated in Bz resistance, and could potentially 
serve as an alternative pathway to alleviate ER stress.  
We went on to assess basal CMA activity in KMS11 sensitive and resistant cells by analysing the 
number of CMA active lysosomes. All lysosomes possess LAMP2A, however, only lysosomes that 
possess HSC70 as well are CMA competent and active (Kaushik et al., 2008b). When the pathway is 
activated, HSC70 chaperones CMA substrates to the lysosome where HSC70 and the substrate 
molecule are internalised into the lysosome through LAMP2A. We therefore analysed the number of 
colocalised LAMP2A/HSC70 puncta by confocal microscopy. Basal CMA levels in sensitive and 
resistant cells were compared to their corresponding serum starved controls. Serum starving fully 
activates CMA, enabling the total number of possible active lysosomes within each cell type to be 
determined (Kaushik et al., 2008b). Both the Bz sensitive and resistant cells were observed to have an 
almost identical number of CMA active lysosomes under serum starved conditions with less than 1% 
difference between the two cell lines (Figure 4.2). However, under basal conditions, the resistant cells 
displayed substantially higher numbers of HSC70/LAMP2A puncta (CMA active lysosomes) 
compared to the sensitive cells. We identified that basal CMA activity differed in resistant cells from 
the sensitive cells by 33.35%, where resistant cells were identified in having higher basal levels. In 
comparison to serum-starved control cells, the resistant cells appeared to be at almost maximum 
activation, with basal activity measured at 95.29% maximum active capacity. Sensitive cells however 
had considerably lower activity at 64.05% of the maximum capacity.  
We are therefore able to conclude using our Bz resistant cell line model that CMA is upregulated in 
Bz resistance. LAMP2A gene and protein expression is seen to be significantly upregulated in Bz 
resistance, which supports and correlates with the increased number of CMA active lysosomes 
identified in the resistant cells. Our results support our hypothesis that CMA activity is upregulated in 
Bz resistance and is likely assisting in alleviating ER stress in Bz resistance.  
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Figure 4.1: Analysis of LAMP2A expression in KMS11 bortezomib sensitive and resistant cells.  
a) Relative fold difference in mRNA expression between KMS11 sensitive and resistant cells by Real-
time PCR. Increased mRNA expression in KMS11 cells resistant (black bar) to bortezomib relative to 
Bortezomib-sensitive cells (white bar). Data shown as mean ± S.E.M. (n=6; p=0.0002, t-test). b) 
Relative fold difference in LAMP2A protein expression between KMS11 sensitive and resistant cells 
by western blot densitometry analysis. Increased protein expression in KMS11 cells resistant (black 
bar) to bortezomib relative to Bortezomib-sensitive cells (white bar). Data shown as mean ± S.E.M. 
(n=6; p=0.0329, t-test). 
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Figure 4.2: LAMP2A/HSC70 puncta analysis of KMS11 bortezomib sensitive and resistant cells.  
KMS11 bortezomib sensitive and resistant cells were cultured in the presence (Serum +) or absence 
(Serum -) of serum for 24 hours, then fixed in methanol and rehydrated with PBS, before LAMP2A 
(Red) and HSC70 (Green) co-staining. Serum deprived controls were included for each cell type to 
maximally active CMA. Merged LAMP2A/HSC70 is shown in the bottom row (yellow). For each 
experiment, ≥10 cells per condition were analysed in two independent experiments. Objective x63. 
Scale bar is 10 µm. Data is presented as mean number of LAMP2A/HSC70 colocalised puncta per cell 
± S.E.M (**p=0.0015; t test); Pearson coefficient means (from left to right on graph); r = 0.8, r = 0.77, 
r = 0.75, and r = 0.7. 
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4.3 LAMP2A expression in MM patients 
LAMP2A expression was further assessed in ex-vivo patient samples. We first assessed LAMP2A 
gene expression by Real-time PCR in myeloma cells derived from bone marrow aspirates of 30 
patients. The gene expression of LAMP2A was also correlated with patient clinical responses to Bz. 
Myeloma cells were isolated from patient bone marrow aspirates by CD38 and CD138 cell sorting. 
Patient sensitivity following the completion of cycle 2 Bz therapy were determined by haematologists 
(blinded to these results) at Liverpool Hospital (Liverpool, Australia) according to the IMWG uniform 
response criteria (Appendix I) (Rajkumar et al., 2011). Following the completion of cycle 2 Bz 
therapy, SD and PD patients were assigned to the resistant patient cohort. The sensitive patient cohort 
consisted of patients that had CR, VGPR or PR to Bz following the completion of cycle 2 Bz therapy. 
Expression levels in the resistant patient cohort (n=5) consisting of SD and PD patients were seen to 
have substantially higher gene expression levels of LAMP2A (Figure 4.3; p=0.0137) relative to 
sensitive patients (consisting of CR+VGPR and PR) (n=25). This shows that in human MM patients, 
CMA is upregulated in Bz resistance similar to findings in KMS11 Bz sensitive and resistant cell lines.  
In order to confirm the above findings, we examined LAMP2A protein expression by 
immunohistochemistry in an independent cohort of 66 MM patients. Patient responses to Bz were 
determined according to the IMWG uniform response criteria by haematologists at the Alfred Hospital 
(Melbourne, Australia). For each patient bone marrow trephine, slides were stained with an anti-
LAMP2A antibody, with an additional slide stained with an anti-CD138 antibody for each patient 
sample. Clinically, CD138 is used as a diagnostic marker for the diagnosis of MM (Ikeda et al., 2009). 
Therefore, we stained for CD138 to accurately locate and identify myeloma cell populations within 
patient bone marrow trephines, which consist of large heterogeneous cell populations. To ensure 
reproducibility, three independently blind examiners scored LAMP2A staining intensity and the extent 
of LAMP2A staining within myeloma cells (CD138 positive cells) in superimposed images. LAMP2A 
protein expression was identified to increase in patients resistant to Bz (MR+SD+PD; n=24) compared 
patients that were sensitive to Bz (CR/VGPR+PR; n=42) (Figure 4.4; p=0.0071). Relative to the 
sensitive patients, myeloma cells in resistant patients displayed a 1.38 fold increase in LAMP2A 
protein expression. On an individual group basis, LAMP2A appeared to increase in expression as Bz 
increased (Appendix V). Patients with SD (n=6) appeared to have higher LAMP2A protein expression 
than the more resistant group PD (n=7) by up to 20% (p=ns). On a group-by-group basis, CR/VGPR 
(n=20) vs PR (n =22) vs MR (n=11) vs SD (n=6) vs PD (n=7), the means were significantly different 
(p=0.0454). However, on an individual group basis, only CR/VGPR vs PD were found to be 
significantly different (p=0.0319).  
We are therefore able to conclude that in two independent MM patient cohorts, CMA is upregulated in 
Bz resistance. We found that gene expression and protein expression levels of LAMP2A were 
significantly increased in Bz resistant patients relative to Bz sensitive patients. These findings are 
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further supported by earlier findings, which found an upregulation of CMA and LAMP2A expression 
in Bz resistant cells using an in-vitro Bz resistant cell line model. Our results support our hypothesis 
that CMA activity is upregulated in Bz resistance as indicated in increases in gene and protein 




Figure 4.3: Real-time PCR quantification of LAMP2A mRNA expression in MM patient 
samples.  
Increased LAMP2A mRNA expression in bortezomib resistant (black) patients relative to bortezomib 
sensitive (white) patients. According to the IMWG Patient Response Criteria, patients with complete 
response (CR), very good partial response (VGPR) and partial response (n=26) to bortezomib were 
groups together and were assigned to the sensitive patient cohort. Stable disease (SD) and progressive 
disease (PD) (n=5) patients that are resistant to bortezomib were assigned to the resistant patient 
cohort. Data is shown as mean values ± SD. Statistical analysis was performed on sensitive patients 






Figure 4.4: LAMP2A protein expression in CD138 positive MM patient samples.  
CD138 (left panel) (brown stain) and LAMP2A (right panel) (brown stain) staining in bortezomib 
sensitive (top row) and bortezomib resistant (bottom row) multiple myeloma patient bone marrow 
trephines. Increased LAMP2A protein expression in bortezomib resistant (black) patients relative to 
bortezomib sensitive (white) patients. According to the IMWG Patient Response Criteria, complete 
response/very good partial response (CR/VGPR) (n=20) and partial response (PR) (n=22) were 
grouped as a being sensitive to Bortezomib. Minimal response (MR) (n=11), stable disease (SD) (n=6) 
and progressive disease (PD) (n=7) patients that are resistant to bortezomib were grouped and 
assigned to the resistant patient cohort. The staining intensity and extent of staining of LAMP2A was 
scored in CD138 positive stained cells of superimposed images for each bone marrow trephine. 
Staining intensity was scored on a 1-3 scale, 1 = low intensity, 2 = medium intensity, and 3 = high 
staining intensity. The extent of staining was scored on as follows, 1 = 0-25%, 2 = 26-50%, 3 = 51-
75%, and 4 = 76-100%. Data is shown as mean values ± S.E.M. Statistical analysis was performed on 
sensitive patients (groups CR+VGPR and PR) vs resistant patients (groups SD and PD) (p=0.0071, t 
test). Objective x40. Scale bar 50 µm. 
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4.4 Discussion  
With the introduction of PIs, such as Bz, the life expectancy of MM patients has improved 
significantly. However, while Bz has been the most effective drug for treating the disease, MM still 
remains an incurable malignancy. The vast majority of patients undergoing Bz treatment eventually 
develop resistance, no longer responding to further treatment. The cause of resistance still remains 
largely unknown, however a number of mechanisms that manage ER stress, in particular, UPR, have 
been shown to be downregulated (Ling et al., 2012) (Leung-Hagesteijn et al., 2013, Gambella et al., 
2014). Intriguingly though, myeloma cells are heavily reliant on the UPR and the ubiquitin 
proteasome system to reduce ER stress through reducing paraprotein levels. This is facilitated by 
endoplasmic reticulum associated degradation (ERAD), which is activated through either XBP-1 or 
ATF6 (Verfaillie et al., 2010). However, the expression of both XBP-1 and ATF6 are substantially 
decreased in Bz resistant myeloma, resulting in reduced UPR activity. Decreased UPR activity and 
proteasome inhibition provides reason to believe that an alternative mechanism is compensating the 
UPR and alleviating ER stress. Previous studies have shown that there is an increase in expression of 
deubiquitinating enzymes (DUBs) in Bz resistant patients, suggesting an overall reduction in 
ubiquitinated protein (Tian et al., 2014). It therefore seems unlikely that macroautophagy is the 
primary mechanism responsible for compensating the UPR and proteasome in Bz resistance. 
Macroautophagy is dependent upon ubiquitin labelling to recognise substrates scheduled for 
degradation (Yang et al., 2017). With increased DUB expression, it seems that macroautophagy has 
less of a critical role and considered to be less efficient in reducing paraprotein load in resistant cells. 
CMA would appear to have a more decisive role in alleviating ER stress through paraprotein 
degradation, contributing to Bz resistance. CMA differs from macroautophagy by targeting and 
chaperoning single specific cytosolic proteins to the lysosome for degradation (Tasset and Cuervo, 
2016). Approximately 30% of cytoplasmic proteins are believed to contain this motif (Dice, 2007), 
however it has also been suggested that through posttranslational modification, some proteins can be 
modified to include this motif (Gracy et al., 1998) (Zuiderweg et al., 2017).  
On the basis of pre-existing knowledge about CMA and its role in tumour biology, we believed CMA 
would be upregulated in Bz resistance and act as a compensatory stress mechanism in alleviating ER 
stress. By using a MM resistant cell line model, as well through the analysis of ex-vivo patient samples, 
we identified that CMA is increased in Bz resistance. LAMP2A gene and protein expression was 
substantially increased in patients that were resistant to Bz, and further supported by similar results 
seen within our Bz resistant cell line model. These findings coincide with those seen in LAMP2A 
deficient breast cancer cells, where cells that were deficient of LAMP2A displayed increased 
sensitivity to the drug Doxorubicin (Saha, 2012). Being the rate-limiting factor in CMA, our data also 
suggests that the increased LAMP2A expression is a result of increased CMA activity, utilized by 
resistant cells as a compensatory stress mechanism to alleviate ER stress and to maintain cell viability. 
Previous studies have shown that CMA activity is consistently higher in a variety of tumours 
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compared to untransformed control cells and tissue (Kon et al., 2011). Its importance in MM is likely 
to overshadow the role macroautophagy may play, as inhibition of CMA within tumour cells is 
reported to have no effect on the activity levels of macroautophagy (Kon et al., 2011). Furthermore, 
within Bz resistance, CMA appears to be a better-suited compensatory mechanism in alleviating ER 
stress. Reason for this, is that in order for paraprotein to be degraded by macroautophagy, targeted 
substrates must be first ubiquitinated in order to be recognised by the phagosome (Klionsky and Emr, 
2000). However, high expression levels of DUBs within Bz resistance contribute to reducing the level 
of ubiquitinated paraprotein, suggesting that macroautophagy is inadequate to compensate the UPR in 
Bz resistance. Moreover, ubiquilin a regulator of the ERAD pathway and important in autophagosome 
formation in macroautophagy, is also a known substrate of CMA (Rothenberg et al., 2010). Being a 
known substrate of the CMA pathway provides further evidence that CMA is an important and 
necessary mechanism in alleviating ER stress in Bz resistance.  
Our findings are also further strengthened and supported by in-vitro experiments using a KMS11 Bz 
resistant cell line model. Under basal conditions, resistant cells possessed increased basal CMA levels 
relative to the parent sensitive cells. We identified that CMA activity within resistant cells was almost 
at maximum active capacity by confocal microscopy. Sensitive cells on the other hand, were found to 
have significantly lower CMA levels under basal conditions. This supports our initial proposal that 
CMA is acting as a compensatory stress mechanism in Bz resistant MM. Cells sensitive to Bz have 
been shown in earlier chapters and previous studies to be primarily dependant on the UPR to maintain 
proteostasis and to reduce ER stress attributed to accumulating paraprotein (Shoulders et al., 2013) 
(Rozpedek et al., 2016). Having a highly functional UPR, illustrated by higher expressed UPR 
regulators and a larger ER, sensitive cells are less dependent on CMA to alleviate ER stress. Instead, 
UPR appears to be the preferred mechanism in modulating ER stress. This is achieved by not only 
through transcriptional and translational changes, but also through the recruitment of addition 
pathways such as the ubiquitin proteasome system (UPS) (Gardner et al., 2013) (Andreev et al., 2015) 
(Galmiche et al., 2016). With this in mind, resistant cells with a reduced functional UPR, in 
combination with PI, become more dependent upon CMA in managing and reducing proteotoxicity.  
Higher CMA rates are able to facilitate the supply of amino acids necessary for the extensive synthesis 
of paraprotein (Kaushik et al., 2011b). Alterations to CMA activity have been shown to change 
glucose and lipid metabolism of cells, while also able to regulate glucose and lipid metabolism (Kon et 
al., 2011) (Rodriguez-Navarro et al., 2012) (Mony et al., 2016) (Tasset and Cuervo, 2016) (Zhou et al., 
2017). In addition to metabolic regulation, CMA is also expected to be indirectly promoting NF-κB 
(nuclear factor kappa-light-chain-enhancer of activated B cells) activity by targeting and degrading 
IκBα (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha) (Cuervo et 
al., 1998) (Zhou et al., 2016). A known substrate of CMA, IκBα inhibits and regulates NF-κB, 
preventing DNA transcription, cytokine production and cell survival (Hideshima et al., 2002) 
(Annunziata et al., 2007). Within MM and many other cancers, NF-κB is often dysregulated, 
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displaying enhanced activity (Li et al., 2008) (Demchenko et al., 2010). It is possible that CMA is 
further driving MM progression via increasing NF-kB activity.  
It is therefore highly conceivable that the importance of CMA isn’t confined to alleviating ER stress in 
Bz resistance, but also plays a pivotal role in MM biology associated with metabolic regulation, 
tumour development and progression and cell survival. This provides suitable evidence to suggest that 
CMA is a favourable therapeutic target in not only treating Bz resistant MM, but MM in general. 
These findings are the first to establish the role CMA has in Bz resistance, which until now, CMA and 
its role in MM were unexplored.  
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5. Increase in CMA Activity Under ER 
Induced Stress  
5.1 Introduction 
Cells have a number of stress mechanisms on which they rely upon to maintain cellular homeostasis. 
While some pathways are utilised in response to different stress stimuli, many are capable of assisting 
and/or compensating for other pathways in managing stress and restoring cellular homeostasis 
(Nikesitch and Ling, 2016). The UPR and autophagy are capable of cross-talk, as well as 
compensating each other when either one is compromised (Senft and Ronai, 2015, Shapiro et al., 2016, 
Song et al., 2017). However, the bulk of these studies establish this relationship by only focusing on 
macroautophagy, while neglecting analysis of the CMA pathway. Since CMA is a specific pathway 
responsible for the targeting and degradation of soluble cytosolic proteins, it is feasible that CMA 
could assist in the regulation of ER stress, attributed to accumulating paraprotein, in myeloma cells. 
Therefore, this chapter aims to explore the possible relationship between CMA and the UPR, by 
examining CMA under ER induced stress.  
5.2 Increased CMA activity within myeloma cells in response to 
ER induced stress 
Considering that CMA is a degradation pathway and the biological function of proteasomes is to 
degrade unwanted protein, we decided to inhibit proteasomal degradation using low concentrations Bz. 
In doing so, we aimed to induce ER stress to assess if CMA was upregulated in response to increased 
ER stress levels. We hypothesized that CMA would act as a compensatory mechanism to alleviate ER 
stress caused by accumulating protein. Inducing ER stress with two different concentrations Bz, we 
aimed to determine if CMA activity was dependent on the level of ER stress present.  
We cultured the RPMI 8226 MM cell line in the presence of two sub-lethal concentrations Bz, 2 nM 
and 6 nM for 24 hours (Schmidt-Hieber et al., 2012). Cells were harvested after the 24 hours and were 
then homogenised to generate protein lysates, which were subjected to SDS-PAGE and probed for 
LAMP2A and β-actin by western blotting. To accurately determine the effects of ER stress on CMA 
activity, we performed densitometry analysis on the LAMP2A protein of 110 KDa. LAMP2A levels 
mediate the activity of the CMA pathway, with lysosomal membrane levels of LAMP2A directly 
proportional to CMA activity (Cuervo and Dice, 2000) (Agarraberes and Dice, 2001) (Kaushik and 
Cuervo, 2012). For LAMP2A proteins to be functional and reside in the membrane of the lysosome, 
LAMP2A must first undergo heavy post-translational glycosylation (Cuervo and Dice, 2000). This 
results in molecular weight of the LAMP2A (45 KDa) increasing to 110 KDa (Dice, 2007). LAMP2A 
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protein expression was normalised to β-actin within each sample. Relative to the untreated controls, 
LAMP2A protein levels within RPMI 8226 cells were seen to increase under increasing levels of 
stress (Figure 5.1a). We observed a 38% increase in LAMP2A expression in RPMI 8226 cells 
subjected to 6 nM Bz compared to the untreated control (p=0.0196). However, we detected little 
difference within cells treated with 2 nM Bz (p=ns). Increases in LAMP2A protein expression in 
response to ER induced stress, were further replicated in additional cell lines (Figure 5.2). U266 and 
OPM2 cell lines were found to respond in a similar manner to ER induced stress as shown in RPMI 
8226 cells. We further found that relative to the untreated controls, LAMP2A protein levels were seen 
to increase in a dose dependent manner for both cell lines. The greatest response was seen to occur 
within U266 cells, which had an increase of 63% (p=0.0183) and 75% (p=0.023) in LAMP2A protein 
expression at 2 nM and 6 nM. Both concentrations Bz appeared to result in similar expressional 
increases of the LAMP2A protein in OPM2 cells (p=0.028 and p=0.05), relative to the untreated 
control.  
We went on further to show that increases in LAMP2A expression were a direct result of increased ER 
stress, and not a result of proteasome inhibition. ER stress can be induced by DTT as a direct result of 
reducing the disulphide bonds within proteins that causes them to unfold and denature (Konigsberg, 
1972). The increased level of denatured proteins within the cell consequently leads to increased ER 
stress. However, due to the toxic nature of DTT, cells were only treated for 5 hours prior to analysis. 
DTT was used to treat RPMI 8226 cells and we were able to replicate and further support earlier 
findings using Bz that LAMP2A expression increases under ER induced stress (Figure 5.1b). While 
there was an increase in LAMP2A expression in cells treated with both DTT concentrations, the 
increase in LAMP2A protein expression in cells treated with 0.5 mM DTT were of no statistically 
significance (p=0.27). There was however a statistically significant increase in cells treated with 2 mM 
DTT (p=0.0397), which displayed a 32% increase in LAMP2A expression.  
To establish whether or not the increases in LAMP2A expression under ER induced stress were a 
direct result of increased CMA activity; we next assessed the number of CMA active/competent 
lysosomes in treated cells relative to the untreated controls. Despite LAMP2A being a rate-limiting 
factor in the CMA pathway and its expression is directly proportional to CMA activity. CMA 
functionality is also dependent upon HSC70, which is responsible for chaperoning targeted substrates 
to the lysosome (Dice, 2007). While all active and inactive lysosomes possess LAMP2A, only those 
that possess HSC70 within the lysosomal lumen are CMA competent (Kaushik et al., 2008b). We 
therefore assessed CMA activity in cells subjected to ER induced stress by Bz and DTT using 
confocal microscopy. For each experiment, a serum-starved control was included in order to 
maximally activate CMA, as a control to determine the number of CMA active lysosomes at 
maximum CMA activity. RPMI 8226 cells were treated with Bz at 2 nM and 6 nM for 24 hours. The 
number of CMA active lysosomes was seen to increase in a dose dependant manner under ER stress 
induced conditions (Figure 5.3). Relative to the untreated control, the number of co-localised 
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HSC70/LAMP2A puncta were seen to significantly increase by 26% within cells treated with 6 nM Bz 
(p=0.0133). However, we found there was no significant difference in the number of active lysosomes 
within cells treated with 2 nM Bz relative to the untreated control (p=ns), despite having an 8% 
increase in the number of active lysosomes. We also observed that cells reached 98% of the CMA 
active capacity when subjected to 6 nM Bz, while being at only 79% active capacity when treated with 
2 nM Bz. Relative to basal CMA levels (untreated RPMI 8226 cells cultured in the presence of serum), 
we found no significant deviation in CMA activity between untreated cells and cells treated with 2 nM 
Bz. Basal CMA levels were seen to be at 73% active capacity (p=0.0051).  
Under ER stress conditions induced by DTT, increases in the number of CMA active lysosomes were 
observed after 5 hours of treatment (Figure 5.4). Surprisingly, the degree of CMA activity within cells 
treated with DTT almost mimicked the responses seen in Bz treated cells. CMA levels increased by 
9% in cells treated with 0.5 mM DTT, relative to the untreated control (p=ns). We identified a 
significant increase in CMA activity of almost 20% (p=0.0417) in cells treated with 2 mM DTT. CMA 
basal levels of the untreated cells and CMA levels with serum starved cells (maximum CMA activity) 
remained relatively consistent in Bz and DTT experiments. The mean number of co-localised puncta 
under basal conditions differed by 2.5 puncta (8.8%) between Bz and DTT experiments. Co-localised 
puncta numbers of serum-deprived cells were also similar, with a difference of 3.5 puncta (9%). 
Overall, these results were able to demonstrate and support our hypothesis that CMA activity is able to 
be upregulated in MM under ER stress and its activity proportional to stress levels within the cell. 
During ER stress conditions, both LAMP2A protein expression and the number of CMA active 
lysosome were seen to coincide. This has demonstrated that the CMA pathway is able to act as a 
compensatory stress mechanism, capable of alleviating ER stress during instances where ER stress 
levels begin to exceed the UPRs ability to rectify. Furthermore, CMA also appears to have the ability 
to compensate reduced UPR activity in Bz resistant myeloma cells, alleviating proteotoxicity and 




Figure 5.1: Increases in LAMP2A protein expression in response to ER induced stress.  
a) Western blot densitometry analysis of increasing LAMP2A protein expression in RPMI 8226 cells 
treated with bortezomib for 24 hours. Data shown as mean ± S.E.M (n=8; p=ns, *p=0.0218, t test). b) 
Western blot densitometry analysis of increasing LAMP2A protein expression in RPMI 8226 cells 
treated with DTT for 24 hours. Data shown as mean ± S.E.M (n=6; relative to control, p=ns, 




Figure 5.2: Increases in LAMP2A protein expression in response to bortezomib induced ER 
stress.  
Western blot densitometry analysis of increasing LAMP2A protein expression in U266 and OPM2 
cells treated with bortezomib for 24 hours. Data shown as mean ± S.E.M (U266; n=4; *p=0.0183, 






Figure 5.3: Increased CMA activity in response to bortezomib induced ER stress.  
RPMI 8226 cells were treated with bortezomib for 24 hours. Each experiment included an untreated 
control (with serum) and a serum deprived control (without serum) to maximally activate CMA. Cells 
were fixed in methanol, rehydrated with PBS, and then stained for LAMP2A (Red) and HSC70 
(Green) for confocal imaging. Merged LAMP2A/HSC70 is shown in the last row (yellow). For each 
experiment, up to ≥10 cells per condition were analysed in two independent experiments. Objective 
x63. Scale bar is 10 µm. Data is presented as mean number of LAMP2A/HSC70 colocalised puncta 
per cell ± S.E.M (**p=0.0051; *p=0.0133; p=ns; one-way ANOVA); Pearson coefficient means (from 






Figure 5.4: Increased CMA activity in response to DTT induced ER stress.  
RPMI 8226 cells were treated with DTT for 24 hours. Each experiment included an untreated control 
(with serum) and a serum deprived control (without serum) to maximally activate CMA. Cells were 
fixed in methanol, rehydrated with PBS, and then stained for LAMP2A (Red) and HSC70 (Green) for 
confocal imaging. Merged LAMP2A/HSC70 is shown in the last row (yellow). For each experiment, 
up to ≥10 cells per condition were analysed in two independent experiments. Objective x63. Scale bar 
is 10 µm. Data is presented as mean number of LAMP2A/HSC70 colocalised puncta per cell ± S.E.M 
(**p=0.0015; *p=0.0417; p=ns; one-way ANOVA); Pearson coefficient means (from left to right on 
graph); r = 0.88, r = 0.87, r = 0.83, and r = 0.88. 
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5.3 Discussion  
We have demonstrated that CMA activity is upregulated under ER stress and is proportional to the 
level of ER stress. Under ER induced stress, we were able to show that the CMA pathway is capable 
of acting as a compensatory stress mechanism in alleviating ER stress. This was illustrated through the 
increase in both LAMP2A expression and the number of CMA active/competent lysosomes using two 
alternative ER stressors.  
Previous studies and our earlier work (chapter 3) have shown that reduced Bz sensitivity mirrors 
reduced UPR activity in MM (Ling et al., 2012) (Leung-Hagesteijn et al., 2013). With reduced UPR 
activity in Bz resistant MM, it is possible that an alternative mechanism/s are responsible for 
alleviating ER stress in Bz resistance. Studies have already shown that ER stress triggers 
macroautophagic activation (Ogata et al., 2006, Ding et al., 2007). Within myeloma cells, 
macroautophagy has also been shown to be upregulated in response to ER stress inducing stimuli 
(Hoang et al., 2009) (Kawaguchi et al., 2011). While the role of macroautophagy in response to ER 
stress is well described, the role of CMA under such conditions has yet to be determined. During other 
stress conditions such as oxidative stress and nutrient starvation, CMA is known to be upregulated 
(Cuervo et al., 1995a, Kiffin et al., 2004, Kaushik and Cuervo, 2006). Here we were the first to show 
that CMA is upregulated in MM under ER stress inducing stimuli. 
We show that the increase in LAMP2A expression was a result of the upregulation of CMA in 
response to ER induced stress, and was not the result of inhibited LAMP2A degradation by 
proteasome inhibition using Bz. This was confirmed by subjecting cells to DTT, which reduced the 
disulphide bonds within proteins, causing an increased load of unfolded protein on the ER. 
Furthermore, the increase in LAMP2A expression was accompanied by an increase in the number of 
CMA active lysosomes, consistent with the upregulation of CMA activity following DTT treatment. 
These findings mirrored previous results seen in cells when subjected to ER stress using Bz. It thereby 
proved that increased LAMP2A expression and heightened CMA activity was a response to increased 
ER stress and not through proteasome inhibition. This can be further supported by our existing 
knowledge that the CMA pathway can facilitate the removal and degradation of damaged proteasomes 
(Cuervo et al., 1995b), as subunits of the proteasome are known substrates of CMA (Cuervo et al., 
1995b). Furthermore, lysosomal LAMP2A is regulated by Cathepsin A (Cuervo et al., 2003).  
In summary, CMA is an important compensatory stress mechanism capable of alleviating ER stress 
and restoring cellular homeostasis in MM. In instances where ER stress levels exceed the UPRs ability 
to rectify, CMA is upregulated in order to restore cellular proteostasis. Within this study, we are the 
first to confirm a direct relationship between CMA and the UPR, by showing the upregulation of 
CMA during ER induced stress. This has established the importance of CMA as a compensatory stress 
mechanism in MM, which has suggested that CMA may play a pivotal role in Bz resistance. These 
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findings able to suggest that reduced UPR activity can be compensated by CMA in Bz resistant MM, 
conferring resistance to Bz. The inhibition of CMA in MM is likely to provide a significant 
improvement in the treatment of the disease, while it also could be highly effective in treating patients 
that are resistant to Bz. 
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6. Inhibition of CMA in Bz Sensitive and 
Resistant Myeloma Cells 
6.1 Introduction 
LAMP2A is the rate-limiting factor within the CMA pathway (Dice, 2007) (Kon and Cuervo, 2010). 
Located within the lumen of the lysosome, the LAMP2A protein functions as the ‘gateway’ to the 
lysosome, allowing the translocation of CMA substrates into the lysosome (Orenstein and Cuervo, 
2010). In order for this to occur, CMA substrates must first be recognised and bound to by the CMA 
chaperone complex (Dice, 2007) (Cuervo, 2010). Within the CMA chaperone complex, HSC70 
recognises and binds to the KFERQ motif sequence within the targeted substrates (Kon and Cuervo, 
2010). Once bound to HSC70, the substrate is then chaperoned to the lysosome where it binds to 
LAMP2A (Orenstein and Cuervo, 2010). The binding to LAMP2A results in the multimerisation of 
the LAMP2A protein, leading to the translocation of the HSC70 protein and the bound substrate into 
the lysosome, and subsequently degraded (Kaushik et al., 2011b). Following this process, the 
LAMP2A multimer is either disassembled in the lysosomal membrane lipid microdomain by 
Cathepsin A, leading to reduced CMA activity, or reinserted into the lysosomal membrane (Cuervo et 
al., 2003). 
Regulation of the pathway is facilitated through three lysosomal proteins, PHLPP1, mTORC2 and Akt. 
Both mTORC2 and Akt kinases regulate CMA activity by eliciting an inhibitory effect on CMA 
competent lysosomes, through the phosphorylation of GFAP. When phosphorylated, GFAP loses its 
binding affinity with LAMP2A. This disrupts the dynamics of the CMA translocation complex, which 
inhibits the pathways activity. Activation of CMA is mediated through the recruitment of PHLPP1 to 
the lysosome.  Present on the lysosome, the PHLPP1 protein counters the inhibitory effect of 
mTORC2 and Akt has on CMA by dephosphorylating Akt (Arias et al., 2015). GFAP is in turn 
dephosphorylated, enabling it to bind with LAMP2A, enhancing its stability in the CMA translocation 
complex and activating CMA (Bandyopadhyay et al., 2010). 
The results from previous chapters have shown that CMA is increased in Bz resistant cell lines and 
MM patients resistant to Bz. Increases in CMA activity is likely to have a significant role in mediating 
resistance to Bz and targeting CMA appears to be a potential therapeutic strategy. MM remains an 
incurable malignancy and almost all MM patients become resistant to Bz. Therefore, there is an unmet 
need to look for therapeutic targets that can overcome resistance to Bz and other PIs. This chapter 
aims to test the effect of targeting CMA on the growth and apoptosis Bz sensitive and resistant cells. It 
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also aims to test the hypothesis of CMA being a mechanism of resistance through the inhibition of 
CMA. 
6.2 Knockdown of LAMP2A 
To determine the importance of CMA in myeloma cells and its role in Bz resistance, we aimed to 
knockdown LAMP2A expression in Bz sensitive and resistant KMS11 cells to assess its effect on cell 
viability, as well its effect on Bz sensitivity.  
We initially transduced both Bz sensitive and resistant KMS11 cells with shRNA constructs using 
lentiviral particles (Kon et al., 2011), and selected transduced cells by puromycin screening. However, 
our first attempts to knockdown LAMP2A expression by shRNA were unsuccessful. The multiplicity 
of infection (MOI), the number of viral particles used to infect cells, was too low to sufficiently 
knockdown LAMP2A expression in both the sensitive and resistant cells (data not shown). We were 
therefore required to have the lentiviral constructs manufactured once again to repeat lentiviral 
transductions. The lentiviral particles containing the LAMP2A shRNA constructs required 8 weeks to 
be manufactured before cells could be transduced once again. Considering the first attempt to 
knockdown LAMP2A with a lentiviral MOI of 1.5 was unsuccessful, we subsequently transduced 
cells with a higher MOI of 3. We decided to not increase the MOI to 5 (the maximum MOI), in order 
to prevent 100% knockdown of LAMP2A. Instead, we aimed to acquire 70-90% knockdown in 
LAMP2A expression, considering CMA is essential for cell functioning, therefore making 100% 
knockdown not viably stable.  
Following the transduction of cells for the second time, visually there was a noticeable decline in cell 
viability and proliferative rates in LAMP2A knockdown [L2A(-)] cells of both the Bz sensitive and 
resistant KMS11 cells (Figure 6.1). L2A(-) sensitive and resistant cell numbers appeared to rapidly 
decline 7-10 days after being transduced with LAMP2A shRNA. Cell viability and proliferation 
appeared to be unaffected in shRNA control cells, which was made evident by the regular passaging of 
the control cells every 3 – 4 days. Nevertheless, L2A(-) cell populations eventually reached 
confluence and were able to be expanded after 2 – 3 weeks. Protein levels were analysed by western 
blotting and revealed no difference in LAMP2A protein expression between shRNA control cells and 
L2A(-) cells for either cell type (Figure 6.2). Analysis of LAMP2A mRNA levels revealed that there 
was a 60% knockdown in Bz sensitive cells, while only a 22% knockdown in Bz resistant cells 
relative to the corresponding negative shRNA controls (Figure 6.3).  
As a result of not being able to stably establish L2A(-) knockdown cell lines, we used siRNA 
transfections as an alternative method to achieve desirable levels of LAMP2A knockdown. Using 
siRNA, it was feasible to achieve a more immediate knockdown of LAMP2A expression within 96 
hours and assay the level of knockdown at each desirable time point, without having to expand or 
compromise the entire cell population for analysis. We therefore designed specific stealth siRNA to 
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target within exon 8 of the LAMP2 gene, which is specific to the LAMP2A isoform, without silencing 
either LAMP2B or LAMP2C.  
Initial transfections using 50 nM – 150 nM of siRNA were unable to sufficiently knockdown 
LAMP2A protein expression levels in either Bz sensitive or resistant KMS11 cells. The greatest level 
of LAMP2A knockdown achieved was 60% at 48, 72 and 96 hours (data not shown). The LAMP2A 
protein levels appeared to be relatively unaffected at 24 hours across all siRNA concentrations. 
Therefore, further optimisation experiments did not include 24-hour time points. Increases to the 
electroporation voltage slightly improved the transfection efficiency of cells with siRNA, however the 
increased voltage resulted in substantially increased levels of cell death in mock control cells by more 
than 15% (data not shown). Therefore, 240 volts was chosen as the most suitable voltage cell 
electroporation, without significantly reducing the viability of cells.  
To achieve knockdown of LAMP2A by more than 70%, cell number were reduced to 5.0 x 106 cells 
(from 6.0 x 106 cells) for the sensitive and resistant cells, and transfected with 300 nM of LAMP2A 
siRNA, or 300 nM scrambled negative control siRNA (negative control siRNA) in supplement free 
media. Transfection was performed by electroporation using 240 volts, with the level of LAMP2A 
knockdown determined by western blot analysis (Figure 6.4). Within the KMS11 sensitive cells, we 
observed a 78%, 71% and 50% knockdown in LAMP2A protein expression at 48, 72 and 96 hours. 
Resistant cells were found to have 65%, 76 % and 56% knockdown in LAMP2A protein levels at 48, 




Figure 6.1: Viable KMS11 cell colonies following lentiviral transductions with shRNA.  
KMS11 bortezomib sensitive (left panel) and bortezomib resistant (right panel) cell colonies following 
lentiviral transductions with negative control shRNA (top row) and LAMP2A shRNA (bottom row). 
The MOI used to transduce cells was 3. Images were taken of cell colonies in culture 7 days after 






Figure 6.2: Validation of shRNA knockdown of LAMP2A in KMS11 bortezomib sensitive and 
resistant cells.  
KMS11 bortezomib sensitive and resistant cells were selected by puromycin screening for 14 days 
following the transduction of cells with lentiviral particles containing either negative control shRNA 
or LAMP2A shRNA constructs. Protein lysates were the subsequently subjected to SDS-PAGE and 




Figure 6.3: LAMP2A mRNA levels following shRNA knockdown of LAMP2A.  
Differences in LAMP2A mRNA expression between negative control and LAMP2A(-) cells were 
determined using Real-time PCR. KMS11 bortezomib sensitive and resistant cells were selected by 
puromycin screening for 14 days following the transduction of cells with lentiviral particles containing 
either negative control shRNA or LAMP2A shRNA constructs. LAMP2A mRNA levels were 
normalised to GAPDH within each sample. Differences in LAMP2A mRNA levels were determined 




Figure 6.4: LAMP2A knockdown in bortezomib sensitive and resistant KMS11 cell lines.  
LAMP2A protein expression following the knockdown of LAMP2A in bortezomib sensitive and 
resistant cells. Cells transfected with either 300 nM Stealth Negative Control siRNA or with 300 nM 
of LAMP2A siRNA by electroporation using 240 volts in supplement free media. LAMP2A protein 
levels were analysed in cells by western blotting at 48, 72 and 96 hours post transfection using anti-
LAMP2A and anti-GAPDH antibodies. The level of LAMP2A knockdown in sensitive and resistant 
cells at each time point was determined by western blot densitometry analysis. LAMP2A levels were 
normalised to GAPDH within each sample, before the level of knockdown determined by comparing 
knockdowns to corresponding negative controls.  
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6.3 Effect of LAMP2A knockdown on the cell viability of KMS11 
cells 
We first assessed the effect of knocking down LAMP2A on cell viability in Bz sensitive and resistant 
KMS11 cells. By impairing/inhibiting CMA, we hypothesised that cell viability would be significantly 
reduced in L2A(-) cells. Cells were first transfected with siRNA and seeded at 200,000 cells/well, 
before being left to culture overnight. Following the culturing of cells overnight, the media from each 
well was aspirated, removing the dead cells caused by electroporation, and replaced with fresh culture 
media. Cells were then allowed to grow for a further 48, 72 and 96 hours. The effects of LAMP2A 
knockdown on the viability Bz sensitive and resistant cells were analysed by flow cytometry using 
Annexin V apoptosis assay.  
In order to preserve the cell surface expression of the apoptotic marker Annexin V, cells were 
harvested with 2 mM EDTA, instead of using trypsin. The differentiation between the alive, early 
apoptotic, late apoptotic and necrotic cell populations were achieved using Annexin V/7-AAD staining 
and implementing a two-parameter (dual-fluorescence) scatter plot method. Annexin V - PE channel 
was assigned to the x-axis of the scatter plot, while the 7-AAD - APC channel was assigned to the y-
axis of the scatter plot. Quadrant gating was setup using positive control samples, which were 
generated for each experiment. The controls included an unstained control (alive cells), Annexin V 
only control (apoptotic cells) and a 7-AAD only control (necrotic cells), which was permeabilised with 
0.005% Saponin. The flow cytometry parameters were setup so that live cell events (Annexin-/7-AAD-
) were detected in the bottom left quadrant of the scatter plot. Cells that were early apoptotic 
(Annexin+/7-AAD-) appeared in the bottom right quadrant, and the late apoptotic (Annexin+/7-AAD+) 
appeared in the top right quadrant of the scatter plot. The remaining necrotic cells (Annexin-/7-AAD+) 
would subsequently appear in the top left quadrant. Cell population percentages of each quadrant were 
collected for data analysis.  
The level of LAMP2A knockdown we achieved had little effect on the viability Bz sensitive cells. The 
number of viable sensitive cells were seen to decrease by only 2% in L2A(-) cells relative to the 
negative control cells at 48 and 72 hours (Figure 6.5a; p=ns). However, there was no noticeable 
difference between the negative control and L2A(-) cells after 96 hours. L2A(-) cells were initial seen 
to have more early apoptotic cells than the negative control cells after 24 hours. However, the 
difference observed between L2A(-) and negative control cells was only 2%, and of no significance. 
This difference rapidly diminished over each time point, with no difference seen after 72 hours. We 
saw no significant difference in late apoptotic cell numbers between the negative control and L2A(-) 
cells. Considering that early and late apoptotic cell numbers declined over time for both the negative 
control and L2A(-) cells, this suggested that initial apoptotic cell populations were possibly the result 
of the electroporation process.  
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Similar to the result seen in sensitive cells, we also observed little difference between the L2A(-) Bz 
resistant cells and negative Bz resistant control cells (Figure 6.5b; p=ns). While differences between 
L2A(-) and negative control cells were more than those seen in the sensitive cells, the differences were 
of no significance. The greatest difference in cell viability was seen after 24 hours, where there was a 
4.5% decrease in cell viability of the L2A(-) cells. Following 96 hours, the number of viable cells 
remained lower in L2A(-) cells compared to the negative controls, however the difference was only 
3.2% and not statistically significant. Early apoptotic cell numbers were higher in L2A(-) cells 
compared to the negative control cells, which remained relatively consistent. Late apoptotic cell 
numbers were seen to be consistently more in L2A(-) cells, with the greatest change being seen after 
24 hours, though this was of no significance. Unlike the sensitive cells, late apoptotic cell numbers 
gradually declined over time. Necrotic cell numbers remained relatively unchanged throughout all the 
experiments for both the sensitive and resistant cells between negative control and L2A(-) cell groups.  
In summary, the knockdown of LAMP2A was not associated with any significant change in cell 
viability Bz sensitive or resistant cells. The level of LAMP2A knockdown achieved seemed to be 
inadequate to effectively inhibit or impair CMA. Therefore, the remaining LAMP2A levels after 
LAMP2A knockdown were likely to be sufficient enough to maintain CMA activity and manage basal 







Figure 6.5: Effects of LAMP2A knockdown on cell viability in bortezomib sensitive and resistant 
KMS11 cell lines.  
Cell viability of bortezomib sensitive (left panel) and resistant (right panel) KMS11 cells after 
LAMP2A knockdown. Cells were transfected with either LAMP2A siRNA or Stealth Negative 
Control siRNA, and cultured for 48, 72 and 96 hours. Cell viability was analysed by flow cytometry 
using PE-Annexin V (apoptotic cell marker) and 7-AAD (live cell exclusion stain) staining. For each 
experiment, a total of 10,000 cells were analysed per sample. Data is presented as mean population 
percentage ± S.D (n=3). Statistical analysis was performed between Neg Ctrl vs L2A(-) of each cell 
population (Sensitive cells: p=ns) (Resistant cells: p=ns) (t test). 
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6.4 Effect of LAMP2A knockdown on Bz sensitivity  
We next aimed to determine the effect of LAMP2A knockdown on Bz sensitivity in KMS11 Bz 
sensitive and resistant cells. We hypothesised that knockdown of LAMP2A would inhibit or impair 
CMA, resulting in reduced cell viability and proliferation rates, while also sensitising KMS11 resistant 
cells to Bz. To test our hypothesis, we used MTS assays to measure Bz sensitivity (IC50) in Bz 
sensitive and resistant cells following LAMP2A knockdown. Transfected cells (negative control and 
L2A(-) cells) were seeded into 96 well plates at 10,000 cells/well, and cultured overnight. Following 
the culturing overnight, cells were treated for 24, 48 and 72 hours with 0 nM – 512 nM Bz. For each 
time point, the viability of cells were determined by measuring the light absorbance readings of 
formazan in wells produced by viable cells reducing the MTS reagent (to formazan). Absorbance 
readings were subtracted form blank wells (no cells), with the percentage of viable cells relative to the 
untreated control cells calculated as mentioned in chapter 2.15. 
The level of LAMP2A knockdown obtained within Bz sensitive cells had little to no effect on Bz 
sensitivity (Figure 6.6a). These results were consistent to those found in previous knockdown 
experiments using lower siRNA concentrations (result not shown). Using 300 nM of siRNA (the 
highest concentration used), we saw a slight decrease in cell viability of L2A(-) cells after 24 hours Bz 
treatment. Although, we were unable to detect any difference in the IC50 values between the negative 
control cells and L2A(-) cells. The minor differences in cell viability observed in the sensitive cells at 
24 hours, were not seen to increase any further after 48 and 72 hours Bz treatment. Instead, there was 
no difference in cell viability between the negative control cells and L2A(-) cells at either 48 or 72 
hour time points.  
Within the Bz resistant cells, the level of LAMP2A knockdown obtained had little to no effect on Bz 
sensitivity (Figure 6.6b). Differences between the negative control and L2A(-) cells were variable and 
lacked any consistency from previous experiments performed (data not shown). On one occasion, 
changes to Bz sensitivity were seen to occur in the Bz resistant L2A(-) cells after 72 hours of Bz 
treatment. Relative to the negative control cells, the IC50 of L2A(-) cells decreased by 49%, to 14.72 
nM of Bz. However, these results were unable to be replicated in repeated experiments. Therefore the 
effect was probably due to technical variability.  
In summary, LAMP2A knockdown had no effect on Bz sensitivity within the sensitive cells and 
resistant cells.  These findings are inconclusive because the amount of knockdown might not be 




Figure 6.6: Effects of LAMP2A knockdown on bortezomib sensitivity in bortezomib sensitive 
and resistant KMS11 cell lines.  
Cell viability of bortezomib sensitive (left panel) and resistant (right panel) KMS11 cell lines with or 
without LAMP2A knockdown after treatment with Bortezomib. Cells were transfected with either 
LAMP2A siRNA or Stealth Negative Control siRNA by electroporation and seeded into 96 well plates 
at 10,000 cells/well. Cells were treated in triplicate with 0 – 512 nM of bortezomib for 48, 72 and 96 
hours, with each plate including 3 blank wells (no cells). Each plate was incubated with MTS reagent 
for 4 hours, with absorbance readings measured at 490 nm. Cell viability was calculated relative to the 
untreated control, following the subtraction of blank values from each well. Each data point is 
presented as the mean viability of three replicates relative to the untreated control ± S.D of sample 
triplicate (presented data; n=1). 
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6.5 Effect of CMA inhibition on Bz sensitivity  
PHLPP1 has been shown to mediate CMA activity by countering the inhibitory effect of mTORC2 
and Akt on CMA activity (Arias et al., 2015). Inhibition of the phosphatase activity of PHLPP1 by a 
selective inhibitor molecule (NSC ID: 117079) (referred to PHLPPi here on in) has been previously 
shown to effectively inhibit CMA activity (Arias et al., 2015). We therefore decided to use a PHLPPi 
to overcome difficulties associated with acquiring sufficient CMA inhibition through LAMP2A 
knockdown. We aimed to determine if inhibiting CMA using a PHLPPi would sensitise Bz resistant 
cells to Bz, and reduce cell viability in both Bz sensitive and resistant KMS11 cells. We hypothesised 
that the inhibition of CMA would reduce cell viability, while also enhancing the sensitivity of KMS11 
resistant cells to Bz. We further hypothesised CMA inhibition would have less of an effect on the 
viability of the Bz sensitive cells as it would on the Bz resistant cells. 
Published data has shown 30 µM of the PHLPPi almost completely inhibits CMA activity in-vitro 
(Arias et al., 2015). For each experiment, 200,000 cells/well were seeded into 6 well plates and 
cultured overnight before being treated. Our previous experiments suggested that the IC50 of KMS11 
sensitive cells were approximately 5 nM following 48 hours of Bz treatment. For the KMS11 sensitive 
cells, we treated the cells with two different concentrations of Bz, 5 nM and 10 nM. To determine the 
effects of CMA inhibition on Bz sensitivity, we also combined both Bz concentrations with the 
PHLPPi (30 µM). Each experiment also included the treatment of cells with the PHLPPi (30 µM) 
without Bz, in order to determine the effect of CMA inhibition on the viability of myeloma cells. Cells 
were treated over 72 hours, with cell viability analysed by flow cytometry at 24, 48 and 72 hours using 
Annexin V/7AAD staining. The same experimental procedure was carried out on KMS11 resistant 
cells, however using higher Bz concentrations of 10 nM and 20 nM. The IC50 of KMS11 resistant cells 
was approximately 20 nM after 48 hours of treatment with Bz. The reason for choosing 10 nM and 20 
nM Bz concentrations, is that we hypothesised that CMA inhibition would sensitise the resistant cells 
to Bz.  
For the KMS11 Bz sensitive cells at 24 hours (Figure 6.7a) (Table 2), there was a decrease in cell 
viability of 37% and 61% in cells treated with 5 nM Bz and 10 nM Bz. The inhibition of CMA using 
the PHLPPi alone resulted in almost a 20% decrease in cell viability, relative to the untreated control. 
The combination of 5 nM Bz + PHLPPi led to a 75% reduction in cell viability, with the combination 
of 10 nM Bz +PHLPPi resulting in a 88% reduction in cell viability. Therefore, 5 nM + PHLPPi led to 
a 2-fold increase in cytotoxicity and 10 nM Bz + PHLPPi led to a 1.44-fold increase in cytotoxicity. 
Interestingly, early apoptotic cell numbers were noticed to be higher in cells treated with Bz, 
compared to cells treated with Bz + PHLPPi. The Bz + PHLPPi combination appeared to induce 
apoptosis more rapidly, which was indicated by higher late apoptotic cell numbers in Bz + PHLPPi 
treated samples. We identified a 62% and 61% increase in late apoptotic cell numbers in 5 nM Bz + 
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PHLPPi and 10 nM Bz + PHLPPi samples, relative to the sensitive cells treated with 5 nM and 10 nM 
Bz. 
We were unable to determine the effect of the PHLPPi + Bz combination in the sensitive cells at 48 
and 72 hours. This was a direct result of the unexpectedly high sensitivity of the sensitive cells to Bz. 
Relative to the untreated control, the viability of the sensitive cells was substantially reduced when 
treated with either Bz alone or PHLPPi + Bz for 48 and 72 hours. There was an 83% reduction in cell 
viability with 5 nM Bz at 48 hours and 95% reduction in cell viability at 72 hours. This made it 
difficult to assess the effect of the Bz + PHLPPi combination. CMA inhibition alone was also seen to 
elicit an increased cytotoxic effect on the sensitive cells at 48 and 72 hours. Relative to the untreated 
control, the PHLPPi alone reduced the viability of the sensitive cells by 42% after 48 hours and 76% 
after 72 hours. Non-apoptotic cell death was also noticed to increase over each time point in cells 
treated with the PHLPPi or PHLPPi + Bz. 
Within KMS11 Bz resistant cells, the inhibition of CMA with the PHLPPi sensitised the cells to Bz 
(Figure 6.7b) (Table 3). Bz treatment by itself appeared to have little effect on the viability of the 
resistant cells after 24 hours. Relative to the untreated control, the viability of the resistant cells was 
identified to decrease by 4% and 12% in response to 10 nM and 20 nM Bz, whereas treatment with 10 
nM Bz + PHLPPi decreased the viability of the resistant cells by 20%. The treatment of cells with 20 
nM Bz + PHLPPi was seen to have the greatest cytotoxic effect on the resistant cells, reducing the 
viability of the cells by 30%. Therefore, by adding the PHLPPi to 10 nM Bz, there was a 5-fold 
increase in cytotoxicity, and adding the PHLPPi to 20 nM, there was a 2.5-fold increased in 
cytotoxicity. It appeared that the inhibition of CMA sensitised the resistant cells to Bz. The PHLPPi 
alone decreased the cell viability of the resistant cells by 10%, and was only 3% less cytotoxic than 20 
nM Bz.  
After 48 hours, 10 nM and 20 nM Bz reduced the viability of the resistant cells by 19% and 36% 
relative to the untreated control. The greatest cytotoxic effect on the resistant cells was seen in samples 
treated with 10 nM Bz + PHLPPi and 20 nM Bz + PHLPPi, which reduced the viability of cells by 
31% and 44% respectively. Relative to the cytotoxicity seen at 24 hours, there was a 1.62-fold and 
1.21-fold increase in the cytotoxicity as seen in 10 nM Bz + PHLPPi and 20 nM Bz + PHLPPi cells 
after 48 hours. Difference between early and late apoptotic cell numbers were relatively similar 
throughout each sample. However, the addition of the PHLPPi with 20 nM Bz did appear to induce a 
more rapid apoptotic response than 20 nM Bz alone. Resistant cells treated with 20 nM Bz possessed 
22% more early apoptotic cells than late apoptotic cells. The 20 nM Bz + PHLPPi combination saw a 
shift in early/late apoptotic cells numbers, which resulted in a 28% increase in late apoptotic cells. 
After 72 hours of treatment, the viability of the resistant cells was seen to decline further in response 
to Bz treatment. Relative to the untreated control, we detected a 29% and 58% decrease in cell 
viability in response to 10 nM and 20 nM Bz. Cells treated with 10 nM Bz + PHLPPi and 20 nM Bz + 
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PHLPPi resulted in a 38% and 63% decrease in cell viability relative to the untreated control. At this 
72-hour time point, the cytotoxic effects caused by PHLPPi, without the combination of Bz, was the 
greatest. Relative to the untreated controls, the PHLPPi reduced the viability of the resistant cells by 
26%, while it was previously found to have reduced the viability of the resistant cells by only 16% 
after 48 hours. This was a 37% improvement in the cytotoxic effect induced by the PHLPPi within 24 
hours. The combination of the PHLPPi + Bz appeared to induce apoptosis at a more rapid rate than 
just Bz alone. The late/early apoptotic ratio was also substantially increased in PHLPPi + Bz treated 
cells, compared to Bz treated cells. There was 2.5-fold and 3.4-fold more late apoptotic cells in 10 nM 
+ PHLPPi and 20 nM + PHLPPi treated samples, than early apoptotic cells. The late/early apoptotic 
cell ratio seemed to be a lot less in 10 nM and 20 nM Bz treated samples, with only a 1.4-fold and 1.7-
fold increase in the number of late apoptotic cells. CMA inhibition also appeared to result in an 
increase in non-apoptotic cell death within cells treated with the PHLPPi, compared to cells treated 
with just Bz. 
In summary, we demonstrated that CMA is an important mechanism in MM biology. The inhibition of 
CMA alone, without proteasome inhibition, significantly reduced the viability of Bz sensitive and 
resistance myeloma cells, relative to the untreated controls. This demonstrated the importance of CMA 
in regulating ER stress and MM survival. More importantly, CMA inhibition appeared to sensitise 
resistant cells to Bz, further establishing the role and importance of CMA in Bz resistance. The 
clinical utility of CMA inhibition in treating Bz resistant MM seems promising. However, this will 
depend on the pharmacokinetics, pharmacodynamics and toxicity of chemotherapeutically inhibiting 





Figure 6.7: Effect of CMA inhibition on bortezomib response in sensitive and resistant KMS11 
cell lines.  
Bortezomib sensitive (left panel) and resistant (right panel) KMS11 cell lines were either treated with 
bortezomib (sensitive cells: 5 nM or 10 nM) (resistant cells: 10 nM or 20 nM), PHLPPi (30 µM), or 
treated in combination with the PHLPPi and Bz. Cells were treated for 24, 48 and 72 hours, with the 
viability of cells analysed at each time point by flow cytometry using PE-Annexin V (apoptotic cell 
marker) and 7-AAD (live cell exclusion stain) staining. For each experiment, a total of 10,000 cells 
were analysed per sample. Data is presented as mean population percentage ± S.E.M (n=3). Statistical 
analysis was performed using a one-way ANOVA across all samples for each cell population (alive, 
early apoptotic, late apoptotic and necrotic populations) (p-values in table 2 and table 3).  
 
Table 2: Mean cell population (%) values of KMS11 sensitive cells as presented in figure 6.7a.  
 
% p-value % p-value % p-value % p-value
Untreated 90.3 - 3.76 - 4.8 - 0.53 -
5 nM Bz 57.6 0.99 31.7 0.99 9.8 0.99 0.9 0.99
10 nM Bz 35.1 0.0005 43.8 0.0004 19.27 0.04 1.8 0.99
PHLPPi 73.6 0.58 1.7 0.99 5.3 0.5 19.43 0.33
5 nM Bz + PHLPPi 23.07 0.17 24.77 0.99 25.67 0.19 26.47 0.16
10 nM Bz + PHLPPi 11.03 0.0001 29.03 0.0001 49.03 0.0001 10.9 0.0003
% p-value % p-value % p-value % p-value
Untreated 91.23 - 3.1 - 5.33 - 0.36 -
5 nM Bz 15.8 0.62 26.9 0.49 56.4 0.99 0.9 0.99
10 nM Bz 4.5 0.0001 25.77 0.0001 69.03 <0.0001 0.63 0.6
PHLPPi 53.07 0.014 1.23 0.99 9.7 0.61 36.03 0.0002
5 nM Bz + PHLPPi 11.87 0.01 12.2 0.73 60.63 0.32 15.33 0.049
10 nM Bz + PHLPPi 2.73 0.0001 13.8 0.01 80.63 <0.0001 2.8 0.51
% p-value % p-value % p-value % p-value
Untreated 93.17 - 3.7 - 2.96 - 0.23 -
5 nM Bz 3.4 0.14 10.7 0.13 85.23 0.29 0.7 0.99
10 nM Bz 0.76 0.0001 8.66 <0.0001 89.93 0.0001 0.7 0.99
PHLPPi 22.43 0.0001 0.53 >0.99 10.73 0.03 66.3 0.0009
5 nM Bz + PHLPPi 7.96 0.0001 6.66 0.04 67.47 0.004 17.87 0.09













Table 3: Mean cell population (%) values of KMS11 resistant cells as presented in figure 6.7b.  
% p-value % p-value % p-value % p-value
Untreated 90.3 - 4.93 - 4.26 - 0.46 -
10 nM Bz 86.96 0.93 7.2 0.78 5 0.99 0.83 0.99
20 nM Bz 79.4 0.17 11.96 0.03 7.6 0.63 9 0.99
PHLPPi 81.53 0.32 2.96 0.85 5.8 0.97 9.7 0.0007
10 nM Bz + PHLPPi 72.37 0.01 7.73 0.63 10.7 0.13 9.2 0.001
20 nM Bz + PHLPPi 63.1 0.0007 13.4 0.01 17.6 0.002 5.96 0.02
% p-value % p-value % p-value % p-value
Untreated 90.7 - 4.36 - 4.3 - 0.66 -
10 nM Bz 73.8 0.006 13.7 0.007 11.9 0.02 0.6 0.99
20 nM Bz 58.4 0.0001 22.8 0.0001 17.8 0.0003 1 0.97
PHLPPi 75.87 0.01 2.9 0.95 8.2 0.34 13.03 0.0001
10 nM Bz + PHLPPi 62.8 0.0001 13.83 0.006 14.63 0.003 8.7 0.0001
20 nM Bz + PHLPPi 51.2 0.0001 16.43 0.001 22.73 0.0001 9.63 0.0001
% p-value % p-value % p-value % p-value
Untreated 89.83 - 4.23 - 5.13 - 0.76 -
10 nM Bz 63.77 0.05 14.67 0.007 20.77 0.25 0.8 0.99
20 nM Bz 37.7 0.0004 23.03 <0.0001 38.67 0.005 0.56 0.99
PHLPPi 66.43 0.09 2.86 0.99 9.7 0.96 21 0.0001
10 nM Bz + PHLPPi 55.6 0.01 10.37 0.15 26.23 0.08 7.83 0.02
20 nM Bz + PHLPPi 33 0.0002 13.23 0.02 44.73 0.001 9.03 0.01
48 hours









By using an in-vitro Bz resistant cell line model, we are the first to demonstrate the role of CMA in Bz 
resistance, and the potential therapeutic benefit of targeting the CMA pathway in treating Bz resistant 
MM. In combination with Bz, we were able to demonstrate that the inhibition of CMA, using a 
PHLPP1 inhibitor, further enhanced the cytotoxic effect of Bz in MM. We found that Bz resistant cells 
were sensitised to Bz during the inhibition of CMA. Inhibition of CMA alone was also shown to 
reduce the viability of both sensitive and resistant cells, though not as effective as combining CMA 
inhibition with Bz.  
Previous studies have illustrated the importance of CMA within a number of different cancers (Kon et 
al., 2011, Saha, 2012, Zhou et al., 2016, Han et al., 2017). The CMA pathway has been shown to have 
the ability to directly regulate the metabolism of tumour cells, and is also important in driving tumour 
metastasis and cell proliferation (Kon et al., 2011, Saha, 2012, Suzuki et al., 2017). The expression of 
LAMP2A, the rate-limiting factor in CMA activity, is also increased in a number of tumour tissues, 
relative to the surrounding healthy tissue (Kon et al., 2011). While critical in maintaining the viability 
of tumour cells, the involvement of CMA in chemotherapy resistance remains poorly understood. One 
previous study has found that breast cancer cells deficient of LAMP2A possess increased sensitivity to 
the drug Doxorubicin (Saha, 2012). Considering that LAMP2A is required for CMA, it is probable 
that LAMP2A deficient cells had a nuclear accumulation of checkpoint kinase 1. It has been shown in 
one previous study that nuclear accumulation of checkpoint kinase 1 within CMA deficient cells leads 
to prolonged DNA damage (Park et al., 2015). Furthermore, the same study had also found that 
hyperphosphorylation and destabilisation of the MRN complex involved in early stages of some DNA 
repair mechanisms, also occurred in CMA deficient cells when subjected to DNA damage (Park et al., 
2015). Additional studies are yet to provide any further insight into the potential role CMA may play 
in chemotherapy resistance. This is despite autophagy having the ability to compensate the proteasome 
system during proteasome impairment (Nedelsky et al., 2008, Wong and Cuervo, 2010). Nevertheless, 
Bz resistance in MM still remains the biggest hurdle in treating the disease, while our understanding 
surrounding the development of Bz resistance is still poorly understood. We currently know that 
sensitivity to Bz is dependent on the expression of XBP-1 (Ling et al., 2012). Reduced expression of 
XBP-1 and downregulation of the UPR is known to be associated with Bz resistance (Ling et al., 
2012) (Leung-Hagesteijn et al., 2013). However, the mechanisms responsible for compensating the 
UPR in resistant cells are yet to be identified. Increases in the expression of proteins involved in stress 
responses, such as HSP70 and HSP90 proteins, have been previously identified in MM (Khong and 
Spencer, 2011) (Heimberger et al., 2013). Considering that both HSP70 and HSP90 proteins play 
important roles in the CMA chaperone complex, and that LAMP2A expression is increased in Bz 
resistant MM (as shown in previous chapters), CMA appears to be a likely mechanism in conferring 
Bz resistance.  
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In this study, we were the first to prove that CMA plays a pivotal role in conferring resistance to Bz in 
MM, compensating the UPR in alleviating ER stress, and maintaining the viability of myeloma cells. 
This can be supported by the significant decrease in cell viability seen as a result of CMA inhibition 
using a PHLPP1 inhibitor. The PHLPPi alone, without proteasome inhibition, was able to reduce the 
viability of resistant cells, but also reduce the viability of sensitive cells. This confirmed that CMA 
compensates the UPR in Bz resistant MM, acting as a compensatory stress mechanism. These findings 
also further demonstrated the importance of CMA in maintaining the viability of myeloma cells, as its 
inhibition also reduced the viability of Bz sensitive cells. This can confirm that independent of the 
proteasome, CMA activity is necessary in maintaining the viability of myeloma cells. Supported by 
earlier findings (chapter 5), these results are the first to show that CMA is able to confer Bz resistance 
by compensating reduced UPR activity in Bz resistant MM. This finding suggests that there is a link 
between UPR and CMA. Our data support the notion that CMA in cancer is important, and could be 
driving cell proliferation and tumour metastasis in MM, as seen in other cancers (Kon et al., 2011, 
Saha, 2012, Suzuki et al., 2017). Like in many other cancers, CMA inhibition reduces the viability and 
proliferation of tumour cells (Kon et al., 2011, Zhou et al., 2016, Han et al., 2017). 
CMA inhibition also appeared to sensitise resistant cells to Bz, while also enhancing the cytotoxicity 
of Bz. The sensitising of resistant cells to Bz was attributed to the inhibition of CMA. As illustrated in 
earlier chapters (chapter 3), myeloma cells resistant to Bz have reduced dependence of on the UPR, 
reflected by reduced ATF6 expression and the overall reduction in ER size. This subsequently leads to 
the upregulation of CMA in Bz resistance (as shown in chapters 4 and 5), compensating the UPR in 
alleviating ER stress. Therefore, the inhibition of CMA reverts the resistant cells to be reliant upon the 
proteasome in order to alleviate ER stress. This sensitises the resistant cells to Bz, as the inhibition of 
the proteasome rendered the resistant cells defenceless against increasing proteotoxicity, and enhanced 
the cytotoxic effect of Bz. Moreover, as seen in previous studies (Kon et al., 2011, Suzuki et al., 2017), 
we also found that CMA inhibition mediated a rapid apoptotic response compared to Bz, while also 
resulting in an increase non-apoptotic cell death. We are therefore the first to provide substantial 
evidence to suggest the potential therapeutic benefit of targeting CMA in the treatment of Bz resistant 
MM.  
Limitations to this study were found in acquiring sufficient knockdown of LAMP2A to inhibit CMA. 
Early attempts to transduce sensitive and resistant KMS11 cells with LAMP2A shRNA were lethal to 
cells. Due to the high expression levels of LAMP2A, myeloma cells were required to be transduced 
with a high multiplicity of infection (MOI) to sufficiently knockdown LAMP2A. However, this 
consequently caused a rapid decline in viable cell numbers after 7 – 10 days following cells being 
transduced with LAMP2A shRNA. The decline in cell numbers was a result of LAMP2A knockdown, 
considering the viability of cells transduced with the control shRNA (negative control) remained 
unaffected and underwent regular passaging. The same LAMP2A shRNA constructs have previously 
shown to inhibit CMA by knocking down LAMP2A, and reduced the proliferation of cancer cells, 
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while also inducing cell death (Kon et al., 2011). We believe that the remaining cells that survived 
lentiviral transductions (with LAMP2A shRNA) were transduced with a lower number of lentiviral 
particles. As a result, these cells were believed to possess the puromycin resistant gene, enabling them 
to survive puromycin screening, while lacking sufficient expression of LAMP2A shRNA to 
effectively inhibit CMA by LAMP2A knockdown. This is supported by the small decreases in mRNA 
levels detected in cells transduced with LAMP2A shRNA.  
To overcome the difficulties in establishing stable knockdown lines, siRNA transfections were used as 
alternative approach to knockdown LAMP2A expression. While the knockdown of LAMP2A using 
siRNA enabled a more immediate knockdown of LAMP2A, the knockdown was relatively short lived. 
Considering that knockdown of LAMP2A using shRNA resulted in a rapid decline on the viability of 
cells 7-10 days after lentiviral transductions, the short-term knockdown produced by siRNA was 
inadequate to elicit the same lethal effect. This was evident at 96 hours post transfection, where 
LAMP2A protein levels were beginning to increase in both sensitive and resistant cells. Furthermore, 
the limited effect LAMP2A knockdown had on the viability of cells was also largely attributed to the 
long half-life of the LAMP2A protein (Cuervo and Dice, 2000). During CMA inducing conditions, the 
half-life of LAMP2A is altered to accommodate increased CMA activity, with the half-life of 
LAMP2A seen to increase by 2-fold (Cuervo and Dice, 2000). Under such conditions, lysosomal 
membrane degradation of LAMP2A is also inhibited, whilst the reinsertion of luminal LAMP2A into 
the lysosomal membrane can also increase membrane levels (Cuervo et al., 2003) (Majeski and Dice, 
2004). In turn, this facilitates increased CMA activity, independent of protein expression arising from 
de novo synthesis. As we have shown in earlier chapters, ER stress is able to activate CMA. 
Considering myeloma cells are under continual ER stress, LAMP2A degradation would be inhibited, 
ultimately reducing LAMP2A turnover. Furthermore, it is also possible that the impairment of CMA 
by LAMP2A knockdown could have placed an increased dependence on the proteasome, considering 
that the impairment of the proteasome has previously shown to upregulate autophagy (Lilienbaum, 
2013). It is possible this compensatory mechanism is reciprocated during CMA inhibition. Therefore, 
it is conceivable that LAMP2A knockdown using siRNA is not effective in the inhibition of CMA. 
Furthermore, it is possible that Bz exposure in L2A(-)cells could possibly have lead to an upregulation 
of LAMP2A expression. 
Difficulties in determining the effect LAMP2A knockdown had on Bz sensitivity were largely 
attributed to reproducibility issues, in combination with what has been discussed previously. 
Nevertheless, the clumping of cells following the electroporation process is a side effect of the 
transfection method. It was because of this technical issue that repeated attempts to replicate the 
results seen in chapter 6.4 were unachievable. Reason being, is that great care is required during the 
re-suspension of electroporated cells, as the electroporation process weakens the structural integrity of 
cells making them easily damaged to vigorous pipetting (Tsong, 1991). Due to the large level of 
difficulty in dissolving clumped cells, cell-seeding numbers deviated between replicates. Deviations in 
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cell numbers across replicate samples subsequently resulted in variations in absorbance readings of 
MTS assays. This resulted in poor reproducibility and uncertainty in the results, as differences 
between the negative control and L2A(-) cells to Bz were not known to be a result of LAMP2A 
knockdown or variation in cell seeding numbers. This is because MTS assays measure the 
mitochondrial membrane potential of the entire cell population within each well, not on a cell-by-cell 
basis (Goodwin et al., 1995). For this very reason, this is why flow cytometry analysis was better 
suited to measure the viability of cells, and was implemented in experiments using the PHLPPi. Flow 
cytometry allowed a more accurate and precise measurement of cell viability within cell populations 
but was also able to identify the percentage of cells within each population that were apoptotic and 
necrotic, which MTS assays are unable to detect.  
In summary, we are the first to demonstrate the role of CMA in Bz resistance and the potential benefit 
of therapeutically targeting the CMA pathway in treating Bz resistant MM. In combination with Bz, 
inhibition of CMA using a PHLPPi further enhanced the cytotoxic effect of Bz in MM. CMA 
inhibition also sensitised the Bz resistant cells to Bz. Inhibition of CMA alone was also shown to 
reduce the viability of both sensitive and resistant cells without Bz, though not as effective as 
combining CMA inhibition with Bz. However, these findings were difficult to replicate through the 
knockdown of LAMP2A expression. The long half-life of LAMP2A, coupled with the inability to 
obtain adequate knockdown of LAMP2A expression resulted in insufficient inhibition of CMA. 
Nevertheless, CMA is an important regulator of ER stress, capable of compensating the UPR in Bz 
resistant MM, while also important in maintaining the viability of myeloma cells. Therefore, CMA is a 
contributing element of Bz resistance in MM, and is a suitable target for the treatment of Bz resistance. 
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7. Concluding Remarks 
7.1 Conclusion  
The purpose of this thesis was to establish the underlying cause of Bz resistance in MM, propose 
alternative approaches that could overcome Bz resistance and to establish the biological role of CMA 
in MM. Currently, Bz resistance remains the greatest challenge in treating MM, with the mechanisms 
Bz resistance still poorly understood. This thesis was able to establish within a Bz resistant cell line 
model and ex-vivo patient samples that Bz resistance was associated with reduced dependence on the 
UPR and the upregulation of CMA. Resistance to Bz was associated with the decreased expression of 
ATF6 expression in Bz resistant cell lines and Bz resistant MM patients. Like XBP-1 expression, 
ATF6 expression was identified to mirror Bz sensitivity in both cell line models and ex-vivo patient 
samples, reflecting reduced UPR activity. Live cell imaging and electron microscopy was able to 
further support these findings, which identified Bz resistant cells having a significant reduction in the 
overall size of the ER compared to Bz sensitive cells. Resistant cells were also found to have limited 
capability in ER expansion, reflecting a less functional UPR. The reduction in ER size morphology 
was a direct result of reduced ATF6 and XBP-1 expression levels, as ER expansion is dependent upon 
XBP-1 and ATF6. Therefore, Bz resistant myeloma cells were less dependent on the UPR. 
The downregulation of the UPR could not be explained solely by mutations or SNPs occurring in the 
splice site of XBP-1 mRNA. The occurrence of XBP-1 SNPs within our MM patient cohort was rare, 
with only 3% of MM patients in our cohort possessing XBP-1 SNPs. While we found no correlation 
between SNPs in the splice site of XBP-1 and Bz resistance. However, we did notice a poor patient 
outcome within patients that possessed SNPs occurring in the splice site of XBP-1. Despite only one 
patient possessing a SNP in the splice site of XBP-1, its occurrence in our patient cohort was almost 
identical to that of a previous study. The same study also highlighted the poor prognostic outcome of 
patients that possessed a SNP in the splice site of XBP-1. Therefore, SNPs affecting the XBP-1 
splicing site was a potential mechanism of resistance, although this occurred in a small number of MM 
patients, resulting in no statistical significance.  
This thesis proposed that CMA was a potential compensatory mechanism in mediating Bz resistance. 
LAMP2A, a lysosomal transmembrane protein receptor is the rate-limiting factor in CMA activity. 
The ex-vivo analysis of 2 independent MM patient cohorts, LAMP2A mRNA and protein expression 
was upregulated in MM patients who were resistant or refractory to Bz. These findings were further 
supported by in-vitro modelling Bz resistance, which revealed that mRNA and protein expression 
levels of LAMP2A were also significantly increased within Bz resistant cells. Within the same in-vitro 
model, we further identified that basal CMA levels in Bz resistant cells were significantly higher than 
those seen in Bz sensitive cells. Basal CMA activity was identified to be at almost maximum activity 
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in Bz resistant cells, while basal CMA levels within cells sensitive to Bz were almost half the active 
capacity. Basal CMA levels further complemented the increased expression of LAMP2A in Bz 
resistant cell lines, which further confirmed the upregulation of CMA in Bz resistant MM. These 
findings illustrated the importance of the pathway in Bz resistant MM and show a strong correlation 
between LAMP2A expression and Bz resistance. 
This study was the first to show that the CMA pathway is utilised in managing ER stress in MM. 
CMA activity was shown to be upregulated under ER stress conditions, reflected by the increase in 
LAMP2A protein expression and the increase in CMA active lysosomes. CMA activity was also seen 
to be proportional to the level of ER stress in MM. Not only did we find that the CMA pathway was a 
compensatory stress mechanism in MM, but we were the first to establish a link between the UPR and 
CMA. The compensatory stress mechanism of CMA in response to increasing ER stress levels has 
provided a new understanding into how Bz resistant myeloma cells manage ER stress. It has further 
provides mechanistic evidence of how Bz resistance may develop in MM patients and possibly 
mediate Bz resistance. 
The knockdown of LAMP2A was to test the fundamental relationship between CMA and Bz 
resistance. This part of the project was inconclusive as a result of the inability to achieve adequate 
levels of LAMP2A knockdown. The stable knockdown of LAMP2A with shRNA was unfeasible due 
to its lethal effect on cells at a high MOI, while cells transduced with low MOI were inadequate to 
effectively reduce LAMP2A expression. Transient transfections using LAMP2A siRNA yielded 
inadequate levels of LAMP2A knockdown that was short lived. To overcome limitations associated 
with the knockdown of LAMP2A and the long half-life of the LAMP2A protein, a PHLPP1 inhibitor 
was used to inhibit CMA. The inhibition of PHLPP1 prevented the activation of CMA and yielded an 
immediate inhibitor effect on the CMA pathway. The PHLPPi alone, without Bz, was shown to 
significantly reduce the viability Bz sensitive and resistant cells relative to the untreated controls. This 
exemplified the importance of CMA in the survival of myeloma cells. More importantly, the inhibition 
of CMA by the PHLPPi also sensitised resistant cells to Bz. The combination of the PHLPPi with Bz, 
also further enhanced the cytotoxic effects Bz in resistant cells, confirming the role of CMA in 
conferring resistance to Bz. Therefore, CMA is important in the growth of both Bz sensitive and 
resistant cells, while also important in mediating Bz resistance. Inhibition of CMA has the potential of 
becoming a therapeutic target to treat MM and in the sensitising of MM to Bz.  
Overall, the work in this thesis has improved the understanding Bz resistance in MM, deciphered the 
role of CMA in MM and Bz resistance, and more importantly discovered a novel therapeutic target 
that can could be potentially used in the treatment of MM. Further work exploring therapeutic benefit 
of targeting CMA in MM is worthwhile and promising. 
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7.2 Future directions for this work 
1) Further investigation into CMA inhibition in MM. 
Further in-vitro studies are required to better understand the therapeutic potential of CMA inhibition in 
treating Bz resistant MM. Investigation into the effects of CMA inhibition on cell growth and 
treatment outcomes needs to be explored in-vitro using Bz sensitive and resistant (myeloma) cell lines, 
and primary myeloma cells. Inhibition of CMA by PHLPPi should be also further explored in-vitro by 
performing cytotoxicity assays and apoptotic assays on Bz sensitive and resistant cells.  
2) Determine the drug interaction between the PHLPPi and Bz  
Secondly, the interaction between the PHLPPi and Bz in eliciting a cytotoxic effect in MM needs 
further exploration. It appeared in this project that PHLPPi sensitised Bz resistant cells to Bz. 
However, further testing is required to determine whether PHLPPi and Bz have synergistic or additive 
effects on MM. This can be performed using cytotoxicity assays. If synergistic activity and additive 
effects is confirmed, PHLPPi could be further developed for treatment of MM. 
3) In-vivo inhibition of CMA in Bz sensitive and resistant MM using a tetracycline-controlled 
transcriptional activation (TET) system.  
Thirdly, in-vitro inhibition of CMA in Bz sensitive and resistant MM using a tetracycline-controlled 
transcriptional activation (TET) system could overcome the problems associated with the knockdown 
of LAMP2A using shRNA. Bz sensitive and resistant cells could be transfected with a TET inducible 
expression system, which expresses LAMP2A shRNA. This would enable the controlled expression of 
LAMP2A shRNA in Bz sensitive and resistant cells. The effects of CMA inhibition on Bz sensitivity, 
cell proliferation and apoptosis could be then assessed by cytotoxic assays, cell proliferation assays 
and apoptosis assays. This inducible expression model could also be further expanded into in-vivo 
studies, to investigate CMA inhibition in the treatment and progression of MM in-vivo. 
4) Explore the toxicology of the PHLPPi in-vitro and in-vivo 
While the PHLPPi was successful in the inhibition of CMA and also effective in sensitising resistant 
cell to Bz, we are unsure about its suitability for clinical use. In order to potentially use the PHLPPi in 
the treatment Bz resistant MM, the toxicology of the PHLPPi must be first explored in-vitro and in-
vivo. Whether or not there will be any off-target effects using the inhibitor must also be established. 
In-depth understanding into the pharmacokinetics and pharmacodynamics of the PHLPPi must also be 
understood in order for it to be suitable and safe for its potential clinical use.  
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8. Appendices  
Appendix I – IMWG uniform response criteria for patient responses to bortezomib 
Patient responses after completion of cycle 2 therapy with Bz were categorized according to the 
IMWG uniform response criteria (Rajkumar et al., 2011). Briefly, complete response (CR) patients 
were identified having negative immunofixation electrophoresis (IFE) on serum and/or urine, and less 
than 5% plasma cells in bone marrow. Very good partial response (VGPR) patients were identified 
being in very good partial remission, when serum paraprotein is negative on electrophoresis but 
present on serum IFE or there is a ≥90% reduction of paraprotein in serum plus M component 
<100mg/24hour. Partial response (PR) patients had a 50% reduction in serum M-protein and a 
reduction in 24-hour urinary M-protein by 90% or to <200 mg/24 hours. If the serum and urine M-
protein are not measurable, PR constitutes a decrease of ≥ 50% in the difference between involved and 
uninvolved free light chain. Progressive disease (PD) patients had an increase in 25% of the lowest 
response value of serum or urine M component, while stable disease (SD) patients didn’t fit the 
criteria for CR, VGPR, PR or PD. 
. 
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Target Antigen Host/Clonality Company Cat # Application Dilution 
CD38-APC conjugated Mouse/Monoclonal BD Biosciences 340439 Cell Sorting N/A (15 µl per sample) 
anti-CD138-PE 
conjugated 
Mouse/Monoclonal Beckman Coulter A40316 Cell Sorting N/A (15 µl per sample) 
anti-Syndecan-1/CD138 Mouse/Monoclonal Thermo Scientific MA5-12400 IHC 1/50 
anti-LAMP2A Rabbit/Polyclonal Abcam ab18528 WB, IHC and IF 
WB: 1/500; IHC: 1/1000; 
IF: 1/500 
anti-HSC70 Mouse/Monoclonal Novus NB120-2788 IF 1/200 
anti-β-actin Rabbit/Polyclonal Abcam ab8227 WB 1/4000 
anti-GAPDH Rabbit/Polyclonal Abcam ab22556 WB 1/4000 
anti-Rabbit IgG  
H&L (HRP) 
Donkey/Polyclonal Abcam ab16284 WB 1/2000 
Rabbit IgG Isotype 
Control 
Donkey/Polyclonal Abcam ab27478 IHC 1/1000 
Alexa 488 conjugated 
anti-Mouse IgG  
Goat/Polyclonal Life Technologies A-11029 IF 1/1000 
Alexa 555 conjugated 
anti-Rabbit IgG 
Donkey/Polyclonal Abcam ab150074 IF 1/1000 
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Appendix IV – LAMP2A shRNA construct 
 
(Sourced from the Sigma-Aldrich website) 
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U6 U6 promoter 
Cppt Central polypurine tract 
hPGK Human phosphoglycerate kinase eukaryotic promoter 
puroR Puromycin resistance gene for mammalian selection 
SIN/3’ LTR 3’ self inactivating long terminal repeat 
F1 ori F1 origin of replication 
ampR Ampicillin resistance gene for bacterial selection 
pUC ori pUC origin of replication 
5’LTR 5’ long terminal repeat 
Psi RNA packaging signal 
RRE Rev response element 
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Appendix V – LAMP2A protein expression in MM patient bone marrow trephines of individual patient 
groups 
 
LAMP2A protein expression in bone marrow trephines of MM patients. The same data as presented in 
figure 4.4, with each patient group presented individually. Patient responses were determined according to the 
IMWG Patient Response Criteria. Data is shown as mean values ± S.E.M. Statistical analysis was performed on 
complete response/very good partial response (CR/VGPR) (n=20) vs partial response (PR) (n=22) vs minimal 
response (MR) (n=11) vs stable disease (SD) (n=6) vs progressive disease (PD) (n=7) using a one-way ANOVA. 
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